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infection, potential mechanisms and the role of the different drug 
classes. 
o Changes in body fat distribution.  
o Dyslipidemia. 
o Insulin resistance. 
o Bone mineral density. 
• Consequences of the metabolic effects of antiretroviral therapy. 
o Psychological impact of morphological changes. 
o Cardiovascular disease risk. 
• Strategies to limit the metabolic complications of treatment for HIV 
infection. 
o Drug or drug class sparing initial regimens. 
o Switch strategies. 
• Brief outline of the thesis 
• .
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Background 
 
The first patients with symptoms consistent with what was later to be called 
”acquired immunodeficiency syndrome” (AIDS) were described in 1981[1]. Two 
years later, the virus causing this syndrome, human immunodeficiency virus, was 
identified[2]. Since then, the HIV epidemic has rapidly grown. In 2007, the total 
number of persons with HIV infection worldwide was estimated to be 33.2 million, 
with 2.5 million new infections in that year[3].  
Zidovudine, the first antiretroviral drug of the nucleoside reverse transcriptase 
inhibitor (NRTI) class, was approved in 1987. Since then, more than 20 
antiretroviral drugs from 6 different classes have been introduced. These target 
different steps in the replication life cycle of HIV, from fusion and entry (fusion 
inhibitors, CCR5 antagonists), reverse transcription (nucleoside, nucleotide and 
non-nucleoside reverse transcriptase inhibitors), integration into host cell DNA 
(integrase inhibitors) to the cleavage of polyproteins (protease inhibitors).  
A combination of several antiretroviral drugs (highly active antiretroviral therapy 
(HAART) or combination antiretroviral therapy (cART) generally leads to adequate 
suppression of HIV and at least partial restoration of immunity. Since the 
introduction of cART in 1996, morbidity and mortality in patients with HIV-infection 
has declined dramatically[4]. However, with the long-term use of these 
combinations, adverse events, which include several metabolic abnormalities, are 
increasingly reported.   
 
 
Description of the metabolic complications of treatment for HIV 
infection, potential mechanisms and the role of the different 
drug classes. 
 
Changes in body fat distribution 
Before the introduction of cART, loss of body weight was often observed in patients 
with advanced HIV infection. In its extreme form, this was called HIV associated 
wasting syndrome, an AIDS defining condition which is characterized by loss of 
both fat and lean body mass[5]. Within a year after cART had become widely 
available, the first cases of a different form of body composition changes were 
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described, affecting adipose tissue only and consisting of an abnormal fat 
distribution. The distinct clinical features were gradually recognized, ranging from 
buffalo hump[6], hypertrophy of the breasts[7] and lipomatosis[8] to wasting of 
subcutaneous fat in the face, arms, legs, and buttocks[9] and accumulation of 
visceral abdominal fat[10], often accompanied by dyslipidemia and insulin 
resistance. The term “lipodystrophy syndrome” was introduced in analogy to rare 
congenital lipodystrophy syndromes. Lipodystrophy is a heterogeneous syndrome, 
with different patterns identified, and the subjectivity of the criteria for these body 
shape changes have lead to methodological issues in studies. A case definition of 
lipodystrophy was developed in 2003, based on clinical data and objective 
assessment of regional fat distribution [11].  
Estimates of the prevalence of lipodystrophy vary, depending on the populations 
studied and the criteria used. Recent large studies have reported prevalence rates 
of 40-50%, all based however on subjective criteria[12-14].  
Lipodystrophy is characterized by an initial gain in both limb fat and central 
abdominal fat after the start of cART, followed by a progressive decline in limb fat 
and stabilization of central abdominal fat, leading to relative central adiposity[15]. 
After 24 months of cART, clinically evident subjective changes in peripheral and 
central fat mass were reported in 23% of patients [16].  
Although lipodystrophy has been reported in patients who have never used 
antiretroviral therapy[12], most changes in body composition have been 
demonstrated after start of cART. As fat redistribution was first reported soon after 
the introduction of protease inhibitors (PI), lipodystrophy was initially attributed to 
the use of this drug class. However, exclusive use of PI without nucleoside reverse 
transcriptase inhibitors (NRTI) was shown not to lead to lipoatrophy[17] and use of 
NRTI alone, without a PI, is sufficient for lipoatrophy development[18, 19]. 
Nevertheless, use of PI may contribute to an increased risk of lipoatrophy, as 
demonstrated in a longitudinal cohort study in which dual NRTI therapy in 
combination with a PI was associated with faster progression to fat wasting than 
the same treatment without a PI[18]. The NRTI most strongly associated with 
lipoatrophy are the thymidine analogues stavudine, especially in combination with 
didanosine, and, to a lesser extent, zidovudine. Regimens containing stavudine 
were associated with greater loss of limb fat and increased incidence of facial 
atrophy compared to regimens containing zidovudine in prospective randomized 
trials[20, 21]. Regimens based on the NRTI abacavir or tenofovir seem to have the 
least effect on body fat distribution, when compared with stavudine/didanosine 
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containing regimens [22], and zidovudine/lamivudine containing regimens[23], 
respectively.  
Until recently, non-nucleoside reverse transcriptase inhibitors (NNRTI) were 
considered not to be clearly associated with body composition changes. However, 
in a large trial of class sparing regimens a higher incidence of lipoatrophy was 
found in patients treated with efavirenz + 2 NRTI than in those using lopinavir/ 
ritonavir + 2 NRTI, suggesting possibly that efavirenz may contribute to limb fat 
loss[24]. In contrast, in an earlier study patients using the PI nelfinavir had greater 
limb fat loss than those using efavirenz, after adjustment for NRTI backbone[20]. 
Concerning the pathogenesis underlying HIV associated lipodystrophy syndrome, 
several potential molecular mechanisms have been proposed. NRTI have been 
linked to mitochondrial toxicity through the inhibition of DNA polymerase gamma 
within mitochondria[25], or alternatively through inhibition of mitochondrial RNA 
expression [26], both resulting in a depletion of mitochondrial DNA. In adipose 
tissue, this may ultimately lead to lipoatrophy due to adipocyte apoptosis. Both 
NRTI and PI may also, independent of any effect on mitochondrial DNA or RNA, 
induce oxidative stress which may result in accelerated adipocyte senescence and 
apoptosis[27].  Furthermore, PI may cause adipocyte toxicity through interference 
with cellular transcription factors such as sterol regulatory element binding proteins 
(SREBP) and peroxisome proliferator-activated receptors (PPAR-gamma)[28, 29]. 
These are essential for the regulation of intracellular cholesterol- and fatty acid 
metabolism and adipocyte function, respectively. Patients with lipodystrophy have 
lower adipose tissue expression of SREBP-1 and PPAR gamma than those without 
lipodystrophy[30, 31]. Interestingly, down-regulation of PPAR gamma and altered 
expression of genes involved in lipid metabolism has also been observed in 
adipose tissue of healthy volunteers who had received dual NRTI therapy without 
PI for two weeks[26], suggesting that some of these changes may be caused by 
more than one drug class only. Inflammation has also been considered to play a 
role in inducing and maintaining lipoatrophy. In adipose tissue of patients with 
lipoatrophy, an accumulation of macrophages has been observed, which may 
secrete proinflammatory cytokines[32]. Adipose tissue may also secrete cytokines 
such as TNF alpha and IL-6. TNF alpha may increase adipocyte lipolysis, thereby 
contributing to lipoatrophy and insulin resistance.  
A completely different hypothesis was suggested by Fliers et al[33]. They postulate 
that fat redistribution may be caused by selective damage by antiretroviral drugs to 
the autonomic pathways in the central nervous system, that separately innervate 
the subcutaneous and visceral fat depots[33]. A change in autonomic balance, with 
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predominant sympathetic activity in subcutaneous fat and parasympathetic activity 
in visceral fat, could lead to subcutaneous fat loss and visceral fat accumulation. In 
patients with lipodystrophy, increased local sympathetic nervous system activity in 
subcutaneous adipose tissue has been observed[34]. 
Although all these mechanisms may contribute to the metabolic abnormalities 
observed with the lipodystrophy syndrome, a unifying explanation is lacking up to 
this date.  
In addition to the choice of antiretroviral drugs, various other risk factors for the 
development of fat redistribution have been identified. These include host-related 
factors such as older age, white race, female gender and possibly TNF alpha gene 
promotor polymorphisms[13, 18, 35-38], HIV-related factors such as lower nadir 
CD4 count and prior AIDS diagnosis[13, 35], and the presence of hepatitis C 
coinfection[36, 39-41]. 
 
Dyslipidemia 
Lipid abnormalities were commonly observed in HIV-1 infected patients before the 
introduction of cART, especially in those with advanced infection [42]. These 
abnormalities included hypertriglyceridemia and reduced levels of total and LDL 
cholesterol. HDL cholesterol levels remained unchanged or decreased. In addition, 
there was an increased prevalence of small dense LDL particles, which are known 
to be more atherogenic than larger particles[43]. Suggested mechanisms for these 
abnormalities include increased hepatic synthesis of very low density lipoprotein 
(VLDL), decreased clearance of triglycerides and increased apolipoprotein E 
levels[42, 44, 45].Treatment with the first antiretroviral drugs such as zidovudine 
was shown to decrease plasma triglyceride levels[46]. Later, after the introduction 
of cART, marked dyslipidemia was observed mainly in patients using PI-based 
regimens[9]. This dyslipidemia is characterized by high levels of total and LDL 
cholesterol and hypertriglyceridemia, without changes in HDL levels. Currently, 
dyslipidemia is a frequent finding in patients with HIV-1 infection. In a large cross-
sectional study, 22.2 % of patients had hypercholesterolemia (total cholesterol ≥ 
6.2 mmol/l), 33.8% hypertriglyceridemia (triglyceride level ≥ 2.3 mmol/l) and 25.7% 
had low levels of high density lipoprotein (HDL) cholesterol (HDL ≤ 0.9 mmol/l)[47]. 
Prevalence rates vary according to the drug classes used and to specific 
antiretroviral drugs used within each class[47, 48]. Part of these lipid changes are 
likely to result from a “restoration to health” phenomenon due to suppression of 
HIV, after accounting for expected age-related changes. Longitudinal assessment 
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of patients with documented seroconversion indeed showed that, after the initiation 
of cART, total and LDL cholesterol increased to pre-seroconversion levels, 
whereas little change was observed in HDL levels[49]. This is unlikely to be the full 
explanation for lipid changes after initiation of cART, especially for the 
hypertriglyceridemia, as lipid changes are also seen in healthy volunteers treated 
with antiretroviral drugs, especially PI[50]. Currently, the pathogenesis of 
dyslipidemia in patients with HIV is thought to be a combination of the direct effects 
of different antiretroviral drugs, not only PI, possibly maintained or aggravated by 
the frequently coincident body composition changes and insulin resistance induced 
by these drugs. 
 
The direct effects of PI on lipid metabolism have been studied in HIV-negative, 
healthy volunteers and appear to be drug specific. Indinavir, amprenavir and 
atazanavir had no effect on the lipid profile in healthy volunteers[51];[52];[53], 
whereas ritonavir increased triglycerides, VLDL, IDL, apolipoprotein B and 
lipoprotein (a)[52, 54], and lopinavir/ritonavir induced increases in fasting 
triglycerides, free fatty acids (FFA) and VLDL cholesterol[55]. In some of these 
studies a rapid induction of a modest degree of insulin resistance was found, which 
could have contributed to the increases in triglycerides and VLDL[53]. In contrast to 
the findings in healthy volunteers, most PI, with the exception of atazanavir, have 
been found to induce hyperlipidemia in patients with HIV infection, with ritonavir 
having the most pronounced effect, particularly triglyceride elevation[56-59]. 
Several mechanisms have been proposed for the dyslipidemia induced by PI. 
Studies in mice found that ritonavir induces the accumulation of activated sterol 
regulatory element binding proteins (SREBP) in the nucleus of hepatocytes and 
adipocytes, leading to an increase in fatty acid and cholesterol biosynthesis[60]. A 
more recent study in mice however had different findings, demonstrating that 
ritonavir decreases lipoprotein lipase mediated clearance of VLDL-TG and impairs 
the uptake of FFA in adipose tissue[61]. Studies in humans investigating the 
mechanisms of PI induced dyslipidemia also have conflicting results. Some 
suggest that PI increase VLDL-TG production [54], whereas others find an 
inhibition of VLDL-TG clearance, either alone [62] or in combination with increased 
VLDL production[63]. In addition, an increased rate of apolipoprotein B synthesis 
has been described[64]. 
 
In contrast to PI based regimens, NNRTI based regimens are associated with 
marked increases in HDL cholesterol and lesser increases in LDL and 
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triglycerides[65, 66]. Comparing the two most commonly used NNRTI, patients 
using nevirapine had significantly greater increases in HDL (up to 42.5%), and 
smaller increases in total and LDL cholesterol and triglycerides compared with 
those using efavirenz[67]. The mechanism by which nevirapine increases HDL 
appears to be by stimulation of apolipoprotein AI production[68]. 
 
Less is known on the specific effects of NRTI on lipid metabolism. In a randomized 
clinical trial patients using NRTI only (zidovudine/lamivudine/abacavir) had minimal 
changes in LDL at 96 weeks compared to patients using a PI based regimen[69], 
suggesting that NRTI as a class have fewer effects on lipid profile than PI. 
However, differences between NRTI with respect to their effect on lipid profile do 
seem to exist, as patients using stavudine had a significantly greater increase in 
total and LDL cholesterol and triglycerides and less increase in HDL cholesterol 
compared to those using tenofovir, both combined with lamivudine and 
efavirenz[70]. Also, total cholesterol and triglyceride levels drop in patients in whom 
stavudine or zidovudine is substituted by tenofovir [71-75].  
 
Insulin resistance 
Before the introduction of cART, asymptomatic HIV- infected men were shown to 
have increased sensitivity of the peripheral tissues to insulin and higher rates of 
insulin clearance compared to healthy controls[76]. However, in the era of cART, 
an increased prevalence of insulin resistance in up to 50% of patients has been 
described, depending on the criteria used to define it[77]. Diabetes mellitus 
remains relatively uncommon, with a prevalence of 2-5% in most studies[47]. In 
patients with lipodystrophy, insulin resistance has been reported in multiple 
metabolic pathways, including peripheral glucose uptake, lipolysis and endogenous 
glucose production[78].  
The pathogenesis of insulin resistance in patients with HIV infection is most likely 
multifactorial. Besides known risk factors such as genetic disposition and obesity, 
hepatitis C coinfection and hypogonadism may be contributing factors. Of the 
antiretroviral drug classes, both PI and NRTI have been implicated in the 
pathogenesis of insulin resistance, either directly or as a result of associated 
changes in fat distribution. Studies in healthy volunteers employing 
hyperinsulinemic euglycemic clamps have shown that several, but not all PI have 
an acute inhibitory effect on glucose uptake when given in single dose[79-81], 
during 5 days[53] or 10 days[82]. Comparing the single dose studies, there 
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appears to be a hierarchy in the ability of PI to acutely induce insulin resistance, 
with indinavir having the greatest effects, followed by ritonavir and 
lopinavir/ritonavir, and amprenavir having the least effect. This effect appears to be 
dose- dependent, in an in- vitro study glucose uptake was moderately affected with 
low dose ritonavir but significantly inhibited with higher doses of this drug[82]. In-
vitro research has shown that several PI, including ritonavir, are able to acutely 
inhibit the activity of glucose transporter-4 (GLUT-4), which is the rate limiting step 
for glucose uptake into muscle and adipose tissue[83, 84]. This may represent the 
major mechanism by which PI acutely induce insulin resistance. However, in two of 
the three studies with healthy volunteers, insulin resistance was no longer present 
after PI were administered for a longer period of 4 weeks[55, 85].Therefore it 
remains unclear whether PI are responsible for insulin resistance after longer term 
use in HIV infected patients. Evaluating the role of antiretroviral drug classes and 
individual drugs in the pathogenesis of insulin resistance in HIV infected patients is 
difficult, as other factors such as the effect of suppression of viral replication and 
restoration of immunity, the use of combinations of antiretroviral drugs with 
potential additive effects and the consequences of body fat redistribution, all have 
to be taken into account. 
NRTI are thought to contribute to insulin resistance mainly indirectly by inducing 
changes in fat distribution and lipoatrophy in particular[86, 87]. This could explain 
why cumulative exposure to particular NRTI was found to be independently 
associated with markers of insulin resistance[88]. However it has also been 
reported that in cART-naïve, HIV-1-infected patients, insulin resistance develops as 
early as four weeks after initiating cART containing didanosine+stavudine, but not 
after abacavir+lamivudine[22]. This could suggest that particular NRTI may also 
disturb glucose metabolism more directly. More recently, a study in healthy HIV-
uninfected volunteers demonstrated that administration of stavudine during four 
weeks indeed resulted in a significant decrease in insulin sensitivity measured by 
hyperinsulinemic-euglycemic clamps, without changes in body composition[89]. 
Interestingly, reduced mitochondrial function in skeletal muscle and reduced 
mitochondrial DNA-content was found in muscle biopsies of these stavudine 
recipients, suggesting that NRTI, particularly stavudine, may induce insulin 
resistance by way of mitchondrial dysfunction [89].  
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Bone mineral density 
An increased prevalence of reduced bone mineral density has been reported 
among HIV-infected patients. A meta-analysis of cross-sectional studies reported 
an odds ratio of 6.4 for reduced bone mineral density (osteopenia and osteoporosis 
combined, defined as bone density less than respectively 1 and 2.5 standard 
deviations of the mean bone mineral density of a sex-matched, young, healthy 
population) and 3.7 for osteoporosis in HIV-infected patients compared to 
uninfected controls. The prevalence of decreased bone mineral density was 67% 
and of osteoporosis 15%[90]. Longitudinal studies have generally observed a 
decrease in bone mineral density after the initiation of cART in cART- naïve 
patients[15, 70, 91]. In contrast, prospective studies in cART experienced patients 
have shown either an increase in or stable bone mineral density over time[92-96], 
suggesting that bone mineral density may stabilize after an initial decline in the first 
period after the start of cART.  
The mechanisms for the reduced bone mineral density in HIV-infected patients 
have not been fully elucidated. HIV proteins have been shown to modulate 
osteoblast function and development [97], and may also affect 
osteoclastogenesis[98]. Persistent pro-inflammatory activation in HIV infection has 
been associated with disturbed bone formation and resorption, as has also been 
shown in other inflammatory diseases such as rheumatoid arthritis[99], and 
restoration of the bone remodelling process was observed after start of cART[100]. 
Other traditional risk factors that are frequently found in HIV- infected patients, 
including low body weight, hypogonadism and a high prevalence of smoking, may 
also play a role[101]. The contribution of antiretroviral drugs to reduced bone 
mineral density in HIV- infected patients is controversial. Different PI appear to 
have heterogeneous effects on osteoclast and osteoblast activity and 
differentiation[102, 103]. Cross-sectional studies have generally found a higher 
prevalence of decreased bone mineral density in patients using PI compared to PI 
naïve patients, although in most studies no adjustment was made for potential 
confounders such as severity of disease and duration of cART[90]. Prospective 
studies on bone mineral density comparing patients initiating first-line PI containing 
regimens with those initiating non-PI containing regimens have had conflicting 
results[91, 104, 105]. Two of these studies observed more pronounced loss of 
bone mineral density after 48 weeks in patients starting PI containing regimens 
compared with either triple NRTI [91], or efavirenz with 2 NRTI[105]. In contrast, 
during 96 weeks of follow-up, similar decreases in total bone mineral density 
occurred in patients starting either lopinavir/ritonavir or efavirenz –based 
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regimens[104]. Among the NRTI, zidovudine, lamivudine and didanosine have 
been shown to enhance osteoclastogenesis in vitro[106]. Tenofovir has been 
associated with renal phosphate wasting and osteomalacia[107]. In a prospective 
study, greater loss of bone mineral density in both the hip and lumbar spine was 
observed during 144 weeks of follow-up in patients initiating tenofovir compared to 
those starting stavudine, both in combination with lamivudine and efavirenz [70].  
Whether the observed decreased bone mineral density will eventually lead to a 
greater risk of osteoporotic fractures, especially in the growing group of elderly 
HIV-infected patients, remains to be determined. Among aging HIV-infected men, 
decreased bone mineral density, but not HIV infection itself, was associated with 
increased fracture risk[108]. In a recent large population-based study the fracture 
prevalence was found to be increased in HIV-infected patients compared to non-
infected patients[109]. 
 
 
Consequences of the metabolic effects of antiretroviral therapy 
 
Although currently the benefits of antiretroviral therapy with respect to mortality and 
morbidity clearly outweigh the risks, there is concern about the long-term effects of 
the described metabolic side effects both on individual well-being and on 
cardiovascular disease risk. 
 
Psychological impact of morphological changes 
A high prevalence of self-perceived body changes up to 64% has been reported in 
cross-sectional studies[110, 111], not necessarily corresponding with objective 
measures. These body changes may have enormous impact, due to stigma and 
prejudice, on self-esteem and may lead to severe psychological distress[110, 112, 
113]. Facial lipoatrophy is often seen as a visible marker of HIV disease and the 
worry that these changes would lead to unintentional disclosure of HIV status may 
lead to a narrowing of the patient’s social world, sometimes to social isolation. The 
self-evaluated quality of relationships with partners, friends and family has been 
shown to be inversely associated with the self-perception of peripheral fat 
loss[110]. Also, worries about body changes may lead to harmful health behavior 
such as non-adherence to medication[114].  
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Cardiovascular disease risk 
As several of the metabolic side effects described above are known risk factors for 
cardiovascular disease in the general population, concern has arisen that HIV-
infected patients are at increased risk for cardiovascular disease. Several studies 
indeed suggest that the incidence of cardiovascular events is elevated in HIV-
infected patients compared to HIV-uninfected populations, after adjustment for age 
and sex[115-117]. The Data Collection on Adverse Events of Anti-HIV Drugs 
(D:A:D), a large observational cohort trial, found that each year of exposure to 
cART was associated with a 26% relative increase in risk of myocardial infarction 
(adjusted relative rate per year of exposure)[118]. Comparing the effects of the 
different drug classes in this study, increased exposure to PI was associated with 
an increased risk of myocardial infarction, whereas no such association was 
observed for exposure to NNRTI[119]. The association between PI exposure and 
myocardial infarction risk was reduced when controlling for lipid levels, suggesting 
at least a partial link between the dyslipidemia induced by these drugs and the risk 
of cardiovascular disease[119]. As different drugs in the PI class have different 
effects on lipid profile and other metabolic effects, studies of individual drugs will 
eventually be necessary. Recently, the role of NRTI in the risk of myocardial 
infarction was also studied in this abovementioned cohort[120]. Interestingly and 
unexpectedly, current (but not cumulative) exposure to abacavir and to a lesser 
extent didanosine, but not to the thymidine analogues stavudine and zidovudine, 
was associated with an increased risk of myocardial infarction, and this risk was 
reversible upon discontinuation of the drugs[120]. As abacavir and didanosine, in 
contrast to the thymidine analogue NRTI, have not been associated with 
dyslipidemia and insulin resistance, and this increased risk remained after 
adjustment for these parameters and other cardiovascular risk factors not affected 
by antiretroviral therapy, these findings remain unexplained until now.  
Besides effects of antiretroviral drugs and their metabolic side effects, several other 
factors may contribute to the increased cardiovascular risk profile in HIV-infected 
patients, including traditional cardiovascular risk factors and HIV infection itself. In 
general, risk factors for cardiovascular disease in the general population are also 
associated with increased risk of cardiovascular disease in HIV-infected 
patients[118]. The prevalence of smoking is high in HIV-infected patients compared 
to the general population[47, 121]. Other traditional risk factors, such as 
dyslipidemia, may be influenced by HIV infection and various antiretroviral drugs, 
as outlined above. Whether HIV and/or cART are associated with hypertension 
remains to be determined, several studies have had conflicting results[122, 123]. 
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Recent findings also suggest that untreated HIV infection itself may increase the 
risk of cardiovascular disease. In the SMART trial, a study comparing CD4 cell 
guided interruption of cART (drug conservation strategy) with continuous cART, 
patients who interrupted cART had a greater risk of major cardiovascular events 
compared to those on continuous cART[124]. The drug conservation strategy 
resulted in a deterioration of the total to HDL cholesterol ratio. Also, recently an 
increase in interleukin-6 and D-dimer, markers of inflammation and coagulation, 
was described in patients interrupting cART in this study[125]. The increase in 
these markers correlated with increasing HIV-1 RNA levels and was strongly and 
independently associated with an increased risk of death, suggesting that 
inflammation and coagulation induced by HIV may contribute to this increased risk.  
 
 
Strategies to limit the metabolic complications of treatment for 
HIV infection 
 
Several strategies have been employed to attempt to limit metabolic side effects. 
Lifestyle interventions, pharmacologic treatment with lipid lowering drugs, 
metformin and thiazolidinediones, growth hormone and uridine, and surgical 
interventions have all been tried with in general small effects. Other options are the 
use of antiretroviral drug or drug class sparing regimens to prevent the occurrence 
of side effects ascribed to certain drugs or drug classes, and switching away from 
certain drugs or drug classes in an attempt to reverse (or prevent from 
deteriorating) already developed complications.  
 
Drug or drug class sparing initial regimens 
Few studies have evaluated the effects of NRTI class sparing regimens on body 
composition changes and other side effects. In a small pilot study, a double PI 
regimen of lopinavir/ritonavir with saquinavir led to a decrease in limb fat of 6% 
during 48 weeks, in contrast to an increase of 19% observed with a NRTI 
containing regimen of lopinavir/ritonavir with zidovudine/lamivudine[126]. Trunk fat 
increased similarly in both arms in this study. 
Two other studies compared thymidine analogue NRTI-sparing with thymidine 
analogue NRTI containing regimens in cART-naïve patients [70, 127]. In both, the 
thymidine analogue NRTI sparing regimen of tenofovir/lamivudine with efavirenz 
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was associated with significantly less lipoatrophy and smaller increases in total 
cholesterol and triglycerides after 144 weeks than the thymidine analogue NRTI 
containing regimens of zidovudine/lamivudine and efavirenz [127] and 
stavudine/lamivudine/efavirenz[70]. However, these studies were limited by the 
absence of baseline DEXA scans in one[127] and the lack of objective measures of 
body composition in the other[70]. 
Recently, the results of a large randomized trial of NRTI-, PI- and NNRTI sparing 
regimens were reported[24]. In this study, recovery of limb fat was greatest in the 
NRTI sparing regimen (consisting of lopinavir/ritonavir + efavirenz). From baseline 
to week 96, the median increase in limb fat as seen on DEXA was 0.05 kg in the 
efavirenz +2NRTI  group, 0.7 kg in the lopinavir-ritonavir +2NRTI group, and 1.15 
kg in the NRTI-sparing group (P<0.01 for each of the three pairwise comparisons). 
Clinical lipoatrophy was observed in 8/250 (3%) of patients in the efavirenz + 2 
NRTI group, 3/253 (1%) of patients in the lopinavir/ritonavir + 2 NRTI group and in 
none of the 250 patients in the NRTI sparing group (p<0.05 for the comparison 
between the lopinavir/ritonavir group and the NRTI sparing group). However, 
significantly more lipid abnormalities, especially hypertriglyceridemia, were seen in 
the NRTI sparing group[24].  
 
Switch strategies 
Various strategies have been investigated, including switching away from PI, 
replacing one PI with another with less side effects, and (thymidine analogue) NRTI 
substitution. Substituting abacavir for a PI has been shown to lead to 
improvements in some but not all aspects of insulin sensitivity[128, 129], and 
generally to decreased levels of total cholesterol and triglycerides without changes 
in HDL cholesterol[129-132]. Switching from a PI to a NNRTI has shown more 
variable results. Insulin sensitivity improved in two studies in patients switching 
from a PI to nevirapine[133, 134] and one study in which efavirenz was substituted 
for a PI[135], whereas no change in insulin sensitivity was observed in other 
studies switching from PI to NNRTI[136, 137]. Several studies have found 
improvements in lipid profile after switching from PI to efavirenz[135, 138] or 
nevirapine[133, 134, 138], mostly consisting of decreases in total cholesterol and 
triglycerides, and an increase in HDL after switch to nevirapine[134]. Other trials 
however have observed no improvements in lipid profile after switching from PI to 
NNRTI[136, 139, 140]. 
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Evaluating the effect of switch strategies on fat distribution is difficult as methods to 
determine abnormalities differ considerably between studies. In general, however, 
looking at studies using objective measures of body composition, substitution of a 
PI with abacavir or a NNRTI did not lead to an improvement in lipoatrophy[139, 
141-143]. In one of these studies, further peripheral fat loss was even observed 
after switching away from PI[143]. Also, discontinuation of a PI did not appear to 
reduce visceral fat accumulation in most studies[134, 143-145]. 
 
As the PI atazanavir has been shown to have no significant effects on lipid profile, 
insulin sensitivity parameters and fat distribution in cART-naïve patients [58, 59, 
146, 147], several studies have evaluated the effects of a switch strategy from 
other PI to atazanavir. Decreases in total cholesterol and triglyceride levels were 
generally observed[148-152]. One study also noted an improvement in insulin 
sensitivity[153], and subjective regression of fat accumulation was noted in one 
case report[154]. 
 
Several studies have evaluated the effects of replacing thymidine analogue NRTI 
with abacavir or tenofovir. No improvement in insulin sensitivity (measured by 
fasting insulin and glucose levels) was observed after switching to either abacavir 
or tenofovir[73, 155]. However, an improvement in lipid profile was seen in several 
studies in which a thymidine analogue NRTI was replaced by tenofovir, but not 
after switch to abacavir[72-75, 155]. Thymidine analogue NRTI substitution with 
abacavir or tenofovir leads to modest but significant increases in peripheral fat, in 
some studies accompanied by increases in total fat and trunk fat[72, 73, 155, 156]. 
 
 
Brief outline of the thesis 
 
This thesis focuses on two potential strategies to limit the metabolic complications 
of treatment for HIV infection. First, the metabolic effects of a thymidine analogue 
NRTI sparing first-line therapy are explored in the MEDICLAS (Metabolic Effects of 
Different CLasses of AntiretroviralS) study, a randomized clinical trial of a planned 
36 months duration comparing two first-line cART regimens (nevirapine+ 
lopinavir/ritonavir versus zidovudine/lamivudine+ lopinavir/ritonavir). Second, the 
effects of switching to atazanavir- based regimens are evaluated in treatment -
experienced patients in an observational cohort study (ATHENA cohort).  
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In chapter 2, the effects of a thymidine analogue NRTI sparing first line therapy on 
body composition and lipid profile are compared with those of a thymidine 
analogue NRTI containing regimen within the context of a randomized clinical trial 
(MEDICLAS). 
 
In chapters 3 and 4, we describe the short term and longer term effects of the 
thymidine analogue NRTI sparing first line therapy compared to the thymidine 
analogue NRTI containing regimen on insulin sensitivity, evaluated by serial 
hyperinsulinemic euglycemic clamps, the gold standard of measurement of glucose 
metabolism (MEDICLAS). 
 
In chapter 5, we assess the development of changes in bone mineral density after 
initiation of cART, comparing a thymidine analogue NRTI sparing therapy with a 
thymidine analogue NRTI containing regimen (MEDICLAS). 
 
Chapters 6 and 7 are dedicated to cardiovascular disease in patients with HIV-
infection, evaluated by carotid artery intima-media thickness (C-IMT), a surrogate 
measure of atherosclerosis, and arterial stiffness, a marker of cardiovascular risk. 
We first explored the contribution of HIV infection itself, cART and lipodystrophy to 
these markers in a cross-sectional study performed within the setting of a single 
HIV outpatient clinic. Subsequently, we studied the development of vascular 
abnormalities after initiation of cART and the contribution of different drug classes 
by performing sequential measurements of C-IMT, arterial stiffness and 
biochemical markers of endothelial activation in cART naïve patients after start of 
therapy, comparing a thymidine analogue NRTI sparing therapy with a thymidine 
analogue NRTI containing regimen (MEDICLAS). 
 
In chapter 8, we describe the changes in lipid profile, and the factors influencing 
the extent of these changes, in cART-experienced patients with sustained 
virological suppression switching to atazanavir, compared to patients not switching 
to atazanavir, in an observational cohort study (ATHENA). 
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Abstract 
 
Background 
Lipoatrophy is known to be associated with stavudine treatment, but it is less clear 
if this serious side effect is also related to other NRTI’s like zidovudine. We 
prospectively evaluated body composition and metabolic changes in a randomized 
multicenter trial comparing zidovudine/lamivudine (ZDV/3TC)-containing versus 
ZDV/3TC-sparing first-line antiretroviral therapy (ART).  
 
Methods 
50 ART-naïve men were randomized to lopinavir/ritonavir (LPV/r, 400/100mg 
bid)+ZDV/3TC or LPV/r(533/133mg bid)+nevirapine (NVP). CT, DEXA and lipid 
profile were assessed before and after 3, 12, 24 months of ART.  
 
Results 
In the ZDV/3TC/LPV/r group, from 3 months onward limb fat decreased 
progressively by 684±293 grams up to 24 months whereas abdominal fat 
increased, but exclusively in the visceral compartment (+21.9±8.1 cm2). In contrast, 
in the NVP/LPV/r group, a generalized increase in fat mass was observed. After 24 
months no significant differences in HDL and total/HDL ratio were found between 
treatment groups, but fasting total and LDL cholesterol levels were higher in the 
NVP/LPV/r group (6.1±0.2 vs 5.3±0.2 and 3.6±0.1 vs 2.8±0.1 mmol/l respectively). 
Virologic response (77 vs 80 % HIV-RNA <50 cp/ml) and safety were otherwise 
comparable in both groups. 
 
Conclusions 
ZDV/3TC/LPV/r, but not NVP/LPV/r in ART-naïve patients, is associated with 
lipoatrophy and greater relative intraabdominal lipohypertrophy, suggesting that 
ZDV/3TC contributes to both these features of lipodystrophy. These findings 
support to no longer consider ZDV/3TC as one of the preferred possible 
components of first-line ART where alternative treatments are available. 
(ClinicalTrials.gov number: NCT 00122226, http://www.clinicaltrials.gov)
Chapter 2 
37 
Introduction 
 
Lipodystrophy is a common and serious problem associated with HIV infection and 
its treatment[1]. The alterations in body fat, consisting of lipoatrophy, the loss of 
subcutaneous fat from arms, legs, buttocks and face, and fat accumulation in the 
intraabdominal region, neck or trunk, are associated with metabolic derangements 
including hyperlipidemia and insulin resistance, which may contribute to increased 
cardiovascular risk[1]. Furthermore, they may be stigmatizing and lead to 
considerable psychological distress[2].  
Stavudine, one of the thymidine analogue (TA) nucleoside reverse transcriptase 
inhibitors (NRTI), has been associated with a substantial risk for lipoatrophy 
development [3, 4], and its use in antiretroviral-naïve patients is no longer 
recommended. Less evidence is available concerning the effect on lipoatrophy 
development of the TA-NRTI zidovudine as part of initial treatment for HIV. One 
trial showed that the combination of zidovudine and lamivudine (ZDV/3TC) resulted 
in less limb fat loss than stavudine in combination with didanosine[5], when used 
as part of combination antiretroviral therapy (cART).   
To explore the role of NRTI in more detail, one strategy is to evaluate alterations of 
body fat distribution and other metabolic markers in NRTI sparing regimens. We 
therefore performed a randomized trial comparing the effects of a TA-NRTI sparing 
regimen composed of nevirapine with lopinavir/ritonavir with those of a TA-NRTI 
containing regimen of ZDV/3TC with lopinavir/ritonavir in prior cART naïve patients. 
We hypothesized that patients using ZDV/3TC would develop limb fat loss, in 
contrast to those in the TA-NRTI sparing group. We currently report the results of 
the planned primary analysis after 24 months of follow-up. 
 
 
Patients and methods 
 
Study design and patients  
The MEDICLAS (Metabolic Effects of DIfferent CLasses of AntiretroviralS) trial is a 
multicenter, multinational, single-blinded, randomized trial comparing the TA NRTI-
containing regimen of zidovudine/lamivudine (ZDV/3TC, 300/150 mg bd) + 
lopinavir/ritonavir (LPV/r, 400/100 mg capsules bd) with the TA NRTI-sparing 
regimen of nevirapine (NVP, 200 mg bd, following a 2-week 200 mg od lead-in) + 
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LPV/r (533/133 mg bd). To compensate for any increased LPV/r clearance 
resulting from NVP-associated hepatic enzyme induction, an increased dose of 
LPV/r was used in combination with NVP to aim for comparable therapeutic LPV 
plasma concentrations in both trial arms. Patients were included between February 
2003 and June 2005, the complete 24 month follow-up ended in June 2007. 
Eligible patients were antiretroviral-naïve HIV-1-infected men, 18-70 years old, with 
an indication to start cART according to international and national guidelines. 
Excluded were subjects with extreme obesity (body mass index (BMI)>35 kilogram 
(kg)/m2), diabetes mellitus, a history of hyperlipidemia, or use of lipid lowering 
drugs, nandrolone or testosterone. Patients were recruited from HIV treatment 
centers in the Netherlands, Spain, Finland and the United Kingdom. The study was 
approved by the ethics committees of all participating centers, and each patient 
provided written informed consent. Primary outcome measures were changes in 
body composition, and metabolic abnormalities, secondary outcome measures 
were virologic and immunologic efficacy and overall safety. 
 
Randomisation  
At the central study coördinating center a treatment allocation sequence (1:1 for 
ZVD/3TC/LPV/r and NVP/LPV/r) was generated using the minimisation variable 
BMI (≤25 kg/m2 versus >25 kg/m2).  
 
Assessments 
Fat distribution, fasting lipid profile and markers of glucose metabolism were 
assessed at baseline and 3, 12, and 24 months following start of treatment. These 
assessments were performed by blinded investigators in the Hospital Clinic 
Barcelona for Spanish participants, and in the VU University Medical Center and 
the Academic Medical Center in Amsterdam for all other participants. Assessments 
for routine patient care were performed at the participating hospitals by different 
physicians who were not blinded to treatment allocation. 
 
Body composition 
We measured BMI in kg/m2. Waist-to-hip ratio was calculated from waist 
circumference, measured midway between the lowest rib margin and the iliac crest, 
and hip circumference, measured at the widest levels over the greater trochanters. 
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Skinfoldthickness using a skinfold caliper were measured at the level of the m. 
biceps brachii, m. triceps brachii (both halfway the upper arm), subscapular (just 
below the inferior angle of the scapula) and supra-iliacal (just above the iliac crest, 
in the midaxillary line), all on the non-dominant side of the body.  
Arm circumference was measured halfway between the acromion and olecranon in 
the non-dominant arm.  
Fat weight was measured using a body impedance analyzer (STA BIA, Akern 
Bioresearch, Italy), and fat percentage was calculated from fat weight and total 
weight. These measurements were performed by a single blinded investigator in 
the Netherlands, and another in Spain. 
Limb fat, trunk fat, and lean weight were quantified by DEXA (Hologic QDR-
4500W, software version whole body v8.26A:5). A standardized single slice 
abdominal CT-scan was performed from which the area of visceral (VAT) 
subcutaneous (SAT), and total adipose tissue (TAT) was determined. CT scans 
were evaluated at the level of the third (L3, in the Netherlands) or fourth (L4, in 
Spain) lumbar vertebra. Results are shown for the pooled L3 and L4 scans, as 
changes in VAT, SAT and TAT over time at levels L3 and L4 were highly correlated 
(in a subset of patients in whom CT scans were performed at both levels at 
consecutive visits), and results of the analyses after exclusion of L4 scans were 
comparable to those of all scans combined. 
At all visits lipodystrophy scores were calculated according to the complete model 
of the international lipodystrophy case definition[6]. 
 
Lipid profile and markers of glucose metabolism 
Fasting lipid levels included total, high-density (HDL) and low-density lipoprotein 
(LDL) cholesterol and triglycerides. LDL levels were calculated with the Friedewald 
formula, if triglyceride values were < 4.52 mmol/l. Insulin sensitivity was estimated 
by the homeostasis model assessment of insulin resistance (HOMA), calculated as 
(fasting insulin (µU/ml) x fasting glucose (mmol/l))/22.5.  
 
Virology, immunology and safety 
Plasma HIV-1 RNA measurements (lower limit of quantification 50 copies/mL), 
CD4 cells, routine hematology and chemistry were monitored at baseline, after 1 
and 3 months of treatment, and every three months thereafter. The Adult AIDS 
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Clinical Trial Group (ACTG) table for grading severity of adverse experiences was 
used for reporting of clinical and laboratory adverse events[7].  
LPV concentration was analysed centrally by validated HPLC using diode array 
detection: coefficient of variation 1.6% at 1.98 mg/L and 1.7% at 7.96 mg/L; 
detection limit 0.008 mg/L. LPV concentration ratios were calculated by dividing the 
measured concentration by the expected concentration from a reference curve[8].  
 
Statistical analysis  
Analyses were by intention-to-treat, including all randomized patients who received 
at least one dose of allocated treatment. Within group changes, between-group 
differences in overall course and between-group differences at study visits were 
analyzed by mixed model repeated measures analysis with correction for 
differences in baseline values. Data are presented as estimated means ± standard 
error of the mean. Data that were not analyzed longitudinally were compared 
between groups using Mann Whitney U tests and Chi square/ Fisher exact tests 
(where applicable). Measures of body composition were correlated using Pearson 
correlation. Alpha<0.05 was considered statistically significant. SAS version 9.1 
(SAS Institute, Cary, North Carolina, USA)(for the longitudinal analysis) and SPSS 
statistical software version 15.0 (SPSS Inc, Chicago, IL) were used for the 
analyses. 
 
 
Results 
 
Patient characteristics 
Fifty patients were included between February 2003 and June 2005; 23 were 
randomly assigned to ZDV/3TC/LPV/r and 27 to NVP/LPV/r. Two patients, one in 
each group, did not start allocated therapy and were not included in the analysis 
(Figure 1). Eight patients, 4 in each group, whose data were included in the intent-
to-treat analysis, prematurely discontinued the study (4 were lost to follow-up, 3 
withdrew consent and one patient died at home, presumably due to an acute 
myocardial infarction). The groups had comparable baseline demographic and HIV 
disease characteristics (Table 1).  
Antiretroviral therapy was modified in eight patients. In the ZDV/3TC/LPV/r group, 
one patient switched from ZDV to tenofovir after 3 months for anemia, one patient 
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switched to tenofovir/lamivudine/efavirenz after 4 months for anemia and 
hypercholesterolemia and one patient switched from LPV/r to NVP for 
hypercholesterolemia after 17 months. In the NVP/LPV/r group, two patients 
switched to ZDV/3TC/NVP, one after 3 months because of diarrhea and one after 
24 months at his own request. In three other patients NVP was replaced by 
efavirenz because of hepatotoxicity and/ or rash after 1, 2 and 5 months, 
respectively. 
 
Body composition (Figure 2, Table 2) 
Body composition at baseline was comparable between groups. 
Body weight remained stable during 24 months in the ZDV/3TC/LPV/r group, 
whereas it increased in the NVP/LPV/r group. Lean weight remained stable in both 
groups. The changes in fat mass showed significantly different patterns between 
the groups. Limb fat remained stable during the first three months in the 
ZDV/3TC/LPV/r group but progressively declined thereafter, with a total loss of 
684±293 grams from 3 to 24 months (p=0.02). Total fat remained unchanged in 
this group, resulting in a significant decrease of the limb to total fat ratio 
(0.47±0.008 to 0.44±0.008; p=0.0015). In contrast, in the NVP/LPV/r group, limb fat 
and total fat both increased, with no change in the limb to total fat ratio. After 24 
months, limb fat in the ZDV/3TC/LPV/r group was 1223±318 gram lower than in the 
NVP/LPV/r group (p=0.0002). 
Trunk fat and TAT increased in both groups during follow-up. In the 
ZDV/3TC/LPV/r group VAT increased (+21.9±8.1 cm2 over 24 months (p=0.008)), 
while SAT remained unchanged. In contrast, in the NVP/LPV/r group, SAT and 
VAT both increased after the first 3 months. As a result, the ratio of VAT to SAT 
increased significantly in the ZDV/3TC/LPV/r group, but remained unchanged in 
the NVP/LPV/r group, resulting in a significant difference between groups after 24 
months. 
Of the 40 patients with complete lipodystrophy scores at 24 months, 3/18 (16.7%) 
in the ZDV/3TC/LPV/r group and 0/22 (0%) in the NVP/LPV/r group had 
lipodystrophy according to the international case definition (Fisher exact p=0.083). 
 
Anthropometry and BIA findings were consistent with CT and DEXA results (Figure 
3, Table 2). Biceps skinfold thickness decreased by 3.0±0.9 mm (p=0.0008) and 
triceps by 4.0±1.2 mm (p=0.0007) in the ZDV/3TC/LPV/r group, but remained 
stable (biceps) or increased (triceps) in the NVP/LPV/r group. After 24 months, 
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patients in the ZDV/3TC/LPV/r group had 3.8±1.0 mm (p=0.0002) lower biceps and 
6.4±1.3 mm (p<0.0001) lower triceps skinfold thickness compared to those in the 
NVP/LPV/r group. Arm circumference did not change in the ZDV/3TC/LPV/r group 
but increased in the NVP/LPV/r group. Changes in biceps and triceps skinfolds and 
arm circumference were significantly correlated with changes in limb fat (correlation 
coefficients 0.21, 0.39 and 0.48, respectively, p=0.007, 0.007 and <0.0001). Hip 
circumference increased by 1.9±0.6 cm (p=0.0019) in the NVP/LPV/r group, but 
remained stable in the ZDV/3TC/LPV/r group, whereas waist circumference 
increased in both groups (+2.0±0.9 cm (p=0.03) and +2.6±0.8 cm (p=0.002) for the 
ZDV/3TC/LPV/r and NVP/LPV/r groups respectively). This resulted in a significant 
increase in the waist-to-hip ratio in the ZDV/3TC/LPV/r group, and no change in the 
NVP/LPV/r group. Changes in waist circumference were correlated with changes in 
TAT and VAT (correlation coefficients 0.38 and 0.60, p<0.0001). The suprailiac 
skinfold remained unchanged in the ZDV/3TC/LPV/r group, but increased in the 
NVP/LPV/r group (+3.0±1.3 cm, p=0.03), and changes in suprailiac skinfold 
correlated with changes in SAT (correlation coefficient 0.50, p<0.001). 
 
Lipid profile (Table 2) 
Total cholesterol increased significantly in both groups (+23.2±5.8% in the 
ZDV/3TC/LPV/r group compared to +36.5±5.2% in the NVP/LPV/r group; 
difference between groups 13.3±7.8%, p=0.09). HDL cholesterol increased 
significantly by 32.8±7.4% in the ZDV/3TC/LPV/r group and by 38.8±6.6% in the 
NVP/LPV/r group (difference between groups 6.0±9.9%, p=0.5). The total over 
HDL cholesterol ratio did not change significantly over time in either of the groups. 
Whereas LDL cholesterol did not increase in the ZDV/3TC/LPV/r group 
(+11.5±7.4%, p=0.13),  a significant rise by 31.1±6.4% was observed in the 
NVP/LPV/r group, difference between groups 19.6±9.8%, p=0.05). Triglycerides 
increased in both groups (+108±30% and +81±27% for the ZDV/3TC/LPV/r and 
NVP/LPV/r group, respectively), with no significant difference between groups.  
 
Markers of glucose metabolism (Table 2) 
There were no significant overall changes in fasting glucose, insulin and HOMA in 
either of the treatment groups, with no overall difference between groups. 
 
 
Chapter 2 
43 
Virologic and immunologic parameters and lopinavir concentrations 
(Table 2) 
Patients in both groups had similar immunologic and virologic responses to cART. 
The median CD4 cell increase over 24 months was 280 (205-455) and 308 (191-
410) x 106 cells/l in the ZDV/3TC/LPV/r and NVP/LPV/r group, respectively. At 24 
months, 17/22 (77%) of the patients in the ZDV/3TC/LPV/r group and 21/26 (80%) 
in the NVP/LPV/r group had a plasma HIV-RNA below 50 copies/ml. After 24 
months there was a trend for the LPV concentration to be greater in the NVP/LPV/r 
group (8.0 (4.0-9.3) mg/l compared with 5.5 (3.8-6.9) mg/l for the ZDV/3TC/LPV/r 
group (p=0.065).  
 
Adverse events 
The proportion of patients who developed grade 3 and 4 adverse events was 
similar in both groups (10/22 (45.8%) in the ZDV/3TC/LPV/r group and 14/26 
(54.2%) in the NVP/LPV/r group, p=0.77). The most commonly observed adverse 
events were hyperlipidemia (4/22 (18%) in the ZDV/3TC/LPV/r group and 6/26 
(23%) in the NVP/LPV/r group) and gastrointestinal complaints (4/22 (18%) in the 
ZDV/3TC/LPV/r group and 5/26 (19%) in the NVP/LPV/r group).  
 
 
Discussion 
 
The main finding from this trial is that ZDV/3TC contributed to the development of 
limb fat atrophy in HIV-1-infected men not previously exposed to cART. Whereas 
limb fat after 24 months had increased by 851±255 grams in patients allocated to 
NVP/LPV/r, a progressive loss of limb fat commencing after 3 months and reaching 
a decline of 684±292 grams by 24 months was observed in those randomized to 
ZDV/3TC/LPV/r.  Moreover, while patients randomized to NVP/LPV/r demonstrated 
a generalized increase in fat mass, including both subcutaneous and 
intraabdominal compartments, patients assigned to ZDV/3TC/LPV/r experienced 
selective gain of visceral adipose tissue without any change in the subcutaneous 
abdominal compartment, which is characteristic for HIV-associated lipodystrophy. 
Consistent with this observation, lipodystrophy according to the International Case 
Definition was present in 3/18 patients allocated to ZDV/3TC/LPV/r after 24 months 
follow-up, but in none of the 22 evaluable patients allocated to NVP/LPV/r. 
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Although neither designed nor sufficiently powered to allow a formal comparison of 
efficacy, our study demonstrated excellent and comparable virological and 
immunological efficacy for both regimens, consistent with other studies assessing 
LPV/r in combination with a NNRTI in naïve patients [9-11]. 
The rate of limb fat loss in patients on ZDV/3TC-containing therapy in our study 
seems to be of a similar magnitude to what has been reported previously from two 
randomized trials and one observational cohort study in previously treatment-naïve 
individuals[5, 12, 13]. One should be cautious however in directly comparing the 
changes in limb fat in those studies with ours, given the differences in both the 
frequency and timepoints at which DEXA scans were performed in each of the 
studies. The role of ZDV in lipoatrophy development is also supported by a study in 
which patients on ZDV-containing regimens replaced ZDV with either tenofovir or 
abacavir[14], and one in which patients were randomized to either replace ZDV by 
tenofovir, or to continue their existing ZDV-containing regimen[15]. 
Whether LPV/r may also have contributed to lipoatrophy, similar to what has been 
shown for nelfinavir[5], cannot be ruled out given that patients in both groups 
received LPV/r. However, recent results from a randomized trial in which 
antiretroviral naive subjects treated with dual NRTI’s plus LPV/r exhibited 
significantly less loss of limb fat than those treated with two NRTI’s plus efavirenz 
would argue against this[16]. 
Both treatments in our study resulted in similar degrees of intraabdominal fat gain. 
This may represent an improvement in patients’ general health as a result from 
suppressing HIV, although a contribution from the use of LPV/r cannot be ruled 
out. Given that all patients received LPV/r and after 24 months there was a trend 
for patients on ZDV/3TC to have gained more intraabdominal fat, a contribution 
from these NRTI to this feature of lipodystrophy can also not be discarded. The 
finding that visceral fat accumulation in patients on ZDV/3TC/LPV/r was observed 
in the context of stable SAT, whereas in patients on NVP/LPV/r SAT increased in 
parallel with VAT would seem to support this.   
 
In contrast to the advantages with regard to body composition, the TA sparing 
regimen of NVP/LPV/r did not have an unequivocal favorable impact on the lipid 
profile. Compared to patients treated with ZDV/3TC/LPV/r, more patients 
developed high total and LDL cholesterol levels according to NCEP criteria. 
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However, due to the rise in HDL cholesterol, the total/HDL cholesterol ratio, a 
powerful predictor of cardiovascular risk[17], did not increase over time. Our 
findings are consistent with the dyslipidaemia described in patients switching to 
regimens of LPV/r with efavirenz[18], but contrast with results from another small 
trial which also included a regimen of NVP/LPV/r in treatment-naive subjects[10]. 
Adjustment for differences in LPV levels between treatment groups did not change 
the results of the analysis, suggesting that this is not a likely explanation for the 
higher total- and LDL-cholesterol levels found in the NVP/LPV/r group. Differences 
in ritonavir exposure may have influenced the results, but plasma (or intracellular) 
ritonavir concentrations levels were not measured.  HDL levels increased more in 
the NVP/LPV/r group than in the ZDV/3TC/LPV/r group, but this difference did not 
reach statistical significance, other than what may have been expected from prior 
studies[19]. A possible explanation for this is that our sample size was only 
sufficient to demonstrate a statistically significant difference between groups if this 
was 33% (or 0.29 mmol/l) or greater.  
 
Several changes in anthropometric measures of body composition showed a good 
correlation with changes objectively determined by DEXA and CT. This suggests 
that consecutive measurements of skinfold thicknesses in the upper arm and of the 
waist–to-hip ratio, may be able to reliably detect the onset of limb fat loss and 
abdominal fat accumulation. This could potentially be particularly relevant in 
resource limited settings, where it could guide clinicians in the earlier detection of 
fat distribution changes and timely modification of cART to try and prevent further 
deterioration. 
 
As novel antiretroviral drugs are being introduced, alternative TA-sparing strategies 
become feasible, including regimens employing non-TA NRTI, PI – NNRTI 
combinations with other PI than LPV/r, and also NRTI sparing regimens 
incorporating CCR5- and integrase inhibitors. Long term prospective evaluation of 
such alternative treatment strategies incorporating assessments of body 
composition and metabolic effects may identify first-line regimens which lack 
detrimental effects on both body composition and lipid and glucose metabolism.  
 
In conclusion, treatment with ZDV/3TC/LPV/r, in contrast to NVP/LPV/r, during 24 
months in cART-naïve men was associated with significant limb fat loss and 
visceral but not subcutaneous abdominal fat accumulation. This adds to the 
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evidence to remove ZDV/3TC from the list of preferred components of first-line 
antiretroviral regimens.  
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Table 1. Baseline characteristics of the study population.   
 
 ZDV/3TC/LPV/r 
(n=22) 
NVP/LPV/r 
(n=26) 
Age (years) 38 (35-43) 43 (35-52) 
 
Ethnic group 
Black 
Caucasian 
Hispanic 
Other 
 
1 (4.5%) 
19 (86.4%) 
0 (0%) 
2 (9.1%) 
 
2 (7.7%) 
20 (76.9%) 
2 (7.7%) 
2 (7.7%) 
 
Mode of infection 
Heterosexual 
Heterosexual/MSM 
MSM 
Unknown 
 
2 (9.1%) 
0 (0%) 
20 (90.9%) 
0 (0%) 
 
3 (11.5%) 
1 (3.8%) 
21 (80.8%) 
1 (3.8%) 
 
CDC category 
A 
B 
C 
 
14 (63.6%) 
3 (13.6%) 
5 (22.7%) 
 
16 (61.5%) 
6 (23.1%) 
4 (15.4%) 
   
CD4 cell count (106/l) 225 (170-280) 200 (120-360) 
HIV-RNA (log 10 copies/ml) 5.1 (5.0-5.3) 4.9 (4.6-5.3) 
 
Shown are median (interquartile range) or number (percentage). 
ZDV/3TC/LPV/r zidovudine/lamivudine/ lopinavir/ritonavir.  
NVP/LPV/r nevirapine/lopinavir/ritonavir.  
MSM men who have sex with men. 
CDC Centers for Disease Control. 
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Table 2a. Body composition, lipid profile, insulin sensitivity, virology/immunology and 
lopinavir levels.  
 
ZDV/3TC/LPV/r  
Mo 0 Mo 3 Mo 12 Mo 24 
CT/Dexa     
Total arm fat (gram)† 1756±82 1909±88* 1715±85 1680±88*$ 
Total leg fat (gram)† 4590±160 4750±172 4769±165 4295±172*$ 
Trunk fat (gram) 7522±255 7527±274 8237±267 8271±274#$ 
Total fat (gram)† 13877±425 14194±456 14751±446 14254±457* 
Lean body mass (gram) 53369±421 53179±440 53842±424 53897±430 
TAT (cm2) 218.7±9.8 208.6±10.8 230.2±11.0 244.7±10.8#$ 
Anthropometry     
Weight (kg) 74.6±0.7 74.7±0.7 75.9±0.7 75.6±0.7 
Skinfold subscapular (mm) 20.2±1.1 21.6±1.2 21.0±1.2 20.3±1.2 
Waist circumference (cm) 87.7±0.7 88.0±0.7 89.6±0.7 89.6±0.7# 
Hip circumference (cm) † 95.9±0.5 95.7±0.5 96.5±0.5* 96.1±0.5* 
Arm circumference (cm) 29.1±0.3 29.1±0.3 29.5±0.3 29.3±0.3 
BIA fat percentage (%) 18.6±0.6 18.4±0.6 18.4±0.6 18.1±0.6 
Lipid profile (fasting)     
Total cholesterol (mmol/l)† 4.4±0.2 5.3±0.2* 5.4±0.2 5.3±0.2*# 
HDL cholesterol (mmol/l) 1.1±0.05 1.2±0.05 1.4±0.05 1.4±0.05#$ 
LDL cholesterol (mmol/l) 2.7±0.1 2.9±0.1 2.8±0.1 2.8±0.1 
Total/HDL cholesterol  4.3±0.2 4.5±0.2 4.3±0.2 4.2±0.2 
Triglycerides (mmol/l) 1.4±0.3 2.8±0.4 3.2±0.4 2.8±0.4# 
Apolipoprotein A (g/l) 1.0±0.04 1.2±0.04 1.2±0.04 1.4±0.05#$ 
Apolipoprotein B (g/l) 0.9±0.04 1.0±0.05 1.0±0.05* 1.1±0.05# 
Insulin sensitivity (fasting)     
Glucose (mmol/l) 5.1±0.1 4.9±0.1 5.0±0.1 4.9±0.1 
Insulin (pmol/l) 57±6.8 52±7.3 60±7.4 54±7.5 
HOMA 1.9±0.2 1.6±0.2 1.8±0.2 1.7±0.2 
Virology/immunology     
CD4 cell count (x 106/l) 225 (170-280) 344 (250-440) 428 (360-557) 502 (385-685) 
HIV-RNA (log 10 copies/ml) 5.1 (5.0-5.3) 2.1 (1.7-2.5) 1.7 (1.7-1.7) 1.7 (1.7-1.7) 
Lopinavir levels     
Lopinavir concentration (mg/l)  5.2 (3.1-6.9) 5.2 (3.7-6.6) 5.5 (3.8-6.9) 
Lopinavir concentration ratio  1.2 (0.8-1.8) 1.2 (0.8-1.5) 1.0 (0.8-1.6) 
 
Shown are estimated means± standard error of the mean (for variables included in the 
longitudinal analysis) or median (interquartile range) (for other variables).  
 
ZDV/3TC/LPV/r zidovudine/lamivudine/ lopinavir/ritonavir.  
NVP/LPV/r nevirapine/lopinavir/ritonavir.  
VAT visceral adipose tissue. SAT subcutaneous adipose tissue. TAT total adipose tissue. 
BIA body impedance analysis. HDL high density lipoprotein. 
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Table 2b. Body composition, lipid profile, insulin sensitivity, virology/immunology and 
lopinavir levels. 
 
NVP/LPV/r  
Mo 0 Mo 3 Mo 12 Mo 24 
CT/Dexa     
Total arm fat (gram)† 1756±74 1590±77 1811±77 1918±79$ 
Total leg fat (gram)† 4588±144 4677±149 5203±149 5275±155#$ 
Trunk fat (gram) 7492±229 6988±238 8245±238 8438±247#$ 
Total fat (gram)† 13847±381 13265±396 15269±396 15643±412#$ 
Lean body mass (gram) 53404±431 54431±453 54285±453 53943±465 
TAT (cm2) 218.6±9.2 206.3±9.5 240.3±9.5 252.4±9.9#$ 
Anthropometry     
Weight (kg) 74.6±0.6 74.9±0.6 76.9±0.6 77.2±0.7#$ 
Skinfold subscapular (mm) 20.2±1.0 20.9±1.1 22.7±1.1 20.8±1.1 
Waist circumference (cm) 87.7±0.6 88.0±0.6 90.4±0.6 90.2±0.7#$ 
Hip circumference (cm) † 95.9±0.5 96.2±0.5 98.0±0.5 97.8±0.5#$ 
Arm circumference (cm) 29.0±0.3 29.2±0.3 30.0±0.3 30.0±0.3# 
BIA fat percentage (%) 18.6±0.5 18.2±0.6 19.7±0.6 19.7±0.6$ 
Lipid profile (fasting)     
Total cholesterol (mmol/l)† 4.5±0.2 5.8±0.2 5.9±0.2 6.1±0.2# 
HDL cholesterol (mmol/l) 1.1±0.05 1.4±0.05 1.4±0.05 1.4±0.05# 
LDL cholesterol (mmol/l) 2.7±0.1 3.2±0.1 3.1±0.1 3.6±0.1#$ 
Total/HDL cholesterol  4.3±0.2 4.5±0.2 4.7±0.2 4.4±0.2 
Triglycerides (mmol/l) 1.4±0.3 2.7±0.3 3.2±0.3 2.4±0.3# 
Apolipoprotein A (g/l) 1.1±0.04 1.2±0.04 1.3±0.04 1.4±0.04#$ 
Apolipoprotein B (g/l) 0.9±0.04 1.1±0.05 1.2±0.04 1.2±0.05# 
Insulin sensitivity (fasting)     
Glucose (mmol/l) 5.0±0.1 5.0±0.1 5.1±0.1 5.1±0.1 
Insulin (pmol/l) 61±6.3 45±7.0 51±6.8 71±7.0 
HOMA 1.9±0.2 1.5±0.2 1.7±0.2 2.3±0.2 
Virology/immunology     
CD4 cell count (x 106/l) 200 (120-360) 315 (210-520) 370 (284-606) 485 (340-625) 
HIV-RNA (log 10 copies/ml) 4.9 (4.6-5.3) 1.7 (1.7-2.3) 1.7 (1.7-1.7) 1.7 (1.7-1.7) 
Lopinavir levels     
Lopinavir concentration (mg/l)  6.1 (3.7-6.9) 6.3 (5.3-6.9) 8.0 (4.0-9.3) 
Lopinavir concentration ratio  1.2 (1.0-1.4) 1.4 (1.0-1.6) 1.6 (1.1-2.1) 
 
LDL low density lipoprotein. HOMA homeostasis model assessment of insulin resistance. 
*p < 0.05 between groups at each timepoint 
† p < 0.05 overall comparison between groups over time 
# p < 0.05 within group 0-24 months 
$ p < 0.05 within group 3-24 months 
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Figure 1. Patient disposition 
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 * p<0.05 between groups at visit. † p<0.05 overall difference between groups. 
Figure 2. Body composition by Dexa and CT. 
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Figure 3  Body composition by anthropometry. 
Shown are estimated means ± standard error of the mean (mixed model repeated 
measures analysis with correction for differences in baseline values).  
ZDV/3TC/LPV/r zidovudine/lamivudine/lopinavir/ritonavir.  
NVP/LPV/r nevirapine/lopinavir/ritonavir. 
 * p<0.05 between groups at visit. † p<0.05 overall difference between groups 
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Abstract 
 
Objective 
Patients with antiretroviral therapy (ART)-associated lipodystrophy frequently have 
disturbances in glucose metabolism associated with insulin resistance. It is 
unknown whether changes in body composition are necessary for the development 
of these disturbances in ART-naïve patients starting treatment with different 
combination ART regimens. 
 
Design 
Prospective randomized clinical trial.  
 
Methods 
Glucose metabolism and body composition were assessed before and after three 
months of ART in HIV-1+, ART-naïve men comparing a NRTI-containing 
(lopinavir/ritonavir+zidovudine/lamivudine (LPV/r+AZT/3TC)) (n=11) with a NRTI-
sparing regimen (lopinavir/ritonavir+nevirapine (LPV/r+NVP)) (n=9). Glucose 
disposal, glucose production and lipolysis were measured after an overnight-fast 
and during a hyperinsulinemic-euglycemic clamp using stable isotopes. Body 
composition was assessed by CT and DEXA.  
 
Results 
Body composition had not changed significantly after three months of 
LPV/r+AZT/3TC treatment. Insulin-mediated glucose disposal decreased 
significantly by 25% in this arm (p<0.001). Fasting glycerol turnover increased by 
22% after starting this regimen (p<0.005). Hyperinsulinemia suppressed glycerol 
turnover equally before and after starting LPV/r+AZT/3TC treatment. The 
disturbances in glucose metabolism were not accompanied by changes in levels of 
adiponectin or other glucoregulatory hormones. In contrast to the LPV/r+AZT/3TC 
arm, glucose metabolism did not change in the LPV/r+NVP arm. When comparing 
the two arms, glucose disposal significantly differed over time (p<0.01).  
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Conclusions 
Three months of treatment with a NRTI-containing, but not a NRTI-sparing regimen 
resulted in a 25% decrease in insulin-mediated glucose disposal and a 22% 
increase in fasting lipolysis. In the absence of discernable changes in body 
composition, NRTI’s may directly affect glucose metabolism, the mechanism by 
which remains to be elucidated. 
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Introduction 
 
Combination antiretroviral treatment (cART) has remarkably improved the 
prognosis of patients with HIV-1-infection (1), but has become associated with 
changes in body fat distribution or lipodystrophy (2) and metabolic disturbances, 
which include dyslipidemia and alterations in glucose metabolism (3-8). The 
pathogenesis of the disturbances in glucose metabolism is likely multifactorial, in 
which both HIV protease inhibitors (PI’s) and nucleoside reverse transcriptase 
inhibitors (NRTI’s) may play a role (9-23). Prospective studies showed a decrease 
in insulin sensitivity and beta-cell dysfunction in HIV-1-infected patients several 
months after starting a PI-containing regimen (10;14;22). In healthy volunteers, 
administration of a single dose of the PI indinavir reduced peripheral glucose 
uptake during a hyperinsulinemic clamp (17).  
NRTI’s are thought to contribute mainly indirectly to disturbances in glucose 
metabolism by inducing changes in body fat distribution (24;25). This could explain 
why cumulative exposure to particular NRTI’s was found to be independently 
associated with markers of insulin resistance (26). However it has also been 
reported that in ART-naïve, HIV-1-infected patients, insulin resistance develops as 
early as four weeks after initiating cART containing didanosine+stavudine, but not 
after abacavir+3TC (27). This could suggest that particular NRTI’s may also disturb 
glucose metabolism more directly. In contrast to PI’s and NRTI’s, non-nucleoside 
reverse transcriptase inhibitors (NNRTI’s) have not been implicated in being 
involved in affecting glucose metabolism. 
In order to obtain more insight into the contribution of individual drug classes, 
NRTI’s in particular, and into the sequence of onset of metabolic disturbances, we 
studied body composition and glucose metabolism in detail in a subset of 20 
participants from a randomized clinical trial in ART-naïve, HIV-1-infected patients. 
This trial compared a NRTI-containing regimen of zidovudine (AZT)+lamivudine 
(3TC) plus ritonavir-boosted lopinavir (LPV/r) with a NRTI-sparing regimen of 
nevirapine (NVP) plus LPV/r. The primary objective of the substudy was to assess 
the impact of both regimens on glucose metabolism (peripheral glucose disposal, 
endogenous glucose production) and body composition over time, as well as to 
compare the effects between both arms. Secondary objectives included the effects 
and comparisons of these two arms on lipolyis, free fatty acids (FFA), 
glucoregulatory hormones and lipids. We here report results obtained during the 
first three months of treatment. 
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Patients and methods 
 
Subjects and study design 
Subjects were participants in the ‘MEDICLAS’ (metabolic effects of different 
classes of antiretrovirals) trial. This is an ongoing, multicenter, multinational, single-
blinded, randomized trial of 144 weeks-duration in 50 previously antiretroviral-naïve 
male patients, 18-70 years old, with an indication to start cART, comparing a NRTI-
containing regimen of LPV/r (400/100 mg bd)+AZT/3TC (300/150 mg bd) with a 
NRTI-sparing regimen of LPV/r (533/133 mg bd)+NVP (200 mg bd). Subjects with 
obesity (body mass index (BMI)>35 kg/m2), a history of hyperlipidemia (according 
to the treating physician) or diabetes mellitus were excluded, as well as patients 
using medication which could affect glucose metabolism, e.g. systemic 
corticosteroids. For the purpose of the substudy, patients with active infections in 
the preceding two months and/or patients with wasting (defined as a recent loss of 
>10% of body weight) were also excluded.  
 
In the subgroup, glucose metabolism was investigated by hyperinsulinemic-
euglycemic clamps using stable isotopes at baseline and 3, 12, 24 and 36 months 
following the start of treatment. Body fat distribution was assessed at these same 
timepoints by abdominal computerised tomography- (CT) and dual-energy X-ray 
absorptiometry (DEXA) scan. Patients could be recruited into the substudy if they 
were followed at the Academic Medical Center, The Netherlands or could be 
referred there from neighboring participating centers or at Helsinki University 
Central Hospital, Finland, as these were the only sites able to perform the clamp 
studies according to a common protocol (see below). The study was approved by 
the Medical Ethical Committee of all participating centers. Written informed consent 
was obtained from all participants prior to study entry.  
 
Randomization procedure 
At the central study coordinating center a treatment allocation sequence (1:1 for 
LPV/r+AZT/3TC and LPV/r+NVP) was generated using the minimisation variable 
BMI (≤25 versus >25 kg/m2). Treatment allocation was stratified for patients 
participating only in the main study or patients participating both in the main and 
the substudy. 
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Hyperinsulinemic-euglycemic clamp protocol  
All participants used a balanced diet, containing at least 250 gr. carbohydrates for 
three days prior to each metabolic study. After a 12-hour fast at 10 am, subjects 
were admitted to the metabolic clinical research center and studied in supine 
position. They fasted till the end of the study day and were only allowed to drink 
water. Antiretroviral medication was taken without food on the study day. A 
catheter was inserted in the antecubital vein of each arm. One catheter was used 
for sampling of arterialized blood, using a thermo-regulated (60ºC) box and the 
other for infusion of [6,6-2H2]-glucose, [2H5]-glycerol, insulin and glucose 20%. At 
T=-2.30 (10 AM), after drawing a blood sample for background enrichment of 
plasma glucose and glycerol, a continuous infusion of [6,6-2H2]-glucose (>99% 
enriched, Cambridge Isotopes, Ma, US) was started at a rate of 0.11 µmol/kg/min, 
after a priming dose of 8.8 µmol/kg. At T=-1.30 a continuous infusion of [2H5]-
glycerol at a rate of 0.11 µmol/ kg/min was started, after a priming dose of 1.6 
µmol/kg. From T=-0.30 till T=0 every 10 minutes blood samples were drawn for 
determination of the rate of appearance (Ra) of glucose and glycerol. 
Subsequently at T=0, a primed continuous infusion of insulin (Actrapid 100 U/mL, 
Novo-Nordisk Farma BV, Alphen a/d Rijn, The Netherlands) was started for 2½ 
hours at a rate of 20 mU/m2 body surface area/min. Plasma glucose concentration 
was measured every five minutes (Beckman glucose analyzer-2, Palo Alto, CA, 
USA) and glucose 20% was infused at a variable rate to maintain euglycemia. [6,6-
2H2]-glucose was added to the 20% glucose solution to achieve glucose 
enrichments of 1% to minimize changes in isotopic enrichment, due to changes in 
the infusion rate of exogenous glucose (28;29). During the last hour of insulin 
infusion, every 10 minutes samples were drawn for determination of the Ra 
glucose and glycerol. Blood for measurement of concentrations of cortisol, 
catecholamines, glucagon, insulin, FFA, soluble TNF-α receptor (sTNFR) 1+2 and 
adiponectin was collected at T=-0.30 and T=0 and at the end of the 
hyperinsulinemic clamp at T=2.00 and T=2.30. LPV concentrations were measured 
in the week preceding and at the end of each hyperinsulinemic clamp. Blood 
samples were kept on ice immediately after collection and subsequently 
centrifuged for 10 minutes at 3000 rpm at 4ºC. All plasma samples were stored at –
20°C.  
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Body composition 
Total and regional fat mass were quantified in all patients by DEXA (Hologic QDR-
4500W, software version whole body v8.26A:5) providing a quantitative 
assessment of peripheral (sum of arm and leg fat) and trunk fat mass in kg. A 
standardized single-slice abdominal CT-scan through the level of the third lumbar 
vertebra was performed from which the surface area of visceral- (VAT) and 
subcutaneous adipose tissue (SAT) was determined and expressed in cm2. 
 
Analytical procedures  
Plasma insulin, cortisol, catecholamines, glucagon, FFA, sTNFR 1+2 and 
adiponectin concentrations were measured as described before (30;31). Plasma 
HIV-1 RNA was measured in the participating centers by various tests with a lower 
limit of quantification of 50 copies/mL. LPV concentration was analysed using a 
validated HPLC-method using diode-array detection: coefficient of variation 1.6% at 
1.98 mg/L and 1.7% at 7.96 mg/L; detection limit 0.008 mg/L. Plasma samples for 
enrichments of [6,6-2H2]-glucose and [2H5]-glycerol were determined as described 
before (32;33).   
 
Calculations and statistical analysis 
Ra glucose, peripheral glucose disposal and Ra glycerol were calculated with a 
modified form of Steele-equations, as described before (6;34). LPV concentration 
ratios were calculated by dividing the measured concentration by the expected 
concentration from the reference curve. 
All participants were evaluated as their own control. Analyses were by intent-to-
treat. Mean within group changes were analyzed by paired Student’s t-tests. In 
both groups, for each parameter, the difference was calculated between the value 
at month three and at baseline. Subsequently, the mean differences between the 
two treatment arms were analyzed by Wilcoxon tests. Alpha<0.05 was considered 
statistically significant. Data are presented as median (interquartile range (IQR)). 
SPSS statistical software version 12.0.1 (SPSS Inc, Chicago, IL) was used for all 
analyses. 
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Results 
 
Patient characteristics  (Table 1) 
A total of 50 patients were included in the ‘MEDICLAS’ study between February 
2003 and June 2005. Twenty of these patients were co-enrolled in the substudy. 
Eleven of these 20 patients were randomly assigned to LPV/r+AZT/3TC and 9/20 
patients to LPV/r+NVP. Their demographic and clinical characteristics are shown in 
Table 1. For one patient in the LPV/r+AZT/3TC group, data on glucose metabolism 
during the hyperinsulinemic clamp could not be included in the analysis because of 
technical failure during the conduct of the clamp. In the LPV/r+NVP group, three 
months data were not included in the analysis from two patients, one because he 
didn’t return for his three months visit and the second one because of acute 
hepatitis-A-infection. One patient in the LPV/r+NVP arm discontinued ART after 
four weeks because of toxic hepatitis. Following complete recovery, just after the 
three months visit, he resumed LPV/r, with efavirenz instead of NVP. The data of 
this patient were included in the analysis. None of the patients started concomitant 
medication that could be expected to influence glucose metabolism between start 
of cART and the three months visit. 
 
Virologic and immunologic parameters (Table 1) 
Patients in both groups exhibited an immunological and virological response to 
cART with similar increases in CD4 count and decreases in HIV-1 RNA. At month 
three, there were no significant differences in concentration ratios of LPV taken in 
the week preceding the clamp between the two arms. LPV concentrations and 
concentration ratios during the last hour of the hyperinsulinemic clamp, although 
slightly low due to the previous LPV-dose having been taken while fasting, did not 
differ between the arms.  
 
Body composition (Table 2) 
There were no significant changes in any of the body composition parameters over 
the course of three months, with the exception of a minor decline in abdominal SAT 
(p<0.05) and in trunk fat (p<0.05) in patients randomized to LPV/r+NVP. Of note, 
limb fat did not change significantly in either arm, whereas VAT showed a declining 
trend in both the AZT/3TC and the NVP arm (p=0.06 and p=0.15 respectively).  
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Glucose metabolism (Table 3) 
There were no significant changes in fasting plasma glucose or insulin levels after 
three months compared to baseline in either of the two treatment arms. In addition, 
in both arms there were no changes in fasting endogenous glucose production. 
During hyperinsulinemia, glucose production could also be suppressed equally at 
month three when compared to baseline in both groups. Treatment with 
LPV/r+NVP did not result in a significant change of peripheral glucose disposal 
during the hyperinsulinemic clamp. In contrast, in the LPV/r+AZT/3TC arm, insulin-
stimulated peripheral glucose disposal decreased significantly by 25% after three 
months of therapy (p<0.001) (Figure 1). This resulted in a significant difference in 
glucose disposal over time between patients in the two treatment arms (p<0.01). 
 
Lipolysis (Table 3) 
After a 12h-fast as well as during the hyperinsulinemic clamp, glycerol turnover did 
not change in the LPV/r+NVP group over the course of three months. In contrast, 
in the LPV/r+AZT/3TC group, fasting glycerol turnover had significantly increased 
by 22%, three months after starting therapy (p<0.005). However, during 
hyperinsulinemia, glycerol turnover was suppressed equally at month three when 
compared to baseline in the LPV/r+AZT/3TC arm. In agreement with the enhanced 
glycerol turnover after an overnight fast, fasting plasma FFA levels were 84% 
higher in the LPV/r+AZT/3TC group after three months (p<0.001). In the 
LPV/r+NVP group, fasting FFA levels did not change over time. As a result, the 
change in fasting FFA levels was significantly different when comparing the 
treatment arms (p<0.05). Additionally, after three months of treatment with 
LPV/r+AZT/3TC, FFA concentrations were slightly but significantly higher during 
the clamp (p<0.05). There was no significant correlation between the change in 
insulin-mediated glucose disposal and the change in fasting glycerol turnover (r= 
0.13). 
 
Glucoregulatory hormones and lipid profile (Table 2)  
There were no significant differences in fasting plasma concentrations of cortisol or 
epinephrine over time in either treatment group. In the LPV/r+NVP group, fasting 
plasma levels of glucagon significantly decreased (p<0.05), whereas in the 
LPV/r+AZT/3TC group, norepinephrine levels decreased after starting treatment 
(p<0.05). Plasma adiponectin concentrations had not changed significantly after 
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three months of therapy. STNFR 1+2 levels decreased in both arms, but the 
declines were only significant in the LPV/r+AZT/3TC arm (p<0.005 and p<0.001 
respectively). Plasma total-, HDL-cholesterol and triglyceride levels were 
significantly higher after treatment in both groups (p<0.05) with no significant 
differences between groups.    
 
 
Discussion 
 
Dyslipidemia, body fat redistribution and disturbed glucose homeostasis are 
frequently seen in HIV-1-infected patients treated with cART (3;7). Once patients 
have developed clinically overt signs of lipodystrophy, the disturbances in glucose 
metabolism have been shown to include insulin resistance at the level of peripheral 
glucose disposal, hepatic glucose production and lipolysis (5;6;9;35). The present 
study to our knowledge is the first prospective randomized clinical trial, which 
attempts to investigate the onset of the derangements in glucose kinetics and body 
composition in relation to commencing treatment with different cART regimens, 
which do or do not include NRTI’s, in HIV-1-infected, ART-naïve patients, by 
conducting hyperinsulinemic-euglycemic clamps. Our results show that treatment 
with a NRTI-containing regimen of LPV/r+AZT/3TC, in the absence of significant 
changes in body fat distribution, after as early as three months, resulted in a 25% 
decrease in insulin-mediated peripheral glucose disposal and a 22% increase in 
fasting lipolysis, while this was not the case in patients randomized to a NRTI-
sparing regimen of LPV/r+NVP.   
 
Results from detailed prospective studies on the metabolic side-effects of ART in 
HIV-1-infected patients thus far are limited. Only a few studies have tried to 
investigate the effects of PI’s as a class on insulin sensitivity, measured by 
intravenous glucose tolerance test, the HOMA-index and the hyperglycemic clamp. 
These studies showed that in HIV-1-infected patients, insulin resistance was 
already present several months after starting a PI-containing regimen (10;14;22). 
However, since not all patients were ART-naïve and NRTI’s were included 
concomitantly in the regimens of these patients, it is impossible to conclude 
whether the observed reduction in insulin sensitivity could only be attributed to the 
use of PI’s. The effect of different PI’s on glucose metabolism has been studied in 
HIV-1-uninfected volunteers. Administration of the PI indinavir, both as a single 
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dose and during four weeks, reduced peripheral glucose disposal and increased 
endogenous glucose production during a hyperinsulinemic clamp (16;17;19). The 
effects which have been observed however with short-term exposure to ritonavir-
boosted LPV are different; insulin sensitivity with respect to glucose disposal 
decreased after a single dose and after five days of exposure (13;18), but not after 
four weeks of LPV/r treatment (36). In line with these human studies, studies in 
healthy rodents showed an acute reduction in peripheral glucose uptake after 
administration of several PI’s, including LPV/r (12;23). Moreover, these studies 
showed that both glucose transport in skeletal muscle and adipose tissue was 
affected. In-vitro research has shown that several PI’s, including ritonavir, are able 
to acutely inhibit the activity of GLUT-4 (glucose transporter-4) (11;15), thereby 
offering a possible explanation for the above-mentioned peripheral insulin 
resistance found in healthy volunteers and HIV-1-infected patients with 
lipodystrophy. Besides PI’s, NRTI’s have also been associated with insulin 
resistance in patients with HIV-1-infection. Duration of exposure to NRTI’s has 
been reported to be independently associated with insulin resistance, as measured 
by fasting insulin levels and the QUICKI-index in a number of observational studies 
(26;37). These findings could potentially be explained as indirect effects of NRTI’s 
by virtue of their association with the development of changes in body fat 
distribution, especially lipoatrophy (24;25). However, evidence from a randomized 
trial conducted in previously ART-naïve subjects demonstrated early and sustained 
increases in fasting serum insulin levels and in HOMA-indices, as short as four 
weeks after treatment initiation with a thymidine analogue-containing cART 
regimen, including stavudine+didanosine, but not with a thymidine analogue-
sparing combination of abacavir+lamivudine (27). These results suggested that 
thymidine analogue-NRTI’s in particular may contribute to the early onset of insulin 
resistance, before any clinically noticeable changes in body fat distribution are 
present. A recent placebo-controlled study in healthy HIV-uninfected volunteers 
demonstrated that administration of stavudine during four weeks indeed resulted in 
a significant decrease in insulin sensitivity measured by hyperinsulinemic-
euglycemic clamps, without changes in body composition. Interestingly, 31P 
magnetic resonance spectroscopy studies revealed reduced mitochondrial function 
in skeletal muscle, which correlated significantly with insulin sensitivity. In addition, 
mitochondrial DNA-content was reduced in muscle biopsies of stavudine recipients 
(38).      
In the present study, which employed serial hyperinsulinemic-euglycemic clamps, 
in the absence of significant changes in body fat distribution, we found a reduction 
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in peripheral insulin sensitivity after only three months in patients on 
LPV/r+AZT/3TC, as opposed to those treated with LPV/r+NVP. The latter may 
seem in contrast with the findings from earlier studies assessing changes in insulin 
sensitivity following the introduction of PI’s in patients’ antiretroviral regimens 
(10;14;22). Of note however, the PI’s in those studies did not include LPV/r. 
Furthermore, in most instances patients were concomitantly receiving NRTI’s, 
which could have contributed to the reported changes in glucose metabolism. 
Nonetheless, LPV/r did result in a change in insulin sensitivity when administered 
as mono-therapy to healthy HIV-1-uninfected persons (13;18). The difference in 
duration of LPV/r exposure between our study (three months) and the studies 
conducted in healthy volunteers (single dose and five days) may be relevant and 
an earlier reduction in insulin sensitivity in our patients on LPV/r+NVP, which had 
disappeared after three months cannot be ruled out.  
 
The changes in glucose metabolism in the nucleoside-containing arm, as opposed 
to the nucleoside-sparing arm, suggest that exposure to AZT/3TC may have 
contributed to the development of alterations in glucose metabolism. This is in 
accordance with a number of observations concerning the potential contribution of 
NRTI’s to the development of insulin resistance (26;27;37). NRTI’s, particularly the 
thymidine analogues d4T and AZT, have been demonstrated to play an important 
role in the onset of lipoatrophy (39). Since lipoatrophy has independently been 
associated with insulin resistance, NRTI’s have been suggested to affect glucose 
metabolism indirectly via a decrease in peripheral fat (24;25). However, in the 
present study, LPV/r+AZT/3TC treatment resulted in disturbed glucose metabolism 
in the absence of changes in fat distribution. We can not rule out the possibility of 
having missed a small decline in peripheral fat because of a concomitant increase 
in fat due to recovery from HIV-wasting, as has been described before in patients 
starting ART (40;41), but find it an unlikely confounding factor as patients with 
wasting were excluded and LPV/r+NVP treatment, which is not expected to result 
in lipoatrophy, likewise did not result in increased fat amounts. This suggests that 
AZT/3TC may have directly contributed to the development of reduced insulin 
sensitivity, for which different possible mechanisms could have been responsible. 
Some NRTI’s have been described to disturb the production and secretion of 
adipocytokines, which in turn could affect glucose metabolism. In 3T3-adipocytes, 
d4T and ZDV both decreased adiponectin production, whereas the production of 
TNF-α, IL-6 and IL-1 was enhanced (42). However, in the present study 
adiponectin levels were unchanged after three months, whereas levels of sTNFR 
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1+2 decreased rather than increased in the LPV/r+AZT/3TC arm. These results 
argue against abnormal adipocytokine secretion as an explanation for insulin 
insensitivity. In our study, LPV/r+AZT/3TC treatment resulted in stimulation of 
fasting lipolysis with increased plasma FFA levels, which may indicate resistance to 
insulin’s suppressive effect on lipolysis. As FFA are able to negatively influence the 
signaling-pathway of insulin (43;44), increased levels could have contributed to 
insulin resistance with respect to peripheral glucose disposal in the 
LPV/r+AZT/3TC arm. However, since HIV-lipodystrophic patients remained insulin 
resistant (albeit less so) after acutely lowering FFA levels by administration of the 
lipolysis-inhibitor acipimox (45), additional factors are involved as well. There might 
be an important role for mitochondria in fat and muscle in the development of 
insulin insensitivity. NRTI’s have been associated with mitochondrial toxicity 
(38;46-49). A decline in oxidative phosphorylation, resulting from mitochondrial 
dysfunction could result in accumulation of FFA (-metabolites), which in turn are 
able to negatively influence the signaling-cascade of insulin (43;44) and may 
reinforce mitochondrial dysfunction (44;50). NRTI-induced mitochondrial 
dysfunction as a cause for insulin insensitivity was suggested before by a recent 
study in healthy volunteers (38). 
 
With respect to plasma lipids, total cholesterol and triglyceride levels increased 
significantly in both arms after three months, which was not unexpected given the 
presence of LPV/r in both regimens (51;52). Compatible with what has been 
observed in other trials of potent cART in ART-naïve, HIV-1-infected individuals, 
HDL-cholesterol likewise increased in both arms (53;54). Further follow-up of lipid 
changes in all ‘MEDICLAS’ trial participants will be needed to determine whether 
the rise in HDL-cholesterol will be significantly greater in the NVP-containing arm. 
 
In conclusion, treatment with LPV/r+AZT/3TC, as opposed to LPV/r+NVP, after 
only three months resulted in a 25% decrease in insulin-mediated peripheral 
glucose disposal and a 22% increase in fasting lipolysis, in absence of discernable 
changes in body composition. These findings suggest that certain NRTI’s may 
directly contribute to ART-associated disturbances in glucose metabolism, the 
precise underlying mechanism of which remains to be elucidated, but could include 
NRTI-induced mitochondrial dysfunction. Further follow-up of participants in our 
trial is ongoing and will have to determine to which extent these regimens will 
continue to differ with respect to their effects on peripheral insulin sensitivity and 
over the longer term potentially also on other aspects of glucose metabolism, body 
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fat distribution and lipid abnormalities. Meanwhile avoiding thymidine analogue-
NRTI’s might be appropriate, particularly in patients with (a predisposition to 
develop) diabetes mellitus.  
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Table 1. Patient characteristics, virologic and immunologic parameters 
 LPV/r+AZT/3TC  LPV/r+NVP  
Month 0 3 0 3 
Number  11 11 9 8 
Age (y)  38 (34-41)  46 (41-53)  
Weight (kg) 82 (62-86) 79 (62-87) 78 (75-87) 77 (71-88) 
BMI (kg/m2)  24 (21-26) 24 (21-26) 23 (22-27) 23 (22-27) 
CDC Class (%):     
A 64%  56%  
B 18%  44%  
C 18%  0%  
HIV-1 RNA 
       (log10 c/ml) 
5.1 (4.8-5.3) 2.1 (1.7-2.4) 4.8 (4.6-5.6) 1.7 (1.7-2.5) 
CD4-cell count 
      (x106 cells/l) 
200 (85-272) 250 (145-394) 200 (135-284) 330 (278-490) 
Lopinavir concentration ratios:    
--in week pre- 
  ceding the clamp 
NA 1.34 (0.87-1.91) NA 1.44 (0.73-1.50) 
--during last hour 
       of the clamp 
NA 0.90 (0.52-1.00) NA 0.84 (0.23-1.37) 
Lopinavir concentration (mg/l):    
--during last hour 
      of the clamp 
NA 5.90 (3.65-7.80) NA 6.40 (1.58-9.18) 
 
Data represent median (IQR), NA = not applicable 
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Table 2a.Body composition, glucoregulatory hormones and lipid profile 
 
 LPV/r + AZT/3TC   
Month 0 3 Change 
Body composition N = 11 N = 11  
Limb fat (kg) 7.3 (4.5-9.3) 6.4 (3.2-10.5) 0.3 (-0.9-1.2) 
Trunk fat (kg) 7.3 (3.5-9.1) 7.7 (3.5-9.7) -0.1 (-0.4-0.5) 
VAT (cm2) 115 (40-164) 103 (51-144) -12 (-20-12) 
SAT (cm2) 118 (56-173) 113 (46-171) -4 (-10-8) 
Hormones N = 11 N = 11  
Cortisol (nmol/l) 199 (138-244) 224 (194-286) 2 (-31-107) 
Glucagon (ng/l) 57 (50-71) 58 (47-65) -3 (-12-4) 
Epinephrine (nmol/l) 0.12 (0.10-0.16) 0.13 (0.08-0.15) 0.00 (-0.02-0.04) 
Norepinephrine (nmol/l) 1.04 (0.95-1.39) 0.72 (0.48-1.23) -0.33 (-0.50- -0.06) *  
Adiponectin (µg/ml) 6.5 (4.2-7.5) 6.8 (5.4-7.6) 0.1 (-0.4-1.5) 
Sol TNF-α receptor 1 
(ng/ml) 
2.0 (1.7-2.1) 1.6 (1.4-2.0) -0.2 (-0.5- -0.1)  † 
Sol TNF-α receptor 2 
(ng/ml) 
10.0 (7.7-10.8) 6.7 (5.8-8.6) -2.2 (-3.9- -1.5) ‡ 
Lipid profile  N=11  N=11  
Total cholesterol (mmol/l)   3.8 (3.5-5.1) 5.2 (4.0-6.1) 1.1 (0.2-1.5)‡ 
HDL- cholesterol (mmol/l) 1.04 (0.83-1.23) 1.13 (1.00-1.50) 0.10 (0.00-0.30)*  
LDL- cholesterol (mmol/l) 2.2 (1.7-3.2) 2.1 (2.1-3.2) 0.2 (-0.1-0.6) 
Triglycerides (mmol/l) 1.4 (0.9-2.1) 2.9 (2.0-4.7) 1.2 (0.8-1.8)* 
 
Data represent median (IQR),  *p < 0.05, †p < 0.005,  ‡p < 0.001 within group,  II p < 0.05, 
p < 0.01 between groups 
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Table 2b. Body composition, glucoregulatory hormones and lipid profile 
 
 LPV/r+NVP   
Month 0 3 change 
Body composition N = 9 N = 8  
Limb fat (kg) 6.4 (5.9-7.1) 6.2 (4.6-7.2) -0.3 (-0.6-0.5) 
Trunk fat (kg) 6.8 (4.8-7.7) 6.5 (5.0-8.6) -0.8 (-1.5- -0.2)* II 
VAT (cm2) 113 (67-130) 96 (63-156) -14 (-26- -7) 
SAT (cm2) 110 (80-133) 109 (80-136) -6 (-13--3)* 
Hormones N=9  N=7  
Cortisol (nmol/l) 190 (170-322) 135 (105-401) -44 (-66-80) 
Glucagon (ng/l) 67 (54-87) 56 (46-63) -28 (-30-2)* 
Epinephrine (nmol/l) 0.06 (0.04-0.16) 0.11 (0.08-0.27) 0.04 (-0.05-0.10) 
Norepinephrine (nmol/l) 1.02 (0.52-1.41) 1.62 (0.64-2.54) 0.61 (0.12-0.73) 
Adiponectin (µg/ml) 7.0 (4.7-8.8) 9.5 (5.9-11.3) 1.3 (-0.4-2.5) 
Sol TNF-α receptor 1 
(ng/ml) 
1.7 (1.5-1.8)  1.5 (1.3-2.0) -0.2 (-0.4-0.3) 
Sol TNF-α receptor 2 
(ng/ml) 
9.0 (8.3-12.7)  6.1 (5.6-7.8) -2.8 (-6.6- -0.6) 
Lipid profile  N = 9 N = 8  
Total cholesterol (mmol/l)   4.3 (4.0-4.6) 5.4 (4.8-6.6) 0.9 (0.6-1.7)* 
HDL- cholesterol (mmol/l) 1.12 (1.01-1.48) 1.30 (1.18-1.76) 0.30 (0.10-0.50)* 
LDL- cholesterol (mmol/l) 2.3 (2.1-2.8) 3.1 (2.8-3.3) 0.7 (-0.1-0.8) 
Triglycerides (mmol/l) 1.5 (0.9-1.5) 2.2 (1.7-3.1) 1.0 (0.1-1.3)* 
 
Data represent median (IQR),  *p < 0.05,  † p<0.005, ‡p < 0.001 within group,  II p < 0.05, 
p < 0.01 between groups 
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Table 3a. Glucose metabolism 
 
 LPV/r+AZT/3TC   
Month 0 3 change 
Fasting N=11 N=11  
Glucose (mmol/l) 5.2 (5.1-5.6) 5.5 (5.3-5.8) 0.2 (-0.2-0.5) 
Insulin (pmol/l)  41 (22-55) 40 (34-69) 12 (-11-23) 
Endogenous glucose 
production$ 
11.9 (10.7-13.6) 11.4 (10.9-12.6) -0.2 (-1.0-0.5) 
Glycerol rate of 
appearance$ 
1.63 (1.28-2.23) 1.85 (1.58-2.61) 0.33 (0.11-0.76) † 
Free fatty acid (mmol/l) 0.34 (0.23-0.48) 0.67 (0.56-0.77) 0.30 (0.17-0.46)‡ II 
    
Clamp N=11 N=10  
Glucose (mmol/l) 5.0 (4.9-5.1) 5.0 (4.9-5.0) -0.1 (-0.1-0.0) 
Insulin (pmol/l) 191 (161-203) 171 (151-207) -3 (-26-23) 
Endogenous glucose 
production$ 
3.9 (2.6-4.4) 4.1 (3.5-4.9) 0.3 (-0.6-1.8) 
Peripheral glucose 
disposal$ 
22.8 (20.1-29.6) 16.6 (14.6-24.6) -5.1 (-7.2- -4.0)‡  
Glycerol rate of 
appearance$ 
0.71 (0.62-0.87) 0.76 (0.51-0.79) -0.06 (-0.19-0.14) 
Free fatty acid (mmol/l) 0.05 (0.03-0.07) 0.08 (0.03-0.11) 0.01 (0.00-0.04)*  
 
Data represent median (IQR), $µmol/kg/min, *p < 0.05, †p < 0.005, ‡p<0.001 within group, 
ơp < 0.05, p < 0.01 between groups 
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Table 3b. Glucose metabolism 
 
 LPV/r+NVP   
Month 0 3 change 
Fasting N = 9 N = 7  
Glucose (mmol/l) 5.2 (5.1-5.3) 5.3 (5.1-5.8) 0.3 (0.0-0.5) 
Insulin (pmol/l)  36 (22-77) 40 (34-45) -12 (-17-13) 
Endogenous glucose 
production$ 
11.7 (10.2-12.0) 11.4 (10.8-12.5) 0.5 (-0.6-0.8) 
Glycerol rate of 
appearance$ 
1.63 (1.41-2.17) 1.96 (1.63-2.17) 0.11 (-0.21-0.22) 
Free fatty acid (mmol/l) 0.49 (0.46-0.59) 0.63 (0.46-0.70) 0.09 (-0.11-0.17) 
    
Clamp N = 9 N = 7  
Glucose (mmol/l) 5.0 (4.8-5.1) 4.9 (4.9-5.1) -0.1 (-0.2-0.3) 
Insulin (pmol/l) 179 (133-207) 182 (150-195) -1 (-17-33) 
Endogenous glucose 
production$ 
4.6 (3.1-5.6) 3.9 (2.7-4.8) -0.7 (-1.9-0.3) 
Peripheral glucose 
disposal$ 
19.2 (13.4-22.8) 20.6 (18.6-24.3)  2.2 (-4.2-6.8) 
Glycerol rate of 
appearance$ 
0.76 (0.65-0.87) 0.65 (0.54-0.65) -0.11 (-0.33- -0.11) 
Free fatty acid (mmol/l) 0.05 (0.05-0.13)  0.05 (0.03-0.08) -0.03 (-0.07-0.05) 
 
Data represent median (IQR), $µmol/kg/min, *p < 0.05, †p<0.005, ‡p < 0.001 within group, 
ơp < 0.05, p< 0.01 between groups 
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Figure 1 
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Left: Rate of peripheral glucose 
disposal (Rd) (µmol/kg/min) during 
hyperinsulinemia in the individual 
patients (N=10) before and after 3 
months of therapy with 
LPV/r+AZT/3TC.  
−− = mean of all patients   
∗ p<0.001 
Right: Rate of peripheral glucose 
disposal (Rd) (µmol/kg/min) during 
hyperinsulinemia in the individual 
patients (N=7) before and after 3 
months of therapy with 
LPV/r+NVP. 
−− = mean of all patients   
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Abstract 
 
Context 
The extent and manner by which HIV nucleoside reverse transcriptase inhibitors 
contribute to insulin resistance is unclear.  
Objective 
We evaluated the effect of zidovudine/lamivudine (ZDV/3TC) on glucose 
metabolism in HIV-1-infected patients initiating combination antiretroviral therapy 
(cART).  
Design 
Randomized clinical trial (MEDICLAS (Metabolic Effects of DIfferent CLasses of 
AntiretroviralS), inclusion 2003-2005, two year follow-up.  
Setting 
Referral centers for HIV care. 
Patients 
Twenty cART-naive men. 
Interventions 
Randomization to lopinavir/ritonavir(LPV/r)+ZDV/3TC or LPV/r+ nevirapine (NVP).   
Main outcome measures 
Glucose metabolism and lipolysis (hyperinsulinemic euglycemic clamps using 
stable isotopes), body composition (computerised tomography- and dual-energy X-
ray absorptiometry scans), before and after 3, 12 and 24 months of cART. 
Results 
Insulin-stimulated peripheral glucose disposal decreased by 25% after three 
months in patients on ZDV/3TC/LPV/r (p<0.001) in a persistent manner, followed 
by a transient decrease in insulin-mediated inhibition of lipolysis. In the NVP/LPV/r 
group, hepatic insulin sensitivity had improved after 24 months. Following the initial 
three months, limb fat decreased in the ZDV/3TC/LPV/r arm up to 24 months (-
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849±345 g (p=0.017)). Visceral adipose tissue in this group increased over 2 years 
(+36.2±13.3 cm2 (p=0.009)). In the NVP/LPV/r group, a generalized increase in fat 
mass was observed. Plasma adiponectin increased significantly in both groups, but 
less in patients on ZDV/ 3TC/LPV/r.  
Conclusions 
Treatment with ZDV/3TC/LPV/r versus NVP/LPV/r differentially affects glucose and 
lipid metabolism. The ZDV/3TC/LPV/r regimen induced peripheral insulin 
resistance, a transient increase in basal lipolysis and a transient decrease in 
insulin-mediated inhibition of lipolysis, whereas in the NVP/LPV/r regimen hepatic 
insulin sensitivity actually improved after long-term treatment.  
 
(ClinicalTrials.gov number: NCT 00122226, http://www.clinicaltrials.gov) 
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Introduction 
 
Lipodystrophy in patients with HIV-1 infection on combination antiretroviral therapy 
(cART) has been shown to be associated with insulin resistance in multiple 
metabolic pathways, including a reduction in peripheral glucose uptake, enhanced 
lipolysis and increased endogenous glucose production[1]. The sequence of onset 
of these disturbances in glucose and lipid metabolism, and the contribution of the 
various drug classes or individual drugs have not been elucidated. Both protease 
inhibitors (PI) and nucleoside reverse transcriptase inhibitors (NRTI) have been 
implicated in the pathogenesis of insulin resistance, either directly or as a result of 
associated changes in fat distribution. Studies in healthy volunteers have shown 
that several, but not all PI have an acute inhibitory effect on glucose uptake[2-5], 
although in some studies peripheral insulin resistance was no longer present after 
PI were administered for extended periods [6, 7]. NRTI are thought to contribute to 
insulin resistance by inducing changes in fat distribution and lipoatrophy in 
particular. Recently, however, a significant reduction in insulin mediated peripheral 
glucose uptake was reported after 4 weeks of stavudine administration to healthy 
volunteers. Since body composition did not change, this suggests that stavudine 
has a direct effect on peripheral insulin sensitivity[8]; whether the same is true for 
other NRTI remains to be determined. Short-term studies with monotherapy of 
various antiretroviral drugs in healthy volunteers are probably not representative for 
the clinical situation of patients initiating cART, as in this setting suppression of 
viral replication, restoration of immunity, the use of combinations of antiretroviral 
drugs with potential additive effects and the changes in body fat redistribution each 
may influence glucose and lipid metabolism.  
In order to unravel the sequence of events occurring during the development of 
insulin resistance in relation to changes in body composition and the use of 
different classes of antiretroviral drugs, we performed sequential measurements of 
glucose and lipid metabolism and of body composition after start of therapy in 
cART-naive HIV-1-infected men randomised to either zidovudine/lamivudine/ 
lopinavir/ritonavir or nevirapine/lopinavir/ritonavir. We previously reported a 
decrease in insulin mediated peripheral glucose uptake prior to the development of 
changes in body fat distribution after three months in the ZDV/3TC/LPV/r arm[9]. 
We currently report the results of the planned primary analysis after 24 months of 
follow-up. 
Chapter 4 
83 
Patients and methods 
Subjects and study design 
We studied a subgroup of participants in the MEDICLAS (Metabolic Effects of 
DIfferent CLasses of AntiretroviralS) trial. This is a multicenter, multinational, 
single-blinded, randomised trial of 36 months duration in 50 previously 
antiretroviral-naive male patients, 18-70 years old, with an indication to start cART, 
comparing a NRTI-containing regimen of ZVD/3TC (300/150 mg bd) + LPV/r 
(400/100 mg bd) with a NRTI-sparing regimen of NVP (200 mg bd) + LPV/r 
(533/133 mg bd). The main objective of the trial is to assess and compare the 
impact of both treatments on body fat distribution and metabolic complications. 
Subjects with severe obesity (body mass index (BMI)>35 kilogram (kg)/m2), a 
history of hyperlipidemia or diabetes mellitus were excluded, as well as patients 
using medication that could affect glucose and lipid metabolism, e.g. systemic 
corticosteroids. For the purpose of the sub-study, patients with active infections in 
the preceding two months and patients with wasting (recent loss of >10% of body 
weight) were also excluded.  
 
In the participants of the sub-study, glucose and lipid metabolism was investigated 
in the fasting state and during a hyperinsulinemic euglycemic clamp using stable 
isotopes, at baseline and 3, 12, 24 and 36 months following the start of treatment. 
Body fat distribution was assessed at these same time points by abdominal 
computerised tomography- (CT) and dual-energy X-ray absorptiometry (DEXA) 
scan. Patients could be recruited into the sub-study if they were followed at the 
Academic Medical Center, The Netherlands, the Helsinki University Central 
Hospital, Finland or could be referred to one of these centers as these were the 
only sites able to perform the clamp studies according to the protocol (see below). 
The study was approved by the Ethics Committees of each participating center. 
Written informed consent was obtained from all participants prior to study entry. 
 
Randomization  
At the central study-coordinating center a treatment allocation sequence (1:1 for 
ZDV/3TC/LPV/r and NVP/LPV/r) was generated using the minimization variable 
BMI (≤25 kg/m2 versus >25 kg/m2). Treatment allocation was stratified for patients 
participating only in the main study, or patients participating both in the main and 
the sub-study. 
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Hyperinsulinemic euglycemic clamp protocol  
All participants consumed a balanced diet, containing at least 250 gr. 
carbohydrates for three days prior to each metabolic study. After a 12-hour fast, 
subjects were admitted to the metabolic clinical research center and studied in the 
supine position. A catheter was inserted into an antecubital vein for infusion of [6,6-
2H2]-glucose, [2H5]-glycerol, insulin and glucose 20% and another catheter was 
inserted into a contralateral hand vein and kept in a thermo-regulated (60ºC) 
plexiglas box for sampling of arterialized venous blood. 
 
At T=-2.30 (10 AM), after drawing a blood sample for background enrichment of 
plasma glucose and glycerol, a continuous infusion of [6,6-2H2]-glucose (>99% 
enriched, Cambridge Isotopes, MA) was started at a rate of 0.11 µmol·kg-1·min-1, 
after a priming dose of 8.8 µmol/kg. At T=-1.30 (11 AM) a continuous infusion of 
[2H5]-glycerol at a rate of 0.11 µmol/ kg/min was started, after a priming dose of 1.6 
µmol/kg. From T=-0.30 (12.00 pm) till T=0 (12.30 PM) every 10 minutes blood 
samples were drawn for determination of the fasting rate of appearance (Ra) of 
glucose and glycerol. Subsequently, at T=0 (12.30 PM), a primed continuous 
infusion of insulin (Actrapid 100 U/mL, Novo Nordisk Farma BV, Alphen a/d Rijn, 
The Netherlands) was started for 2½ hours from T=0 till T=2.30 (12.30-15 PM) at a 
rate of 20 mU·m-2 body surface area·min-1. Plasma glucose concentration was 
measured every five minutes (Beckman glucose analyzer 2, Palo Alto, CA, US) 
and glucose 20% was infused at a variable rate to maintain euglycemia (5 mmol/L). 
[6,6-2H2]-glucose was added to the 20% glucose solution to achieve glucose 
enrichments of 1% to minimize changes in isotopic enrichment, due to changes in 
the infusion rate of exogenous glucose[10, 11]. During the last hour of insulin 
infusion, every 10 minutes samples were drawn for determination of Ra of glucose 
and glycerol. Blood for measurement of concentrations of cortisol, catecholamines, 
insulin, glucagon, free fatty acids (FFA), and adiponectin was collected in the 
fasted state at T=-0.30 and T=0 and at the end of the hyperinsulinemic clamp at 
T=2.00 and T=2.30. Blood samples were kept on ice immediately after collection 
and subsequently centrifuged for 10 minutes at 3000 rpm at 4ºC. Plasma samples 
were stored at –20°C. During the clamp, subjects were allowed to drink water only. 
Antiretroviral medication was taken without food on the study day. LPV 
concentrations were measured in the week preceding and at the end of each 
clamp. 
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Body composition 
Total and regional fat mass were quantified in all patients by DEXA (Hologic QDR-
4500W, software version whole body v8.26A:5) providing a quantitative 
assessment of peripheral (limb) as well as trunk fat mass in kilogram. A 
standardized single slice abdominal CT-scan through the level of the third lumbar 
vertebra was performed from which the surface area of visceral (VAT) and 
subcutaneous adipose tissue (SAT) was determined and expressed in centimeter 
square (cm2).  
 
Analytical procedures  
Plasma insulin, cortisol, catecholamines, glucagon, FFA, adiponectin and LPV 
concentrations were measured as described before[9, 12]. Plasma HIV-1 RNA was 
measured in each participating center by different tests, each with a lower limit of 
quantification of 50 copies/mL. Plasma samples for enrichments of [6,6-2H2]-
glucose and [2H5]-glycerol were determined as described before[1, 13].   
 
Calculations and statistical analysis 
Endogenous glucose production (EGP), peripheral glucose disposal (Rd) and Ra of 
glycerol were calculated with a modified form of the Steele equation as described 
before[1, 13]. LPV concentration ratios were calculated by dividing the measured 
concentration by the expected concentration from the reference curve. 
 
Analyses were by intent-to-treat. Within group changes, between-group differences 
in overall course, and between-group differences at each study visit were analyzed 
by mixed model repeated measures analysis with correction for baseline values. 
Alpha<0.05 was considered statistically significant. Data are presented as 
estimated means ± standard error of the mean. SAS statistical software version 9.2 
was used for all analyses. 
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Results 
 
Patient characteristics (Table 1)  
A total of 50 patients were included in the ‘MEDICLAS’ trial between February 2003 
and June 2005, of whom twenty were co-enrolled in the sub-study. Eleven of these 
20 patients were randomly assigned to ZDV/3TCLPV/r and 9/20 patients to 
NVP/LPV/r. Their demographic and clinical characteristics are shown in Table 1. 
For one patient in the ZDV/3TC/LPV/r group, data during the clamp at baseline 
could not be included in the analysis because of technical problems during the 
clamp. In the NVP/LPV/r group, three months data were not included in the 
analysis from two patients, one patient didn’t return for the clamp at this visit (data 
other than the clamp were included) and the other developed acute hepatitis A (all 
data were excluded for this visit). One patient in the NVP/LPV/r arm died at home, 
presumably due to an acute myocardial infarction, shortly after his one-year visit. 
Antiretroviral therapy was switched in some patients because of side effects. One 
patient in the NVP/LPV/r arm discontinued cART after four weeks because of toxic 
hepatitis. Following complete recovery, after three months, he resumed LPV/r, with 
efavirenz instead of NVP. In the ZDV/3TC/LPV/r arm, one patient switched from 
ZDV to tenofovir because of anemia shortly after his 3 months visit, and in another 
patient LPV/r was replaced by NVP after 18 months because of dyslipidemia. Data 
of all patients with medication switches were included in the analysis. None of the 
patients started concomitant medication that could be expected to influence 
glucose or lipid metabolism between start of cART and the 24 months visit. 
 
Virologic and immunologic parameters and LPV concentrations  
(Table 1) 
Patients in both groups exhibited an immunological and virological response to 
cART with similar increases in CD4 count and decreases in HIV-1 RNA. The 
increase in CD4 count from baseline to 24 months was 280 (210-420) x 106/l 
(median (interquartile range) in the ZDV/3TC/LPV/r arm and 320 (260-430) x 106/l 
in the NVP/LPV/r arm. At 24 months, 9/11 (82%) patients in the ZDV/3TC/LPV/r 
arm and 8/8 (100%) patients in the NVP/LPV/r arm had HIV-RNA below 50 
copies/ml. Of the two patients who did not have undetectable HIV-RNA at 24 
months, one had HIV-RNA of 68 copies/ml and for the other HIV-RNA was not 
performed at that time point. Both these patients had HIV-RNA below 50 copies/ml 
at the preceding and following visits, and were not considered to have virological 
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failure clinically. LPV concentrations and concentration ratios during the last hour of 
the hyperinsulinemic clamp did not differ between the arms.    
Body composition (Table 2) 
After 24 months, body weight had increased by 1.7±0.9 kg (p=0.08) and 2.5±1.1 kg 
(p=0.02) in the ZDV/3TC/LPV/r and NVP/LPV/r arm, respectively. Limb fat 
remained stable during the first three months in the ZDV/3TC/LPV/r arm but 
showed a progressive decline thereafter, with a total loss of 849±345 g from 3 to 24 
months (p=0.017). Total body fat remained unchanged in this arm. In contrast, in 
the NVP/LPV/r arm, limb fat and total body fat both increased. After one year of 
cART, limb fat in the ZDV/3TC/LPV/r arm was 990±392 gram lower and after two 
years 1262±403 gram lower compared to the NVP/LPV/r arm (p=0.015 and 
p=0.003 resp.). 
Trunk fat increased in both arms during 24 months follow-up (+1139±393 gram 
(p=0.005) and + 957±446 gram (p=0.04) in the ZDV/3TC/LPV/r arm and the 
NVP/LPV/r arm respectively). VAT increased significantly after 24 months, in the 
ZDV/3TC/LPV/r arm only  (+36.2±13.3 cm2 over 2 years (p=0.009)). The ratio of 
SAT to TAT decreased in the ZDV/3TC/LPV/r arm after 3 months (0.56±0.02 to 
0.50±0.02, mean change 0.057±0.025, p=0.028), but remained unchanged in the 
other arm.  
 
Glucose metabolism (Figure 1, table 3) 
There were no significant changes in fasting plasma glucose levels during follow-
up in either of the two treatment arms. Fasting plasma insulin levels however 
increased significantly over time in the ZDV/3TC/LPV/r arm. Insulin-stimulated 
peripheral glucose disposal decreased significantly by 25% after three months of 
therapy in the ZDV/3TC/LPV/r arm (p<0.001), as previously reported [9], and 
remained stable at this reduced level thereafter. In contrast, treatment with 
NVP/LPV/r did not result in a significant change of peripheral glucose disposal, 
resulting in an overall significant difference between both arms over the 24-month 
period (p<0.05).  
 
Fasting EGP decreased significantly during follow-up in both arms with no 
differences between arms. During hyperinsulinemia, EGP was suppressed equally 
in both groups in the first 12 months. The suppression of EGP by insulin increased 
significantly over 24 months in the NVP/LPV/r arm, leading to a significant 
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difference in hepatic insulin sensitivity between both groups after 24 months with a 
greater suppression of EGP by insulin in the NVP/LPV/r group.  
 
Lipolysis (Table 3) 
In the ZDV/3TC/LPV/r group, fasting glycerol turnover increased significantly by 
0.39±0.16 µmol/kg/min three months after starting therapy, returning to baseline 
levels during further follow-up. No changes in fasting glycerol turnover were 
observed in the NVP/LPV/r group over the course of 2 years. The absolute 
suppression of Ra glycerol during hyperinsulinemia showed a trend to decrease in 
the ZDV/3TC/LPV/r arm from 3 months follow-up onwards (p=0.0599). This led to 
an overall significant difference between the two arms in glycerol turnover during 
hyperinsulinemia due to lower insulin-mediated suppression in the ZDV/3TC/LPV/r 
arm. FFA levels, both in the fasting state and during hyperinsulinemia, showed a 
similar pattern, with a trend for overall difference between the two arms (p=0.07).  
 
Glucoregulatory hormones (Table 2) 
There were no significant changes in fasting plasma concentrations of cortisol over 
time in either treatment group, but after 24 months of therapy cortisol levels were 
significantly higher in the ZDV/3TC/LPV/r arm than in the NVP/LPV/r arm. Fasting 
plasma levels of glucagon decreased over time in both arms, this decrease was 
significant in the NVP/LPV/ arm only. No overall changes were observed in 
epinephrine and norepinephrine levels over 2 years in either arm. Plasma 
adiponectin concentrations increased significantly in both arms during follow-up, 
with the greatest increase in the NVP/LPV/r arm. This resulted in significant 
differences in adiponectin levels between the groups after 12 and 24 months of 
cART (mean differences 1.8±0.8 µg/ml (p=0.03) and 2.4±0.8 µg/ml (p=0,006) at 12 
and 24 months, respectively). 
 
Lipid profile (table 2) 
Plasma total cholesterol increased significantly after initiation of cART in both arms, 
but reached significantly higher levels in the NVP/LPV/r arm. LDL levels increased 
significantly only in the NVP/LPV/r arm and HDL-cholesterol increased significantly 
in both arms. Triglyceride levels increased significantly in both arms up to month 
12, but there was no significant change from baseline to month 24 in either group. 
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Discussion 
 
Body fat redistribution, dyslipidemia and insulin resistance are common findings in 
patients treated with cART. To our knowledge, this is the first prospective study 
employing serial euglycemic hyperinsulinemic clamps which demonstrates 
differences in changes in glucose and lipid metabolism in relation to the 
development of changes in body fat distribution after initiation of treatment in 
cART-naive HIV-1 infected patients, comparing a ZDV/3TC-containing with a 
ZDV/3TC-sparing regimen. We previously reported a decrease in insulin-mediated 
peripheral glucose uptake within three months of initiating cART in the 
ZDV/3TC/LPV/r group without changes in body fat distribution. These changes 
were not observed in patients randomized to the NRTI-sparing regimen of 
LPV/r/NVP[9]. We now report a persistence of this decrease in peripheral insulin 
sensitivity up to 24 months of follow-up in patients treated with ZDV/3TC/LPV/r, 
while insulin-mediated peripheral glucose uptake was not affected during follow-up 
in the LPV/r/NVP group. Other insulin sensitive metabolic pathways like lipolysis 
and endogenous glucose production show a different pattern within and between 
both groups. After 12 months, insulin’s effect on the suppression of lipolysis was 
significantly lower in the ZDV/3TC/LPV/r arm compared to the NVP/LPV/r arm, but 
this difference was no longer apparent at 24 months while hepatic insulin sensitivity 
(i.e. the suppression of EGP by insulin) after 24 months was significantly higher in 
the NVP/LPV/r group. The successive involvement of different insulin-sensitive 
pathways suggests that different underlying pathophysiological mechanisms may 
be responsible. 
 
Concerning the reduction in peripheral glucose disposal in the ZDV/3TC/LPV/r arm, 
we previously hypothesized that ZDV/3TC may interfere directly with insulin-
mediated peripheral glucose uptake [9]. The persistence of this peripheral insulin 
resistance, with no further deterioration despite the onset of peripheral fat loss and 
visceral fat accumulation, argues against an important contribution of these body 
composition changes in the pathogenesis. Several mechanisms may be 
responsible for the effects of ZDV/3TC on insulin sensitivity, including ZDV induced 
mitochondrial dysfunction. This hypothesis is supported by a study in healthy 
volunteers, in which a similar effect on peripheral glucose uptake without changes 
in body composition was observed after treatment with stavudine for 4 weeks and 
was associated with a significant reduction in muscle mitochondrial DNA and 
reduced mitochondrial function[8]. How mitochondrial dysfunction interferes with 
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peripheral insulin sensitivity has not been fully clarified yet, but accumulation of 
intracellular lipids due to reduced oxidative capacity may be one mechanism[14]. 
  
The observed transient changes in lipolysis during hyperinsulinemia (i.e. insulin 
sensitivity of adipose tissue) may be explained in part by direct effects of NRTI on 
adipocytes since it has been shown in vitro[15-17] that  NRTI may induce 
mitochondrial dysfunction within adipocytes leading to oxidative stress, increased 
apoptosis and lipolysis[18]. Another potential mechanism may be via NRTI induced 
inflammatory changes within adipose tissue resulting in dysfunctional adipocytes, 
production of pro-inflammatory cytokines and enhanced lipolysis[19]. PI may act 
synergistically with NRTI in the induction of this inflammatory state[19]. Various 
studies have shown that patients with lipodystrophy have higher adipose tissue 
expression of TNF-alpha and IL-6 compared to healthy controls[20, 21], and that, in 
these patients, higher TNF-alpha is associated with attenuated insulin-mediated 
suppression of FFA[22], which appears to support this hypothesis. The sensitivity 
of adipose tissue for these potential effects of NRTI may be fat depot-specific, with 
limb fat possibly being more sensitive than visceral fat. This may be a potential 
explanation for the changes in body composition and return of lipolysis rates to 
baseline concurrent with the reduction of limb fat and increase in visceral fat. 
Higher rates of lipolysis result in higher plasma FFA which in turn may negatively 
influence insulin-mediated peripheral glucose uptake[23]. 
 
Previous studies have shown that patients with lipodystrophy have low levels of 
adiponectin[24, 25] and that adiponectin is correlated with whole body glucose 
disposal in HIV-infected patients[26]. This has led to the hypothesis that 
adiponectin may play a role in lipodystrophy-associated insulin resistance. Our 
findings do not appear to support this, as adiponectin increased rather than 
decreased in the patients who developed insulin resistance and fat redistribution. A 
similar increase in adiponectin was observed in healthy volunteers after 4 weeks of 
administration of IDV and LPV/r[27, 28]. Adiponectin levels do not appear to 
explain the peripheral insulin resistance in the ZDV/3TC/LPV/r group. However, we 
cannot exclude that, besides the lower glucagon levels, the higher adiponectin in 
the NVP/LPV/r group at 24 months may have contributed to the increase in hepatic 
insulin sensitivity since adiponectin has been reported to decrease hepatic glucose 
production[29]. Whether adiponectin levels stabilize or even decrease if fat 
redistribution progresses to overt lipodystrophy in the ZDV/3TC/LPV/r arm, as 
might be expected from the above- mentioned studies, remains to be determined. 
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Our finding that no deterioration in glucose or glycerol metabolism occurred in 
patients treated with NVP/LPV/r, at least during two years of follow-up, challenges 
the concept that PI’s importantly contribute to the insulin resistance in patients 
treated with cART [30, 31]. This concept is based in part on in vitro research 
showing an acute inhibitory effect on GLUT-4 activity [32, 33]. Although studies in 
healthy humans confirm this acute effect on insulin sensitivity[3-5],  this effect was 
no longer present after 4 weeks of LPV/r monotherapy[7]. Furthermore, the scarce 
prospective data on insulin sensitivity in HIV-infected patients cannot distinguish 
between effects of PI and NRTI, as drugs of these classes are generally combined 
in effective cART [34]. We therefore suggest that the effect of LPV/r alone on 
insulin sensitivity is either transient or compensated for by other mechanisms, 
which may include the observed increase in adiponectin. 
 
In conclusion, we found that treatment with ZDV/3TC/LPV/r versus NVP/LPV/r 
differentially affects glucose and lipid metabolism. The ZDV/3TC/LPV/r regime 
induced a rapid onset of peripheral insulin resistance, a transient increase in basal  
lipolysis and a transient decrease in insulin-mediated inhibition of lipolysis. In the 
NVP/LPV/r arm, increased insulin-mediated inhibition of hepatic glucose production 
was observed after 24 months, probably explained by lower glucagon levels and 
possibly by the increased adiponectin. The early decrease in peripheral insulin 
sensitivity in the ZDV/3TC/LPV/r arm is probably a direct effect of the medication 
since no changes in body fat distribution occurred at that time point, although the 
fat distribution changes occurring later on may have contributed to the persistence 
of peripheral insulin resistance. Finally, the transient changes in lipolysis may be 
caused by fat depot specific sensitivity for the inflammatory and pro-apoptotic 
effects of NRTI with limb fat possibly being more sensitive than visceral fat, 
explaining the return of lipolysis rates to baseline with the reduction of limb fat and 
increase in visceral fat. 
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Table 1a.  Patient characteristics, HIV related characteristics. 
 
 ZDV/3TC/LPV/r 
 baseline Mo 3 Mo 12 Mo 24 
Number 11 11 11 11 
Age (years) 38 (34-41)    
CDC category 
A (n, %) 
B (n, %) 
C (n, %) 
 
8 (73%) 
2 (18%) 
1 (9%) 
   
CD4 cell count (106 cells/l) 200  
(140-264) 
270  
(220-430) 
370  
(293-450) 
458  
(355-590) 
HIV-1 RNA (log 10 
copies/ml) 
     
% <50 copies/ml) 
5.1  
(4.5- 5.3) 
 
0 (0%) 
2.1  
(1.7-2.5) 
 
4 (36%) 
1.7  
(1.7-1.7) 
 
11 (100%) 
1.7  
(1.7-1.7) 
 
9 (82%) 
Lopinavir concentration 
ratio’s 
- in week preceding 
clamp 
 
- during last hour of 
clamp 
  
 
1.3  
(1.1-2.1) 
 
0.9  
(0.5-1.2) 
 
 
1.3  
(1.0-1.7) 
 
0.9  
(0.7-1.2) 
 
 
1.0    
(0.9-1.6) 
 
0.9  
(0.6-1.2) 
Lopinavir concentration 
(mg/l) during last hour of 
clamp 
  
5.9  
(3.9-8.1) 
 
6.6  
(5.8-7.2) 
 
6.4  
(3.7-9.2) 
 
Data represent median (IQR) or number/percentage. 
p<0.05 between arms at visit (Mann Whitney U) 
ZDV/3TC/LPV/r: zidovudine/lamivudine/lopinavir/ritonavir 
NVP/LPV/r: nevirapine/lopinavir/ritonavir 
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Table 1b. Patient characteristics, HIV related characteristics. 
 
 NVP/LPV/r 
 baseline Mo3 Mo 12 Mo 24 
Number 9 8 9 8 
Age (years) 46(41-53)    
CDC category 
A (n, %) 
B (n, %) 
C (n, %) 
 
5 (56%) 
4 (44%) 
0 (0%) 
   
CD4 cell count (106 cells/l) 200  
(170-250) 
330  
(280-406) 
460 
(370-560) 
570 
(430-630) 
HIV-1 RNA (log 10 
copies/ml) 
     
% <50 copies/ml) 
4.8  
(4.7-5.3) 
 
0 (0%) 
1.7  
(1.7-2.3) 
 
4 (44%) 
1.7  
(1.7-1.7) 
 
8 (89%) 
1.7  
(1.7-1.7) 
 
8 (100%) 
Lopinavir concentration 
ratio’s 
- in week preceding 
clamp 
 
- during last hour of 
clamp 
  
 
1.4  
(1.0-1.7) 
 
0.8  
(0.3-1.2) 
 
 
1.5  
(1.2-1.8) 
 
1.0  
(0.8-1.2) 
 
 
1.3  
(1.1-2.1) 
 
0.8  
(0.6-1.2) 
Lopinavir concentration 
(mg/l) during last hour of 
clamp 
  
6.4  
(2.4-8.6) 
 
7.2  
(6.1-8.3) 
 
6.1  
(5.2-8.3) 
 
Data represent median (IQR) or number/percentage. 
p<0.05 between arms at visit (Mann Whitney U) 
ZDV/3TC/LPV/r: zidovudine/lamivudine/lopinavir/ritonavir 
NVP/LPV/r: nevirapine/lopinavir/ritonavir 
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Table 2a Body composition, glucoregulatory hormones and lipid profile. 
 
 LPV/r/ZDV/3TC 
 baseline Mo 3 Mo 12 Mo 24 
Body composition N=11 N=11 N=11 N=11 
Weight (kg) 77.0±0.7 76.8±0.7 77.7±0.7 78.6±0.7 
BMI (kg/m2) 23.2±0.2 23.2±0.2 23.4±0.2 23.8±0.2 
Limb fat (kg)† 6.58 ±0.26 6.83 ±0.26 6.40 ±0.26# 5.98 ±0.26# 
Total fat (kg) † 14.2±0.4 14.5±0.4# 14.8±0.4 14.7±0.4 
Limb/total fat 0.48±0.01 0.48±0.01 0.46±0.01 0.43±0.01*# 
Trunk fat (kg) 7.6±0.3 7.7±0.3# 8.4±0.3 8.8±0.3* 
SAT (cm2) 123.2±5.7 122.0±5.7 133.6±5.9 134.8±5.7 
VAT (cm2) 118.5 ±10.1 108.7 ±10.1 124.2 ±10.4 154.7 ±10.1* 
TAT (cm2) 242.5 ±13.2 231.4 ±13.2 258.9 ±13.6 290.3 ±13.2* 
SAT/TAT 0.53±0.02 0.56±0.02 0.54±0.02 0.50±0.02 
Glucoregulatory 
hormones 
    
Cortisol (nmol/l) † 214±22 251±22 166±22 239±22# 
Glucagon (ng/l) 64±4 63±4# 58±4 55±4 
Epinephrine (nmol/l) 0.12±0.03 0.12±0.03 0.11±0.03 0.12±0.03 
Norepinephrine (nmol/l) † 1.23±0.16 0.98±0.16# 1.23±0.18 1.28±0.16 
Adiponectin (µg/ml) 6.5±0.5 7.0±0.5 8.1±0.5# 8.4±0.5*# 
Lipid profile     
Total cholesterol (mmol/l) 4.3±0.2 5.3±0.2 5.5±0.2 5.4±0.2*# 
HDL-cholesterol (mmol/l) 1.10±0.07 1.24±0.07 1.38±0.07 1.40±0.07* 
LDL-cholesterol (mmol/l) 2.5±0.2 2.7±0.2 2.7±0.2 2.8±0.2# 
Triglycerides (mmol/l) 1.4±0.6 3.2±0.6 3.6±0.6 2.8±0.6 
 
Data represent estimated means±standard error of the mean. 
*p < 0.05 within group 0-24 months, #p<0.05 between groups at visit, †p < 0.05 between 
groups difference overall course 0-24 months 
 
BMI body mass index, SAT subcutaneous adipose tissue, VAT visceral adipose tissue, TAT 
total adipose tissue, HDL high density lipoprotein, LDL low density lipoprotein. 
ZDV/3TC/LPV/r: zidovudine/lamivudine/lopinavir/ritonavir 
NVP/LPV/r: nevirapine/lopinavir/ritonavir 
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Table 2b Body composition, glucoregulatory hormones and lipid profile. 
 
 LPV/r/NVP 
 baseline Mo 3 Mo 12 Mo 24 
Body composition N=9 N=8 N=9 N=8 
Weight (kg) 76.9 ±0.7 76.5 ±0.8 79.2 ±0.7 79.4 ±0.8* 
BMI (kg/m2) 23.2±0.2 23.1 ±0.2 23.9 ±0.2 24.0 ±0.2* 
Limb fat (kg)† 6.57 ±0.29 6.44 ±0.30 7.39 ±0.29 7.25 ±0.31 
Total fat (kg) † 14.2 ±0.5 13.2 ±0.5 15.8 ±0.5 15.8 ±0.5* 
Limb/total fat 0.48 ±0.01 0.50 ±0.01 0.48 ±0.01 0.49 ±0.01 
Trunk fat (kg) 7.6 ±0.3 6.7 ±0.3 8.4 ±0.3 8.5 ±0.3* 
SAT (cm2) 124.0 ±6.3 116.0 ±6.6 134.4 ±6.3 138.9 ±6.7 
VAT (cm2) 119.2 ±11.2 101.6 ±11.6 128.3 ±11.2 127.9 ±11.7 
TAT (cm2) 242.0 ±14.6 216.4 ±15.1 261.5 ±14.6 263.9 ±15.3 
SAT/TAT 0.53 ±0.02 0.53 ±0.02 0.52 ±0.02 0.55 ±0.02 
Glucoregulatory 
hormones 
    
Cortisol (nmol/l) † 221 ±25 209 ±27 193 ±25 159 ±26 
Glucagon (ng/l) 68 ±4 50 ±4 52 ±4 47 ±4* 
Epinephrine (nmol/l) 0.13 ±0.03 0.19 ±0.03 0.10 ±0.03 0.09 ±0.03 
Norepinephrine (nmol/l) † 1.23 ±0.18 1.90 ±0.20 1.49 ±0.19 0.89 ±0.19 
Adiponectin (µg/ml) 6.4 ±0.6 7.7 ±0.6 9.9 ±0.6 10.8 ±0.6* 
Lipid profile     
Total cholesterol (mmol/l) 4.3 ±0.3 5.5 ±0.3 6.2 ±0.3 6.1 ±0.3* 
HDL-cholesterol (mmol/l) 1.12 ±0.08 1.38 ±0.08 1.43 ±0.08 1.55 ±0.09* 
LDL-cholesterol (mmol/l) 2.6 ±0.2 3.0 ±0.2 3.1 ±0.2 3.4 ±0.2* 
Triglycerides (mmol/l) 1.5 ±0.7 2.5 ±0.7 3.5 ±0.7 2.8 ±0.7 
  
Data represent estimated means±standard error of the mean. 
*p < 0.05 within group 0-24 months, #p<0.05 between groups at visit, †p < 0.05 between 
groups difference overall course 0-24 months 
 
BMI body mass index, SAT subcutaneous adipose tissue, VAT visceral adipose tissue, TAT 
total adipose tissue, HDL high density lipoprotein, LDL low density lipoprotein. 
ZDV/3TC/LPV/r: zidovudine/lamivudine/lopinavir/ritonavir 
NVP/LPV/r: nevirapine/lopinavir/ritonavir 
Chapter 4 
100 
Table 3a Glucose metabolism 
 
 ZDV/3TC/LPV/r 
 baseline Mo 3 Mo 12 Mo 24 
Fasting N=11 N=11 N=11 N=11 
Glucose (mmol/l) 5.2 ±0.08 5.4 ±0.08 5.3 ±0.08 5.3 ±0.08 
Insulin (pmol/l) 42 ±4 48  ±4 50 ±4 54 ±4* 
Endogenous glucose 
production& 
11.6 ±0.3 11.4 ±0.3 10.9 ±0.3 10.8 ±0.3* 
Glycerol rate of appearance& 1.7 ±0.1 2.1 ±0.1 1.9 ±0.1 1.8 ±0.1 
Free fatty acid (mmol/l) 0.42 ±0.05 0.74 ±0.05# 0.56 ±0.05 0.52 ±0.05 
Clamp N=11 N=10 N=11 N=11 
Glucose (mmol/l) 5.0 ±0.04 5.0 ±0.04 5.0 ±0.04 5.0 ±0.04 
Insulin (pmol/l) 185 ±7 181 ±7 192 ±7 196 ±7 
Endogenous glucose 
production& 
4.0 ±0.4 4.3 ±0.4 3.8 ±0.4 4.1 ±0.4# 
 Endogenous glucose 
production suppression 
 absolute & (percentage) 
-7.7 ±0.4 
(-66 ±3%) 
-7.3 ±0.4 
(-63 ±3%) 
-7.2 ±0.4 
(-66 ±3%) 
-6.8 ±0.4 
(-64 ±3%) 
Peripheral glucose 
disposal†& 
22.9 ±1.6 17.3 ±1.6# 19.1 ±1.6 19.5 ±1.6# 
Glycerol rate of 
appearance†& 
0.78 ±0.07 0.70 ±0.07 0.94 ±0.07# 0.75 ±0.07 
Glycerol rate of appearance 
suppression 
absolute& (percentage) 
-0.9 ±0.2 
(-52 ±4%) 
-1.4 ±0.2 
(-63 ±4%) 
-0.9 ±0.2 
(-50 ±4%)# 
-1.0 ±0.2 
(-57 ±4%) 
Free fatty acid (mmol/l) 0.06 ±0.01 0.08 ±0.01 0.09 ±0.01 0.07 ±0.01 
Free fatty acid suppression 
absolute (mmol/l)/ 
percentage 
-0.34 ±0.06 
(-82 ±2%) 
-0.65 ±0.06 
(-88 ±2%) 
-0.46 ±0.06 
(-85 ±2%) 
-0.43 ±0.06 
(-86 ±2%) 
 
Data represent estimated means±standard error of the mean. & µmol/kg/min 
 
*p < 0.05 within group 0-24 months,  
#p < 0.05 between groups at visit,  
†p < 0.05 between groups difference overall course 0-24 months.  
 
ZDV/3TC/LPV/r: zidovudine/lamivudine/lopinavir/ritonavir  
NVP/LPV/r: nevirapine/lopinavir/ritonavir 
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Table 3b Glucose metabolism 
 
 NVP/LPV/r 
 baseline Mo 3 Mo 12 Mo 24 
Fasting N=9 N=7 N=9 N=8 
Glucose (mmol/l) 5.2 ±0.09 5.5 ±1.0 5.4 ±0.09 5.3 ±0.09 
Insulin (pmol/l) 43 ±4 40 ±5 51 ±4 44 ±5 
Endogenous glucose 
production& 
11.5 ±0.3 11.6 ±0.3 11.3 ±0.3 10.2 ±0.3* 
Glycerol rate of appearance& 1.7 ±0.2 1.9 ±0.2 2.0 ±0.2 1.6 ±0.2 
Free fatty acid (mmol/l) 0.45 ±0.06 0.53 ±0.07 0.57 ±0.06 0.49 ±0.06 
Clamp N=9 N=7 N=9 N=8 
Glucose (mmol/l) 4.9 ±0.04 5.0 ±0.05 5.0 ±0.04 4.9 ±0.04 
Insulin (pmol/l) 185 ±8 186 ±9 208 ±8 205 ±8 
Endogenous glucose 
production& 
4.6±0.4 3.6 ±0.5 3.8 ±0.4 2.7 ±0.5* 
 Endogenous glucose 
production suppression 
 absolute & (percentage) 
-6.9 ±0.4 
(-60 ±3%) 
-8.0 ±0.4 
(-69 ±4%) 
-7.5 ±0.4 
(-66 ±3%) 
-7.4 ±0.4 
(-73 ±4%)* 
Peripheral glucose 
disposal†& 
22.4 ±1.7 23.5 ±1.9 20.9 ±1.7 24.7 ±1.8 
Glycerol rate of 
appearance†& 
0.78 ±0.07 0.60 ±0.08 0.68 ±0.07 0.57 ±0.07* 
Glycerol rate of appearance 
suppression 
absolute& (percentage) 
-0.9 ±0.2 
(-53 ±4%) 
-1.3 ±0.2 
(-66 ±5%) 
-1.3 ±0.2 
(-63 ±4%) 
-1.1 ±0.2 
(-62 ±4%) 
Free fatty acid (mmol/l) 0.08 ±0.02 0.04 ±0.02 0.06 ±0.02 0.03 ±0.02* 
Free fatty acid suppression 
absolute (mmol/l)/ 
percentage 
-0.37 ±0.06 
(-84 ±2%) 
-0.49 ±0.07 
(-91 ±3%) 
-0.51 ±0.06 
(-89 ±2%) 
-0.45 ±0.06 
(-90 ±2%) 
  
Data represent estimated means±standard error of the mean. & µmol/kg/min 
 
*p < 0.05 within group 0-24 months,  
#p < 0.05 between groups at visit,  
†p < 0.05 between groups difference overall course 0-24 months.  
 
ZDV/3TC/LPV/r: zidovudine/lamivudine/lopinavir/ritonavir  
NVP/LPV/r: nevirapine/lopinavir/ritonavir 
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Shown are estimated means ± standard error of the mean. 
ZDV/3TC/LPV/r: zidovudine/lamivudine/lopinavir/ritonavir 
NVP/LPV/r:nevirapine/lopinavir/ritonavir 
Figure 1 
Graphs of peripheral glucose uptake, rate of appearance of glycerol, endogenous 
glucose production during the clamp and adiponectin levels. 
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Abstract  
 
Objective 
We studied changes in bone mineral density (BMD) and bone turnover after 
initiation of combination antiretroviral therapy (cART) and the contribution of 
zidovudine/lamivudine (ZDV/3TC) in particular. 
 
Design 
Randomized clinical trial comparing lopinavir/ritonavir(LPV/r)+ZDV/3TC with 
LPV/r+nevirapine (NVP) in 50 cART-naïve men. 
 
Methods 
Dual energy X-ray absorptiometry (DXA) and quantitative computed tomography 
scans (QCT) were performed at baseline and 3, 12, and 24 months after cART 
initiation. Serum 25-hydroxy-vitamin D3, parathyroid hormone (PTH), osteocalcin, 
and urine deoxypyridinoline (DPD)/creatinine ratio were measured. 
 
Results 
BMD decreased rapidly in both femoral neck and lumbar spine (DXA and QCT) 
after cART initiation. BMD loss during 24 months measured by DXA was greater in 
the ZDV/3TC/LPV/r group compared to the NVP/LPV/r group (femoral neck: -
6.3%±1.0% (p<0.0001) compared to -2.3%±0.9% (p=0.01), between-group 
p=0.0006), lumbar spine: -5.1% ± 0.8% (p<0.0001) compared to -2.6% ± 0.7% 
(p=0.0006), between-group p=0.07) Osteocalcin (+1.60±0.32 (p<0.0001) and + 
1.81±0.29 (p<0.0001) nmol/l) and the urine DPD/creatinine ratio (+1.35±0.44 
(p=0.0029) and + 1.19±0.38 nmol/mmol (p=0.0024) increased in both groups over 
24 months, with no significant difference between groups. PTH increased to a 
greater degree in the NVP/LPV/r group (+ 2.0±0.31 pmol/l (p<0.0001) compared to 
+0.81±0.33 pmol/l (p=0.021) in the ZDV/3TC/LPV/r group). 
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Conclusions 
BMD in both femoral neck and lumbar spine decreased rapidly after initiation of 
cART, in parallel to an increase in bone turnover. The greater bone loss in the 
ZDV/3TC/LPV/r group compared to the NVP/LPV/r group suggests that ZDV/3TC 
contributes to this process. The PTH increase does not explain this greater bone 
loss. 
 
(ClinicalTrials.gov number: NCT 00122226, http://www.clinicaltrials.gov) 
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Introduction 
 
An increased prevalence of reduced bone mineral density (BMD) has been 
reported among HIV-infected patients [1]. Longitudinal studies have generally 
observed a decrease in BMD after the initiation of combination antiretroviral 
therapy (cART) in cART- naïve patients[2-4]. However, prospective studies in 
cART-experienced patients have shown either an increase in or stable BMD over 
time[5-9], suggesting that BMD may stabilize after an initial decline in the first 
period after the start of cART. Recently, in a large population-based study, fracture 
prevalence was shown to be increased in HIV-infected patients compared to non-
HIV infected controls[10]. 
The mechanisms for reduced BMD in HIV-infected patients have not been fully 
elucidated. HIV proteins have been shown to modulate osteoblast function and 
development [11], and may also affect osteoclastogenesis[12]. Persistent pro-
inflammatory activation in HIV infection has been associated with disturbed bone 
formation and resorption[13]. Other traditional risk factors frequently found in HIV-
infected patients, including low body weight, hypogonadism and a high smoking 
prevalence, may also play a role[14]. The contribution of antiretroviral drugs to 
reduced BMD in HIV-infected patients is a controversial issue. In vitro evidence 
suggests that different protease inhibitors (PI) have heterogeneous effects on 
bone[15, 16]. Among the nucleoside reverse transcriptase inhibitors (NRTI), 
zidovudine, lamivudine and didanosine have been shown to enhance 
osteoclastogenesis[17], whereas tenofovir has been associated with decreased 
BMD[17], potentially due to renal phosphate wasting, a mineralization defect and, 
ultimately, osteomalacia[18]. Prospective randomized trials investigating the effects 
of initiation of different antiretroviral drugs on bone mineral metabolism are scarce 
and have mainly focused on the role of PI and tenofovir[3, 4]. 
We aimed to explore the role of zidovudine and lamivudine (ZDV/3TC) on BMD 
and bone metabolism in patients initiating cART. We performed sequential BMD 
measurements of the femoral neck and lumbar spine and of serum and urine 
markers of bone metabolism in a randomized clinical trial, comparing a thymidine 
analogue (TA)-NRTI sparing regimen of nevirapine with lopinavir/ritonavir with a 
TA-NRTI containing regimen of ZDV/3TC combined with lopinavir/ritonavir in prior 
cART-naïve patients. We hypothesized that bone loss would be greater in patients 
using ZDV/3TC than in patients in the TA-NRTI sparing group. We currently report 
the results of the planned primary analysis after 24 months of follow-up. 
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Patients and methods 
 
Study design and patients 
The MEDICLAS (Metabolic Effects of DIfferent CLasses of AntiretroviralS) trial is a 
multicenter, single-blinded, randomized trial of 36 months duration comparing the 
TA-NRTI-containing regimen of zidovudine/lamivudine (ZDV/3TC, 300/150 mg bd) 
+ lopinavir/ritonavir (LPV/r, 400/100 mg bd) with the TA-NRTI-sparing regimen of 
nevirapine (NVP, 200 mg bd) + LPV/r (533/133 mg bd)[19] . The main objective of 
the trial is to assess and compare the impact of both treatments on body fat 
distribution and metabolic complications. 
Eligible patients were antiretroviral-naïve HIV-1-infected men, 18-70 years old, with 
an indication to start cART according to international and national guidelines in 
each participating country. Subjects with severe obesity (body mass index 
(BMI)>35 kg/m2), diabetes mellitus, a history of hyperlipidemia, or use of lipid-
lowering drugs, nandrolone or testosterone, were excluded. Patients were recruited 
from HIV treatment centers in the Netherlands, Spain, Finland and the United 
Kingdom. The study was approved by the ethics committees of all participating 
centers, and each patient provided written informed consent prior to study entry.  
 
Randomisation procedure 
At the central study coordinating center a treatment allocation sequence (1:1 for 
ZVD/3TC + LPV/r and NVP + LPV/r) was generated using the minimisation variable 
body mass index (BMI, ≤25 kg/m2 versus >25 kg/m2).  
 
Procedures 
BMD was measured by dual energy X-ray absorptiometry (DXA) in all participants 
and quantitative computed tomography (QCT) scans in those recruited in the 
Netherlands, Finland and the United Kingdom at baseline and 3, 12, 24 and 36 
months after start of treatment. DXA scans were performed in the Hospital Clinic, 
Barcelona for the Spanish participants, and in the VU University Medical Center 
and Academic Medical Center, Amsterdam for all other participants. QCT scans 
were performed in the Academic Medical Center at the same timepoints as the 
DXA scans. At the same timepoints, serum and urine markers of bone turnover 
were assessed in all participants, and body fat distribution was measured as 
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previously described[19]. Limb and trunk fat were quantified by DXA (Hologic QDR-
4500W, software version whole body v8.26A:5). A standardized single slice 
abdominal CT-scan was performed from which the surface area of visceral (VAT), 
subcutaneous (SAT), and total adipose tissue (TAT) was determined. Plasma HIV-
1 RNA measurements, CD4 cells, hematology and chemistry tests and adverse 
events were monitored at baseline, after 1 and 3 months of treatment, and every 
three months thereafter. 
 
Dual energy X-ray absorptiometry 
BMD of the lumbar vertebrae (L1-L4) and hip (femoral neck) were measured by 
DXA  (Hologic QDR-4500W, Hologic Inc., Bedford, MA, USA). BMD was defined as 
bone mineral content, divided by the surface of the projected bone area, expressed 
in g/cm2. T- and Z-scores were calculated using hip reference values based on the 
National Health and Nutrition Examination Survey (NHANES III) and Hologic 
reference values for the lumbar spine (L1-L4). The T-score is the patient’s BMD 
expressed as the number of standard deviations difference from the mean BMD of 
the 30 year old reference population (of the same sex), the Z-score is the patient's 
BMD expressed as the number of standard deviations difference from the mean of 
the age-matched reference population. As defined by the World Health 
Organization, a BMD T-score of minus 2.5 or less was classified as osteoporosis 
and a BMD T-score between -1 and -2.5 as osteopenia. Scans were analyzed by 
radiology staff who were blinded to allocated trial treatment.  
 
Quantitative CT scans 
A cross-sectional CT scan (Mx8000 4-slice CT-scanner, Philips Medical Systems, 
Best, the Netherlands) of the abdomen at the level of the lumbar spine was 
performed. A solid calcium hydroxyapatite QCT reference phantom (QCT-5000, 
Image Analysis Inc, Columbia, KY, USA) was placed beneath the patient’s lower 
back. This phantom contains 4 cylinders of calciumhydroxyapatite with different 
concentrations (0, 50, 100, and 200 mg/cm3). A lateral scout image standardized 
the location of the slices at the mid L2 and L3 vertebrae. Standardized scanning 
specifics were set at 120 kV, 100 mAs, 10 mm slice thickness and a field-of-view 
between 300 and 500 mm. Elliptical regions of interest (ROIs) were manually 
defined in the images in the region of the trabecular bone of each vertebral body, 
and the mean CT-number (in Houndsfield Units) within each ROI was calculated. 
Chapter 5 
109 
The mean CT-numbers of the cylinders of calciumhydroxyapatite within the 
reference phantom were determined likewise. The mean CT-number of the 
trabecular bone of each vertebra was converted into a bone density in mg/cm3 
calciumhydroxyapatite by comparing both sets of measurements[20]. All scans 
were analyzed by two blinded investigators. 
 
Markers of calcium metabolism and bone turnover 
25-hydroxy-vitamin D3 was measured by a competitive binding protein assay 
(Diasorin, Stillwater, Minnesota, USA). The intra- and inter-assay coefficients of 
variation are 9% and 10%, respectively. Parathyroid hormone (PTH) was 
measured by an immunometric assay (Abbott laboratories, Illinois, USA). The intra- 
and inter-assay coefficients of variation are both 5%. Osteocalcin, a marker of bone 
formation, was measured by an immunometric assay (Biosource, Nivelles, 
Belgium), with an intra- and inter-assay coefficient of variation of <5% and 7%, 
respectively. Urine deoxypyridinoline (DPD), a marker of bone resorption, was 
measured by a competitive immunoassay (Immulite 2500, Siemens, California, 
USA). The intra- and inter-assay coefficients of variation are both 10%. The ratio of 
urine deoxypyridinoline to urine creatinine (in nmol/mmol creatinine) was 
calculated. 
25-hydroxy-vitamin D3 and PTH were measured at baseline and after 24 months, 
all other markers were perfomed at all study visits. 
  
Statistical analysis  
Analyses were by intention-to-treat, including all randomized patients who received 
at least one dose of allocated treatment. Within-group changes, between-group 
differences in overall course and between-group differences at study visits were 
analyzed by mixed model repeated measures analysis with correction for 
differences in baseline values. A second longitudinal analysis of BMD by DXA was 
performed with adjustment for local changes in fat and lean mass. Data are 
presented as estimated means ± standard error of the mean. Data that were not 
analyzed longitudinally were compared between groups using Mann Whitney U 
tests and Chi square/ Fisher exact tests (where applicable). Alpha<0.05 was 
considered statistically significant. SAS version 9.2 (SAS Institute, Cary, North 
Carolina, USA)(for the longitudinal analysis) and SPSS statistical software version 
15.0 (SPSS Inc, Chicago, IL) were used for the analyses. 
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Results 
 
Patient characteristics  
A total of 50 patients were included in the study; 23 were randomly assigned to 
ZDV/3TC/LPV/r and 27 to NVP/LPV/r. Two patients, one in each group, did not 
start allocated therapy and were therefore not included in the analysis. Eight 
patients, 4 in each group, whose data were included in the analysis, prematurely 
discontinued the study (4 were lost to follow-up, 3 withdrew consent and one 
patient died at home, presumably due to an acute myocardial infarction). The 
groups had comparable baseline demographic and HIV disease characteristics 
(Table 1). Antiretroviral therapy was modified in eight patients. In the 
ZDV/3TC/LPV/r group, one patient switched from ZDV to tenofovir after 3 months 
for anemia, one switched to tenofovir/lamivudine/efavirenz after 4 months for 
anemia and hypercholesterolemia and one patient switched from LPV/r to NVP for 
hypercholesterolemia after 17 months. In the NVP/LPV/r group, two patients 
switched to ZDV/3TC/NVP, one after 3 months for diarrhea and one after 24 
months at his own request. In three other patients NVP was replaced by efavirenz 
because of hepatotoxicity and/ or rash after 1, 2 and 5 months, respectively. Data 
of all patients switching medication were included in the analysis. No fractures 
were reported during the trial period. 
 
Body composition, virology and immunology 
Changes in body composition and virologic and immunologic responses to cART 
were reported previously[19]. In summary, patients in the ZDV/3TC/LPV/r group 
had a progressive decline in limb fat after the first three months, whereas limb fat 
increased in patients randomized to NVP/LPV/r. Trunk fat increased in both 
groups, but VAT increased in patients on ZDV/3TC/LPV/r only. Patients in both 
groups had similar immunologic and virologic responses to cART. The median CD4 
cell increase over 24 months was 280 (205-455) and 308 (191-410) x 106 cells/l in 
the ZDV/3TC/LPV/r group and NVP/LPV/r group, respectively. At 24 months, 17/22 
(77%) of the patients in the ZDV/3TC/LPV/r group and 21/26 (80%) in the 
NVP/LPV/r group had a plasma HIV-RNA below 50 copies/ml. 
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BMD of the femoral neck (table 2, figure 1)  
At baseline, 6/22 (27.3%) patients in the ZDV/3TC/LPV/r group and 8/26 (30.8%) in 
the NVP/LPV/r group had femoral neck osteopenia. One patient in the 
ZDV/3TC/LPV/r group (4.5%) and none in the NVP/LPV/r group had femoral neck 
osteoporosis. Femoral neck BMD decreased significantly in both groups after 
initiation of cART, but this decrease was significantly greater in the ZDV/3TC/LPV/r 
group compared to the NVP/LPV/r group (loss of 6.3%±1.0% (p<0.0001) and 
2.3%±0.9% (p=0.01), respectively, between-group p=0.0006). After 24 months, 
patients in the ZDV/3TC/LPV/r group had significantly lower femoral neck BMD 
compared to patients in the NVP/LPV/r group (between-group difference 
0.036±0.01 g/cm2, p=0.0006). After 24 months, 7/18 (38.9%) of patients in the 
ZDV/3TC/LPV/r group and 9/21 (40.9%) in the NVP/LPV/r group had osteopenia 
(p=0.58), no patients had osteoporosis in either group. The patient with 
osteoporosis at baseline had dropped out of the study after 3 months.  
 
BMD of the lumbar spine (table 2, figure 1) 
At baseline, 8/22 (36.4%) patients in the ZDV/3TC/LPV/r group and 7/26 (26.9%) in 
the NVP/LPV/r group had osteopenia of the lumbar spine. One patient in the 
ZDV/3TC/LPV/r group (4.5%) and two in the NVP/LPV/r group (7.7%) had lumbar 
spine osteoporosis.  
As was the case for the femur, lumbar spine BMD decreased significantly in both 
groups after initiation of cART, and there was a trend for this decrease to be 
greater in the ZDV/3TC/LPV/r group compared to the NVP/LPV/r group (-5.1% ± 
0.8% (p<0.0001) and -2.6% ± 0.7% (p=0.0006), respectively, between-group p 
0.07). Patients in the ZDV/3TC/LPV/r group had significantly lower lumbar spine 
BMD after 24 months than patients in the NVP/LPV/r group (between-group 
difference 0.025 ± 0.01 g/cm2, p=0.01). After 24 months, 6/18 (33.3%) patients in 
the ZDV/3TC/LPV/r group and 8/22 (36.4%) in the NVP/LPV/r group had lumbar 
spine osteopenia (p=0.97). Three patients, two in the ZDV/3TC/LPV/r group and 
one in the NVP/LPV/r group, developed lumbar spine osteoporosis over 24 
months; two patients with osteoporosis at baseline dropped out of the study. 
Lumbar spine BMD measured by QCT also declined significantly in both groups, at 
both levels L2 and L3, over 24 months. However, in contrast to the DXA scan 
results, no difference in BMD decrease was observed between groups. At level L2, 
the BMD decrease was 10.9±2.9 mg/cm3 (6.0±2.0%, p=0.003) in the 
ZDV/3TC/LPV/r group and 11.5±3.0 mg/cm3 (7.7±2.1%, p=0.003) in the NVP/LPV/r 
Chapter 5 
112 
group, between-group p=0.65. At level L3, these differences were 10.5±2.6 mg/cm3 
(5.9±1.7%, p=0.001) and 13.3±2.7 mg/cm3 (9.2±1.8%, p<0.0001) for the 
ZDV/3TC/LPV/r and NVP/LPV/r groups, respectively, between-group p=0.66. 
 
Analysis adjusted for body composition changes 
All longitudinal analyses of BMD measured by DXA scans were repeated after 
adjustment for changes in soft tissue surrounding the measured bone site. For the 
femur, adjustments were made for changes in total leg fat and lean mass, and for 
the lumbar spine, adjustments were made for changes in trunk fat and lean mass. 
These adjustments did not change the results of the analyses as described above 
(data not shown).  
 
Markers of bone mineral metabolism (table 2) 
Osteocalcin increased significantly in both groups over 24 months (+1.60±0.32 
(p<0.0001) and + 1.81±0.29 (p<0.0001) nmol/l for the ZDV/3TC/LPV/r and 
NVP/LPV/r groups, respectively), with no significant difference between the groups, 
overall or at any timepoint. The ratio of urine deoxypyridinoline to urine creatinine 
also increased significantly over 24 months in both groups (+1.35±0.44 nmol/mmol 
(p=0.0029) and + 1.19±0.38 nmol/mmol (p=0.0024) for the ZDV/3TC/LPV/r and 
NVP/LPV/r groups, respectively), between-group p=0.41. Serum 25-hydroxy-
vitamin D and serum calcium (corrected for albumin) did not change over time in 
either of the groups. PTH increased significantly in both groups, but to a greater 
degree in the NVP/LPV/r group (+ 2.0±0.31 pmol/l (p<0.0001) compared to 
+0.81±0.33 pmol/l (p=0.021) in the ZDV/3TC/LPV/r group, between-group 
p=0.009)). After 24 months, PTH was significantly higher in patients in the 
NVP/LPV/r group than in those treated with ZDV/3TC/LPV/r (between-group 
difference 1.24±0.34 pmol/l (p=0.0009). Concurrently, a significant decline in serum 
phosphate was observed in the NVP/LPV/r group (-0.10±0.04 mmol/l (p=0.011)), 
whereas no overall change occurred in this parameter in patients in the 
ZDV/3TC/LPV/r group. 
There was no overall significant difference in serum lactate levels between the 
groups, although there was a transient increase of 0.6±0.22 mmol/l (p=0.008) over 
the first 12 months in the ZDV/3TC/LPV/r group leading to a difference of 
0.58±0.27 mmol/l (p=0.035) between groups at 12 months. 
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Discussion 
 
Osteopenia and osteoporosis are increasingly being reported among HIV-infected 
patients. To our knowledge, this is the first prospective study investigating changes 
in BMD and bone turnover after treatment initiation in cART-naïve HIV-infected 
patients, comparing a ZDV/3TC-containing with a ZDV/3TC-sparing regimen. Our 
findings confirm the high prevalence of osteopenia[1], already present prior to start 
of cART. We observed a rapid BMD decrease in both femoral neck and lumbar 
spine after initiation of cART. The BMD loss measured by DXA was significantly 
greater in patients randomized to ZDV/3TC/LPV/r compared to those using 
NVP/LPV/r. Furthermore, markers of bone formation (osteocalcin), and bone 
resorption (urine DPD/creatinine ratio) increased significantly after start of cART in 
all patients, indicating a rapid increase in bone turnover.  
Our finding that patients treated with ZDV/3TC/LPV/r had significantly greater bone 
loss compared to those using NVP/LPV/r suggests that ZDV/3TC contributes to 
bone loss in patients initiating cART. This result is somewhat consistent with 
another study in which patients using ZDV- or stavudine containing regimens had a 
small but significant BMD decrease during 104 weeks follow-up, whereas those 
switching to abacavir had stable BMD[21]. Both zidovudine and lamivudine have 
been shown to enhance osteoclastogenesis[17], potentially leading to bone loss. 
Lactic acidemia due to NRTI related mitochondrial dysfunction has also been 
suggested to play a role in reduced BMD in HIV-infected patients[22]. Another 
study in which patients switching to low dose stavudine had improvement in 
mitochondrial indices and stable BMD, while those continuing full dose stavudine 
had significant bone loss after 48 weeks, may also support this hypothesis[23]. In 
our study, lactate levels did not differ significantly between the two groups over 
time. However, the transient significant increase in lactate in the ZDV/3TC/LPV/r 
group in the first year, concurrent with the greatest bone loss, could suggest that 
lactic acidemia plays a role in bone loss.  
Alternatively, a protective effect of NVP may theoretically explain the difference in 
bone loss between the two groups, although we are not aware of any clinical or in 
vitro evidence supporting this theory.  
The degree of bone loss over 24 months in the ZDV/3TC/LPV/r group is 
comparable to that observed in patients starting the same regimen in a small 48 
week trial[4]. In that study, patients using ZDV/3TC with abacavir had significantly 
less BMD decrease than those using ZDV/3TC/LPV/r, suggesting a contribution of 
LPV/r to bone loss. As patients in both our study groups were treated with LPV/r, 
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we cannot draw any conclusions concerning the role of this PI in the observed 
BMD changes.  
The difference in decrease of lumbar spine BMD between groups was only visible 
when measured by DXA and not by QCT scan. There are several potential 
explanations for this apparent contrast. First, QCT scan measured the central part 
of the vertebral body, i.e. trabecular bone, whereas DXA scan cannot differentiate 
between trabecular and cortical bone. Our findings therefore suggest that cortical 
bone is mainly affected in the ZDV/3TC/LPV/r group, whereas trabecular bone loss 
was similar in both groups. A histomorphometric study of bone biopsies could 
confirm this hypothesis. Another possible explanation for this discrepancy may be 
underestimation of BMD by DXA scan, which can occur when the ratio of fat to lean 
tissue decreases in the area surrounding the bone, as may be the case in our 
patients[24, 25]. As adjustment of analyses for local fat and lean mass did not 
change the results, this does not appear to be the most likely explanation for the 
observed differences. 
 
The increases in serum osteocalcin and the urinary DPD/creatinine ratio in all 
patients indicate an increase in bone turnover after initiation of cART. High bone 
turnover usually leads to increased bone loss, as is seen for instance in the 
menopausal state and hyper(para)thyroidism. Our findings are in agreement with 
the only other longitudinal study that measured markers of bone metabolism in 
patients initiating cART[13]. In the pre-HAART era, HIV-infected patients were 
generally observed to have low serum osteocalcin concentrations[26-28], 
consistent with a low bone formation rate, and high levels of bone resorption 
markers[28]. Besides direct effects of HIV proteins on osteoblasts and osteoclasts, 
chronic inflammation may play a role, and various cytokines are known to increase 
osteoclast activity[29, 30] and inhibit bone formation[31, 32]. Suppression of HIV 
and the accompanying chronic inflammatory response may reverse or ameliorate 
some of these processes. Unfortunately, the design of our study does not enable 
us to distinguish whether and to what extent these changes may be due to the 
suppression of HIV or to any direct effects of antiretroviral drugs.  
 
cART-naïve HIV-infected patients have been shown to have relatively low levels of 
PTH[33]. Various mechanisms have been suggested, including suppression of 
PTH secretion by TNF-alpha, and parathyroiditis due to HIV[33]. An increase in 
PTH after start of cART is therefore not an unexpected finding, and is in agreement 
with a previous study[13]. The greater increase in the NVP/LPV/r group however 
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remains unexplained, especially as this group showed less bone loss than the 
ZDV/3TC/LPV/r group, suggesting that the PTH increase does not explain the 
greater degree of bone loss on ZDV/3TC/LPV/r. 
 
Previous studies have shown that the relative risk of fracture for a BMD decrease 
of one standard deviation below age-adjusted mean (Z-score) is approximately 2 to 
2.5[34, 35]. Although these studies were performed in a different population, these 
results do suggest that the observed changes in BMD in our study may eventually 
increase the risk of osteoporotic fractures. In particular, the 0.5 SD BMD loss in the 
lumbar spine in the ZDV/3TC/LPV/r group can be calculated to correspond to an 
approximately 50-60% greater relative fracture risk, whereas in the NVP/LPV/r arm 
this risk would be around 30% greater. As the absolute fracture risk is low in this 
age category, a clinically significant difference may only become apparent after 
longer follow-up with older age. 
 
The main limitation of our study is the limited sample size. Smaller differences in 
markers of bone turnover, which might have been expected considering the 
observed differences in bone loss between groups, may therefore have remained 
undetected.  
 
In conclusion, we demonstrated a rapid BMD decrease in both femoral neck and 
lumbar spine after initiation of cART, in parallel to an increase in bone turnover. 
The loss of BMD was significantly greater in the ZDV/3TC/LPV/r group compared 
to the NVP/LPV/r group, suggesting that ZDV/3TC contributes to this process, the 
mechanism of which remains to be elucidated. 
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Table 1. Baseline characteristics of the study population.  
 
 ZDV/3TC/LPV/r 
(n=22) 
NVP/LPV/r 
(n=26) 
Age (years) 38 (35-43) 43 (35-52) 
Current smoking 9 (40.9%) 14 (53.8%) 
Current alcohol use 
(Units/week) 
5 (1-15) 2 (0-14) 
BMI (kg/m2) 23.1 (21.5-24.8) 22.8 (20.4-27) 
Ethnic group 
Black 
Caucasian 
Hispanic 
Other 
 
1 (4.5%) 
19 (86.4%) 
0 (0%) 
2 (9.1%) 
 
2 (7.7%) 
20 (76.9%) 
2 (7.7%) 
2 (7.7%) 
Mode of infection 
Heterosexual 
Hetero/homosexual 
Homosexual 
Unknown 
 
2 (9.1%) 
0 (0%) 
20 (90.9%) 
0 (0%) 
 
3 (11.5%) 
1 (3.8%) 
21 (80.8%) 
1 (3.8%) 
CDC category 
A 
B 
C 
 
14 (63.6%) 
3 (13.6%) 
5 (22.7%) 
 
16 (61.5%) 
6 (23.1%) 
4 (15.4%) 
   
CD4 cell count (106/l) 225 (170-280) 200 (120-360) 
HIV-RNA (log 10 copies/ml) 5.11 (4.98-5.33) 4.88 (4.62-5.34) 
 
 
Shown are median (interquartile range) or number (percentage). ZDV/3TC/LPV/r 
zidovudine/lamivudine/ lopinavir/ritonavir. NVP/LPV/r nevirapine/lopinavir/ritonavir. CDC 
Centers for Disease Control. 
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Table 2a. DXA, QCT and serum and urine markers of bone mineral metabolism.  
 
 ZDV/3TC/LPV/r 
 Mo 0 Mo 3 Mo 12 Mo 24 
DXA  N=22 N=20 N=19 N=18 
lumbar spine BMD (g/cm2) 1.06±0.007 1.04±0.007 1.01±0.007 1.01±0.007#* 
Lumbar spine T score -0.5±0.06 -0.7±0.07 -1.0±0.07 -1.0±0.07#* 
Lumbar spine Z score -0.3±0.07 -0.5±0.07 -0.8±0.07 -0.8±0.07#* 
Lumbar spine osteopenia (T score between 
-1 and -2.5) (n (%))  
8 (36.4%) 7 (35%) 7 (36.8%) 6 (33.3%) 
Lumbar spine osteoporosis (T score ≤2.5) 
(n(%))  
1 (4.5%) 0 (0%) 2 (10.5%) 2 (11.1%) 
Femoral neck BMD (g/cm2) † 0.91±0.007 0.90±0.008 0.87±0.007 0.85±0.008#* 
Femoral neck T score† -0.4±0.06 -0.4±0.06 -0.7±0.06 -0.8±0.06#* 
Femoral neck Z score† 0.04±0.06 0.05±0.06 -0.2±0.06* -0.3±0.06#* 
Femoral neck osteopenia (T score between 
-1 and -2.5) (n (%)) 
6(27.3%) 5(25%) 5 (26.3%) 7 (38.9%) 
Femoral neck osteoporosis (T score ≤2.5) 
(n(%)) 
1 (4.5%) 0 (0%) 0 (0%) 0 (0%) 
QCT N=19 N=18 N=17 N=18 
BMD level L2 (mg/cm3) 170.1±2.3 163.6±2.4 158.9±2.4 159.2±2.4# 
BMD level L3 (mg/cm3) 163.8±2.1 157.8±2.2 152.2±2.2 153.3±2.2# 
Markers of bone mineral metabolism and 
lactate 
    
25-hydroxy vitamin D (nmol/l) 66.0±3.4 - - 62.5±3.7 
Serum calcium (mmol/l) 2.26±0.01 2.30±0.01 2.27±0.01 2.26±0.01 
Serum phosphate (mmol/l) † 1.07±0.03 1.16±0.03* 1.14±0.03* 1.06±0.03 
Parathyroid hormone (pmol/l) † 4.80±0.28 - - 5.61±0.25#* 
Osteocalcin (nmol/l) 1.60±0.22 3.18±0.24 3.88±0.24 3.20±0.25# 
Urine DPD/creatinine ratio (nmol/mmol) 4.51±0.29 6.15±0.31 5.86±0.34 5.87±0.33# 
Lactate (mmol/l) 1.17±0.13 1.60±0.14 1.78±0.18* 1.05±0.39 
 
Shown are estimated means± standard error of the mean (mixed model repeated measures 
analysis with correction for differences in baseline values) or number (percentage) as 
indicated. Serum calcium is corrected for serum albumin. 
 
ZDV/3TC/LPV/r zidovudine/lamivudine/ lopinavir/ritonavir.  
NVP/LPV/r nevirapine/lopinavir/ritonavir.  
BMD bone mineral density.  
DPD deoxypyridinoline. 
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Table 2b. DXA, QCT and serum and urine markers of bone mineral metabolism. 
 
 NVP/LPV/r 
 Mo 0 Mo 3 Mo 12 Mo 24 
DXA  N=26 N=24 N=24 N=22 
lumbar spine BMD (g/cm2) 1.06±0.006 1.05±0.007 1.03±0.007 1.04±0.007# 
Lumbar spine T score -0.5±0.06 -0.7±0.06 -0.8±0.06 -0.8±0.06# 
Lumbar spine Z score -0.3±0.06 -0.5±0.06 -0.6±0.06 -0.6±0.06# 
Lumbar spine osteopenia (T score between -
1 and -2.5) (n (%)) 
7 (26.9%) 10 (41.7%) 11 (45.8%) 8 (36.4%) 
Lumbar spine osteoporosis (T score ≤2.5) 
(n(%))  
2 (7.7%) 1 (4.2%) 1 (4.2%) 2 (9.1%) 
Femoral neck BMD (g/cm2) † 0.91±0.006 0.89±0.007 0.89±0.007 0.89±0.007# 
Femoral neck T score† -0.4±0.05 -0.6±0.05 -0.6±0.05 -0.6±0.05# 
Femoral neck Z score† 0.04±0.05 -0.06±0.05 -0.01±0.05 -0.04±0.06 
Femoral neck osteopenia (T score between -
1 and -2.5) (n (%)) 
8 (30.8%) 8 (33.3%) 9 (37.5%) 9 (40.9%) 
Femoral neck osteoporosis (T score ≤2.5) 
(n(%)) 
0 (0%) 0 (0%) 0 (0%) 0 (0%) 
QCT N=18 N=16 N=16 N=15 
BMD level L2 (mg/cm3) 169.5±2.4 163.3±2.5 157.0±2.5 157.9±2.6# 
BMD level L3 (mg/cm3) 163.4±2.2 157.3±2.3 152.6±2.3 150.1±2.4# 
Markers of bone mineral metabolism and 
lactate 
    
25-hydroxy vitamin D (nmol/l) 64.9±3.2 - - 64.0±3.5 
Serum calcium (mmol/l) 2.29±0.01 2.28±0.01 2.27±0.01 2.28±0.01 
Serum phosphate (mmol/l) † 1.08±0.03 1.06±0.03 0.98±0.03 0.98±0.03# 
Parathyroid hormone (pmol/l) † 4.82±0.21 - - 6.85±0.23# 
Osteocalcin (nmol/l) 1.62±0.21 3.15±0.22 3.79±0.21 3.43±0.23# 
Urine DPD/creatinine ratio (nmol/mmol) 4.49±0.25 5.96±0.30 5.35±0.30 5.68±0.29# 
Lactate (mmol/l) 1.29±0.13 1.40±0.14 1.20±0.20 1.76±0.56 
 
*p<0.05 between groups at each timepoint 
† p<0.05 overall comparison between groups over time 
# p<0.05 within group 0-24 months 
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Figure 1. Bone mineral density (BMD) and Z score of the lumbar spine and femoral neck 
measured by DXA scan. 
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Shown are estimated means± standard error of the mean (mixed model repeated 
measures analysis with correction for differences in baseline values).    
ZDV/3TC/LPV/r zidovudine/lamivudine/ lopinavir/ritonavir.  
NVP/LPV/r nevirapine/lopinavir/ritonavir. 
 
*p<0.05 between groups at each timepoint 
† p<0.05 overall comparison between groups over time 
# p<0.05 within group 0-24 months 
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Abstract 
 
Objectives 
HIV-infected patients using combination antiretroviral therapy (ART) have an 
increased cardiovascular risk. We aimed to identify the effects of HIV, ART and 
lipodystrophy (LD) on carotid artery intima-media thickness (C-IMT), a surrogate 
measure of atherosclerosis, and arterial stiffness, a marker of cardiovascular risk. 
 
Design 
Case control study of 77 HIV infected men (55 exposed to ART, 22 ART-naïve, 23 
with LD) and 52 controls.   
 
Methods 
C-IMT was measured ultrasonically, arterial stiffness was estimated by distensibility 
(DC) and compliance (CC) coefficients of the carotid, femoral, and brachial 
arteries, by the carotid elastic modulus (YEM) and pulse wave velocity (PWV).  
 
Results 
After adjustment for cardiovascular risk factors, HIV infected patients had a 0.067 
mm (10.8%) greater C-IMT than controls, and 13.6% and 29.5% lower DC and 
14.1% and 31% lower CC of the carotid and femoral arteries, respectively, but 
similar YEM and PWV. Patients exposed to ART had similar C-IMT compared to 
ART-naïve patients, but 25.9% lower DC and 21.7% lower CC of the femoral 
artery. Arterial properties did not differ between patients with and without LD. 
 
Conclusions 
HIV infection is independently associated with C-IMT and generally increased 
arterial stiffness. ART use is associated with increased stiffness of the femoral 
artery.  
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Introduction 
 
The use of combination antiretroviral therapy (ART) has resulted in a significant 
reduction in morbidity and mortality in patients with HIV-1 infection[1]. However, 
soon after the introduction of combination ART unexpected vascular events among 
young patients generated concern [2, 3]. Retrospective studies addressing the risk 
of cardiovascular events in ART treated patients showed conflicting results[4-8], 
but a large prospective study found a significant association between cumulative 
exposure to PI-but not NNRTI-containing cART and risk of myocardial infarction[9]. 
More recently, the same study also showed myocardial infarction risk to be 
associated with current but not cumulative use of abacavir, which, contrary to what 
was found for PI, could not be explained through any effect on lipids [10]. Since 
this study did not include an HIV-uninfected control group it remains uncertain 
whether the observed excess risk can be fully explained by the effects of 
antiretroviral drugs and their side effects, or whether chronic HIV infection itself 
may play a role, as has been shown for other chronic inflammatory diseases[11]. 
Premature atherosclerosis has been reported in young adults with HIV infection in 
the pre – HAART era [12]. Also, interruption of ART seems to be associated with 
an increased short-term risk of cardiovascular disease[13]. These findings suggest 
that HIV infection itself may increase the risk for cardiovascular disease. The 
relative contributions of conventional cardiovascular risk factors, metabolic side 
effects of antiretroviral drugs and HIV infection itself on cardiovascular risk are 
difficult to identify, as these factors frequently occur simultaneously in patients and 
large numbers are needed in studies with clinical endpoints. Carotid artery intima-
media thickness (C-IMT), however, is a valid measure of subclinical 
atherosclerosis, which has consistently been related to future cardiovascular 
events in population studies[14] [15, 16]. Arterial stiffening is also a marker of 
increased cardiovascular risk, and an independent predictor of cardiovascular 
events and mortality in a variety of populations[17-20]. The aim of the present 
study was to investigate C-IMT and large artery stiffness in patients with HIV 
infection with and without ART and LD, and compare these data to uninfected 
controls. We hypothesized that HIV infection itself is associated with increased C-
IMT and arterial stiffness, and that ART may either ameliorate this risk by 
suppression of HIV replication or aggravate the risk by its metabolic side effects, 
including lipodystrophy (LD).  
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Methods 
 
Participants and study design 
Between October 2004 and March 2005 we approached all male patients with HIV-
1 infection consecutively attending the outpatient clinic of the VU University 
Medical Center for study participation. We excluded patients receiving treatment for 
hypertension or diabetes mellitus, patients with malignancies, systemic infection in 
the preceding 8 weeks, or severe psychosocial problems. Controls were healthy 
men recruited from hospital staff and by a local newspaper advertisement. HIV-1 
infection was ruled out in controls by serologic testing with their consent. 
The study was approved by the local ethics committee. All participants gave written 
informed consent. 
 
Data collection 
We recorded data on smoking, history of cardiovascular disease, hyperlipidemia, 
and family history of diabetes mellitus type 2 (in first degree relatives) and 
cardiovascular disease (in first degree relatives (male under age 55, female under 
age 65). For the HIV-1-infected patients, mode of HIV-transmission, CDC stage, 
and complete history of prior and current ART use were recorded. Cumulative 
exposure (in months) to ART and to specific drug classes was calculated. Fasting 
plasma glucose, insulin, lipids and lipoproteins were determined and creatinine 
clearance was calculated using the Cockcroft-Gault equation. Finally, serum 
sodium, potassium, chloride and bicarbonate levels were measured to calculate the 
aniongap in order to be able to apply the lipodystrophy case definition[21]. 
 
Body composition 
We measured body mass index (BMI, calculated as weight in kilograms divided by 
the square of height in meters), waist- to- hip ratio using a flexible tape and skinfold 
thicknesses at 4 sites (biceps, triceps, subscapular and suprailiacal) using a 
skinfold caliper. Fat weight and fat percentage were measured using a body 
impedance analyzer (STA BIA, Akern Bioresearch, Italy). 
For all patients using ART, lipodystrophy scores were calculated according to the 
complete model of the international lipodystrophy case definition[21]. To obtain a 
quantitative assessment of peripheral and truncal fat mass needed to apply this 
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case definition, dual-energy x-ray absorptiometry (Hologic QDR-4500W, software 
version whole body v8.26A: 5) was performed. Also, a standardized single slice 
abdominal CT-scan at the level of the fourth lumbar vertebra was performed from 
which the surface area of visceral (VAT) and subcutaneous adipose tissue (SAT) 
was determined.  
 
Arterial properties 
Arterial properties for the estimation of arterial stiffness were assessed according to 
guidelines for user procedures and with the use of reproducible and valid methods 
and devices, as recommended[22]. All measurements were done after an 8-hour 
fast. Participants had abstained from smoking on the study day and had rested in a 
supine position for 15 minutes in a quiet, temperature-controlled room before the 
measurements. Properties of the right common carotid and the common femoral 
and brachial arteries were obtained by a single investigator using an ultrasound 
scanner equipped with a 7.5-MHz linear array probe (Pie Medical Imaging, 
Maastricht, the Netherlands). This scanner was connected to a personal computer 
equipped with an acquisition system and a vessel wall movement detector software 
system (Wall Track System 2; Pie Medical Imaging). This integrated device 
enables measurements of arterial diameter, distension, and C-IMT as described in 
detail elsewhere[22, 23]. The mean diameter, distension, and, for the carotid artery 
only, C-IMT of 3 consecutive measurements (each including 3 to 7 heartbeats) 
were used in the analyses. The carotid artery was measured approximately 10 mm 
proximal to the beginning of the bulb, the femoral artery 20 mm proximal to the flow 
divider and the brachial artery approximately 20 mm above the antecubital fossa. 
C-IMT was measured in a region free of plaque (defined as C-IMT > 1.5 mm). 
Throughout the entire period of ultrasonography, systolic and diastolic blood 
pressure and heart rate were assessed in the left arm at 5-minute intervals with an 
oscillometric device (model BP-8800; Colin Press-Mate, Komaki-City, Japan). 
Mean arterial blood pressure was calculated by the oscillometric device by 
integrating the area under the pressure waveform and dividing this by the duration 
of the cardiac cycle. Brachial artery pulse pressure was defined as systolic minus 
diastolic blood pressure, and pulse pressure at the common carotid and femoral 
arteries was calculated according to the calibration method first described by Kelly 
and Fitchett[24], with the use of distension waveforms as adapted by Van Bortel et 
al[25].  
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The mean diameter, distension, and local pulse pressure  were used to estimate 
the distensibility (DC) and compliance (CC) coefficients as described 
previously[22]. Distensibility reflects the elastic properties, whereas the compliance 
reflects the buffering capacity of the artery. Both DC and CC are indices of 
elasticity and therefore inversely related to arterial stiffness. From C-IMT, diameter, 
and DC, we calculated the carotid Young elastic modulus (YEM)[22].  This is an 
estimate of the intrinsic elastic properties of the vessel wall directly related to 
arterial stiffness. 
The carotid-femoral (i.e. mainly aortic) pulse wave velocity (PWV) was determined 
by a validated non-invasive automated device (Complior; Artech-Medical, Pantin, 
France)[22].  
 
Reproducibility 
Reproducibility was assessed in 10 healthy subjects (5 men, age 30.3 ±8.5 years) 
who were examined by the same observer twice, 1 week apart. The median intra-
observer intersession coefficients of variation were as follows: C-IMT, 2.4%; 
diameters: 1.0% (carotid), 0.3% (femoral), 1.1 % (brachial); distension, 1.9% 
(carotid), 1.4% (femoral), 2.4% (brachial); DC: 4.2% (carotid), 5.6% (femoral), 2.2% 
(brachial); CC: 4.0% (carotid), 3.3% (femoral), 3.3% (brachial); YEM, 5.4%; and 
PWV, 0.9%. 
 
Sample size considerations and statistical analysis 
Primary endpoints were carotid artery intima-media thickness (C-IMT), arterial 
stiffness (DC and CC) of the carotid, brachial and femoral arteries and PWV. At the 
time of the design of the study, insufficient information concerning expected 
differences in the primary endpoints between patients and controls was available to 
support a proper sample size calculation. Only one previous study had investigated 
carotid arterial stiffness at the time, and this study was performed in children[26]. 
Based on the observed differences in carotid artery compliance between HIV 
infected patients and healthy controls in this study, we calculated that with a power 
of 90% and a 5% level of significance, 16 patients in each group would be 
sufficient to detect a similar difference. However, it is very difficult to extrapolate 
these data to our study. We therefore chose to include as much patients and 
controls as logistically feasible, with a minimum of 50 in each group, and attempted 
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to include at least 16 patients in the smaller subgroups of ART-naïve patients and 
patients with lipodystrophy.  
Analyses were done using SPSS statistical software version 12.0.1 (SPSS, 
Chicago, IL, USA). Differences between groups in clinical characteristics were 
analysed by the Mann-Whitney U and Kruskal Wallis tests for continuous variables 
and the Chi square test for categorical variables. Differences between groups in 
arterial properties were analysed using analysis of variance with adjustment for 
confounders. Multiple linear regression analysis was performed to assess the 
association between HIV, ART and arterial properties. The variables of interest 
(HIV, ART) and variables associated with arterial properties in univariate linear 
regression were used for construction of multiple linear regression models. For 
each model the following potential confounders were considered: age, mean 
arterial blood pressure (MAP), body mass index (BMI), creatinine clearance, 
smoking, total cholesterol. A second univariate analysis was performed within the 
HIV group with the variables of interest CD 4 count, nadir CD4, duration of ART, 
cumulative PI, NRTI and NNRTI use. These variables of interest and the potential 
confounders mentioned above were used for the construction of multiple linear 
regression models. 
The regression coefficients are expressed as standardized beta per change of 1 
standard deviation of the independent variables. 
 
 
Results 
 
Characteristics of the study group 
Of the 102 consecutive patients approached for study participation, 81 gave 
informed consent. Of these, 77 were included, as four patients did not return for the 
measurements. Fifty-five of the 77 patients had been exposed to ART, all but two 
of these were currently using ART, and 22 were ART-naïve. Twentythree patients 
had LD according to the lipodystrophy case definition. Fifty-two healthy controls 
were included. Characteristics of the study population are shown in table 1. 
Concerning main cardiovascular risk factors, groups differed in age and smoking 
habits, and mean blood pressure was lower in patients than controls. By definition, 
body composition differed between groups. As expected, glucose and lipid profiles 
showed more abnormalities in the LD group. HIV-specific characteristics, 
antiretroviral medication and fat distribution data of the patients are shown in table 
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2. The two patients who had been exposed to ART in the past but had 
discontinued their ART (both approximately 3 years before study measurements) 
were included in the ART group. Results of all following analyses were essentially 
the same when repeated without these two patients.  
 
HIV infection and arterial properties 
We first compared patients with HIV infection to controls, using analysis of variance 
with adjustment for differences in the main confounders for arterial properties (age, 
BMI, mean arterial blood pressure, smoking and creatinine clearance). Additional 
adjustment for family history of cardiovascular disease, insulin sensitivity (HOMA) 
and lipid parameters (total cholesterol, LDL – and HDL cholesterol, triglycerides, 
each entered separately) did not change the results. Results are shown in figure 1 
and table 3. Patients with HIV infection had significantly greater C-IMT than the 
HIV-negative controls (0.69 (0.67-0.71) mm versus 0.62 (0.59-0.65) mm, mean 
difference 0.067 (0.028 to 0.11) mm) (p=0.001). Also, patients with HIV infection 
had significantly increased stiffness of the carotid and femoral artery, reflected in 
lower DC and CC. The adjusted mean differences (95% CI) between patients and 
controls, expressed as percentages, were –13.6% (-21.6% to –5.6%) for carotid 
artery DC, -14.1% (-24.7% to –3.5%) for carotid artery CC, -29.5% (-42.7% to –
16.4%) for femoral artery DC and –31% (-42.6% to –19.5%) for femoral artery CC. 
For the brachial artery, there was a trend for DC and CC to be lower in patients 
with HIV compared to controls; mean differences (95% CI) were –13% (-28.2% to 
2.2%) and –11.5% (-24.8% to 1.7%) for DC and CC respectively. For all arteries, 
these differences resulted mainly from a decrease in distension, as diameter did 
not differ between groups. The YEM did not differ significantly between patients 
and controls (mean difference 2.3% (-7.6% to 12.5%), suggesting that differences 
in distensibility and compliance in the carotid artery are not explained by 
differences in the intrinsic elastic properties of the intima-media complex. There 
was no difference in aortic stiffness (PWV) between patients with HIV- infection 
compared to HIV-negative controls. 
Linear regression analysis was performed in the whole study population (table 4). 
In this analysis, HIV infection was independently associated with C-IMT and carotid 
artery DC and CC, brachial artery CC and femoral artery DC and CC. For brachial 
artery DC, there was a trend for HIV infection to be an independent predictor. In 
general, the standardized beta of HIV was lower than or comparable to the 
standardized beta of age, and comparable to the standardized beta of BMI and 
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mean arterial pressure in the carotid and brachial arteries. For instance, for C-IMT 
the effect of HIV can be calculated to correspond to a 5.2 years older age or an 
increase in BMI of 3.9 kg/m2. For the femoral artery DC, the standardized beta of 
HIV was greater than that of age. Considering the r2 of the various models, around 
30% of the variation in arterial stiffness parameters within the groups could be 
attributed to differences in the parameters included in the models. Within the HIV 
infected patients, current or nadir CD4 and current viral load were not associated 
with C-IMT or any parameter of arterial stiffness.  
 
ART and LD and arterial properties in HIV-positive patients 
Due to the collinearity between HIV, ART use and LD, these factors could not be 
analysed together in the whole study population. We therefore assessed the 
associations of ART and LD with arterial properties within the group of HIV- 
infected patients. First, analysis of variance was done with adjustment for 
differences in age, BMI, mean arterial blood pressure, smoking and creatinine 
clearance (figure 1 and table 3). No significant difference was found in C-IMT 
between ART exposed and ART-naïve patients. However, patients who had been 
exposed to ART had significantly increased stiffness of the femoral artery 
compared to those who had never used ART. Mean differences (95% CI) 
expressed as percentages were –25.9% (-46.2% to –5.6%) and –21.7% (-40.8% to 
–2.7%) for femoral artery DC and CC respectively. These differences resulted 
mainly from a decrease in distension. No significant differences were found in 
stiffness estimates of the carotid and brachial artery or PWV. Between patients with 
and without LD no differences were found in C-IMT or in any of the estimates of 
local and regional artery stiffness. 
 
In linear regression analysis in the whole HIV positive patient population, use of 
ART and cumulative use of PI and NRTI were independently associated with 
femoral artery stiffness after adjustment  for age, mean arterial pressure, BMI and 
creatinine clearance (standardized beta for femoral artery DC -0.36 (p=0.001), -
0.27 (p=0.013) and -0.24 (p=0.037) respectively, for CC -0.36 (p=0.003), -0.31 
(p=0.009) and -0.21 (p=0.10), respectively).  
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Discussion 
 
The main findings of this study are that patients with HIV had increased C-IMT and 
increased arterial stiffness of the carotid and femoral artery compared to HIV-
negative controls, after adjustment for conventional cardiovascular risk factors. 
Furthermore, within the HIV group, patients exposed to ART had increased 
stiffness of the femoral artery compared to ART-naïve patients, and use of ART 
and cumulative use of PI and NRTI was independently associated with femoral 
artery stiffness after adjustment for classical cardiovascular risk factors.  
 
C-IMT has been shown to be elevated in chronic inflammatory conditions [27] and 
chronic infection [28]. Chronic HIV infection may therefore also lead to vascular 
endothelial damage and increase in vessel wall thickness by sustaining a low 
degree of inflammation[29].   
Although some studies reported increased C-IMT in HIV infected patients 
compared to HIV negative controls [30-34], others did not confirm this[26, 35]. In 
many of these studies, differences in exposure to ART in the study groups make it 
difficult to distinguish between the effects of HIV and ART. Conflicting evidence 
exists on the association between the use of ART in general and of cumulative 
exposure to different drug classes, especially PI, and C-IMT[32-40]. Recently, in a 
very large study, Lorenz reported a significantly higher C-IMT in two of three 
carotid segments in HIV infected subjects than in age- and sex matched 
controls[34]. This effect was still visible in the ART-naive subcohort, strongly 
supporting the hypothesis that HIV infection itself has detrimental effects on the 
arterial wall independent of ART.   
Concerning a role of the immune system or the virus, we found no association 
between current CD4, nadir CD4 and current viral load and C-IMT. Other studies 
have had conflicting results, one reporting a higher progression of C-IMT in 
patients with a low CD4 nadir[30], whereas others found a higher CD4 count to be 
associated with more rapid progression of C-IMT[41]. Larger prospective studies 
may be needed to resolve this issue. 
 
This is to our knowledge the first study investigating local arterial stiffness at 
multiple sites in adult HIV infected patients. Arterial stiffening is a complex process 
involving structural and functional changes in the arterial wall, which occur as part 
of normal ageing and are accelerated by a number of conditions including diabetes 
mellitus type 2 [42], hypertension[43] and renal failure[44]. Evidence is 
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accumulating that in addition to these traditional risk factors, acute and low grade 
inflammation are also associated with large artery stiffness, by promoting structural 
changes [45] or by inducing endothelial dysfunction [46]. Chronic inflammation 
resulting from HIV infection may therefore explain the association between HIV 
infection and increased arterial stiffness, as has been shown for chronic 
inflammatory diseases such as rheumatoid arthritis [11]. Our findings are in 
agreement with the only study previously reported in children with HIV measuring 
carotid arterial stiffness by the same techniques [26].  
 
Concerning a role of ART, we found, in patients with HIV, an independent 
association between ART use and femoral artery, but not carotid or brachial artery 
stiffness. Different arterial segments are known to respond differently to ageing and 
other factors. Central, elastic arteries such as the carotid artery stiffen 
progressively with age[47], whereas the adverse effects of impaired glucose 
metabolism, diabetes mellitus type 2 and metabolic syndrome are more 
pronounced in the muscular femoral artery [42, 48].  Also, abdominal and 
subcutaneous fat are associated with different effects on carotid and femoral artery 
stiffness[49]. Brachial artery stiffness has been studied less extensively and results 
have been conflicting. In patients with diabetes and impaired glucose metabolism 
brachial artery stiffness followed a pattern similar to that of the femoral artery[42], 
whereas this was not observed in patients with metabolic syndrome[48]. Our 
findings may suggest that the effect of ART on arterial wall stiffening in patients 
with HIV may occur preferentially, or earlier, in the muscular femoral artery than in 
the elastic carotid artery. However, prospective studies will be necessary to clarify 
this issue. It also remains to be determined whether these effects are due to direct 
effects of the antiretroviral drugs or caused indirectly by their metabolic side 
effects. 
An alternative explanation for the fact that we could not find an association 
between use of ART and increased stiffness of the carotid artery may be that 
treatment with ART, by reducing the inflammation due to active HIV infection, may 
to some extent counteract any adverse effects of treatment. In fact, a recent study 
showed that endothelial dysfunction actually improved after start of ART despite 
the rapid onset of dyslipidemia[50]. The balance between the beneficial effects of 
diminishing active infection/inflammation and the negative effects of ART such as 
dyslipidemia may be essential to determine the net effect in an individual patient 
and in different arterial segments. Also, our finding that cumulative PI use is 
associated with femoral artery stiffness, while no such association was found for 
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cumulative NNRTI use, may suggest that effects of ART on arterial stiffness vary 
between different drug classes. Clearly, these findings should be interpreted with 
caution as they are based on small subgroups, but they seem in agreement with 
accumulating evidence that exposure to PI is associated with increased 
cardiovascular risk, whereas no evidence of such an association has been found 
for NNRTI [9, 32].  
 
We did not find an independent association between LD and C-IMT and arterial 
stiffness, while several characteristics of this syndrome would be expected to lead 
to vascular abnormalities. Prior studies evaluating the effect of LD on C-IMT have 
had conflicting results, with one study showing an increased C-IMT in patients with 
LD[51], whereas in another study this association disappeared in multivariate 
analysis [36]. Our findings may suggest that the effects of LD on the vascular wall 
are mediated by traditional cardiovascular risk factors, although the sample size of 
our LD subgroup may have been insufficient to detect smaller differences in arterial 
properties. Moreover, by excluding patients with diabetes mellitus and hypertension 
we may have excluded those patients with LD at highest risk for vascular 
abnormalities. Finally, a greater awareness of cardiovascular risk may have 
influenced patient and physician’s attention to conventional cardiovascular risk 
factors in patients with LD, possibly reflected by the greater proportion of patients 
with LD used lipid-lowering drugs, which are known to reduce arterial stiffness.  
 
In contrast to local arterial stiffness, we found no difference in aortic stiffness 
(PWV) in patients with HIV- infection compared to controls, which is in agreement 
with one of the two previous studies investigating PWV in HIV[52, 53]. This may 
imply that there are differences in the effect of HIV along the arterial system. 
Although arterial stiffening is thought to be a generalized phenomenon in elastic 
arteries, and carotid artery and aortic stiffness have been shown to be highly 
correlated in normal subjects, this correlation is weaker in patients with risk factors 
such as diabetes mellitus or hypertension[54]. To our knowledge, these variables 
have not been compared in patients with HIV infection.  
 
Our study has several limitations. First, the cross-sectional design did not allow us 
to investigate progression of abnormalities in arterial properties. We measured 
surrogate endpoints of cardiovascular disease, and although these surrogate 
endpoints have consistently been related to cardiovascular events in population 
studies, changes in these surrogate endpoints do not constitute proof of increased 
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cardiovascular risk. Also, matching for age and other potential risk factors for 
cardiovascular disease was not successful in all cases. We therefore considered all 
potential confounders in the analyses and adjusted for differences between groups 
where appropriate. Finally, sample size of patient subgroups, mainly ART-naive 
patients and patients with LD, may have been insufficient to detect smaller 
differences in arterial properties. For instance, with 23 patients in the LD group, this 
study had 80% power to detect a 0.12 mm difference in C-IMT, a 4.85 x10-3/kPa 
difference in carotid artery DC, and a 0.17 mm2/kPa difference in carotid artery CC 
compared to patients without LD. Therefore it is possible that the true differences 
are smaller and a larger sample size would be required to detect these. 
 
In conclusion, HIV infection seems independently associated with increased C-IMT 
and generally increased arterial stiffness, and ART use with increased stiffness of 
the femoral artery. This suggests that patients with HIV infection may be at 
increased cardiovascular disease risk, independent of the presence of classical 
cardiovascular risk factors, or of any risk contributed by the use of ART. 
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Table 1. Characteristics of the study population. 
 
 Control HIV 
  
(n=52) 
All HIV 
(n=77) 
HIV, no ART 
(n=22) 
HIV, ART, no LD 
(n=32) 
HIV, ART, LD 
(n=23) 
Age (years) 49.6 
(43.7-58.1) 
42.3 
(37.7-49.5)* 
38 
(34.2-40.7) 
42.3 
(38.7-47.2) 
49.7 
(43.7-54.8)** 
Ethnic group 
Asian 
Black 
Caucasian 
Mediterranean 
Other 
 
0 (0%) 
2 (3.8%) 
48 (92.4%) 
0 (0%) 
2 (3.8%) 
 
1 (1.3%) 
6 (7.8%) 
61 (79.2%) 
6 (7.8%) 
3 (3.9%) 
 
0 (0%) 
2 (9.1%) 
17 (77.3%) 
2 (9.1%) 
1 (4.5 %) 
 
1 (3.1%) 
3 (9.3%) 
24 (75%) 
2 (6.3%) 
2 (6.3%) 
 
0 (0%) 
1 (4.3%) 
20 (87%) 
2 (8.7%) 
0 (0%) 
      
BMI (kg/m²) 23.9 
(22.5-26) 
23.2 
(21.6-25.4) 
23.5 
(21.6-26.4) 
23.1 
(20.9-24.8) 
23.8 
(22-24.8) 
Waist-hip ratio 0.94 
(0.91-0.96) 
0.93 
(0.9-0.98) 
0.91 
(0.87-0.93) 
0.92 
(0.89-0.97) 
0.96 
(0.92-1.01)** 
Skinfold biceps 
(mm) 
8 (7-10) 7 (5-9)* 8 (6-10) 7 (6-9) 5 (3-9)** 
Fat % (BIA) 19.1 
(16-22.6) 
17.1 
(12.6-20.9)* 
18.6 
(14.7-23.4) 
17.7 
(12.1-21.4) 
16.1 
(10.4-19.6) 
Smoking current 14 (27%) 42(54.5%)* 17 (77%) 18 (56%) 7 (30%)** 
HOMA 1.2 
(0.94-2.39) 
1.51 
(0.91-2.77) 
1.14 
(0.87-1.72) 
1.18 
(0.86-2) 
2.45 
(1.69-3.67)** 
Total cholesterol 
(mmol/l) 
5.3(4.5-6) 5.1(4.2-5.8) 4.2(3.6-5.0) 5.2(4.4-5.8) 5.7(4.9-6.4)** 
LDL chol. (mmol/l) 3.0(2.5-3.9) 2.8(2.3-3.5) 2.5(2.2-3.2) 2.8(2.2-3.6) 3.2(2.6-3.7) 
HDL chol. 
(mmol/l) 
1.46 
(1.16-1.73) 
1.25 
(1.08-1.53)* 
1.1 
(0.94-1.36) 
1.52 
(1.26-1.63) 
1.11 
(1.04-1.34)** 
Triglycerides 
(mmol/l) 
1.3(0.8-1.5) 1.7(1.2-2.6)* 1.0(0.7-1.8) 1.5(1.3-2.4) 2.6(2.1-6.1)** 
Use of lipid 
lowering drugs 
0 (0%) 9(11.7%)* 0 (0%) 2 (6.3%) 7 (30.4%)** 
Mean arterial 
blood pressure 
(mm Hg) 
87 (82-94) 84 (79-90)* 82 (78-86) 84 (80-90) 86 (79-93) 
Creatinine 
clearance 
(ml/min) 
87 (78-103) 93 (81-107) 102 (91-112) 92 (80-104) 87 (78-106) 
 
 
Data are median (IQR) unless otherwise indicated.  
* p<0.05 between groups HIV(all) vs control. 
** p<0.05 between HIV subgroups (no ART; ART, no LD; ART, LD) 
 (Kruskal Wallis for continuous variables, Chi square for categorical data) 
BMI body mass index, BIA body impedance analysis, HOMA homeostasis model 
assessment of insulin resistance, LDL low density lipoprotein, HDL high density lipoprotein, 
ART antiretroviral therapy, LD lipodystrophy. 
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Table 2. Characteristics of the patients with HIV infection. 
 
 HIV, no ART 
(n=22) 
HIV, ART, no LD 
(n=32) 
HIV, ART, LD 
(n=23) 
Infection mode 
  Homosexual 
  Heterosexual 
  Other/unknown 
 
18 (82%) 
3 (14%) 
1 (5%) 
 
25 (78%) 
5 (16%) 
2 (6%) 
 
19 (83%) 
1 (4%) 
3 (13%) 
Nadir CD4 (106/l)* 330 (265-400) 120 (83-238) 143 (60-240) 
Current CD4 (106/l)* 450 (280-545) 580 (303-670) 620 (450-910) 
Viral load undetectable  26 (81.3%) 18 (78.3%) 
Duration ART (years)*  6.0 (4.0-8.4) 9.3 (8.2-10.9) 
Cumulative PI (years)*  4.1 (1.4-5.8) 5.8 (4.3-7.3) 
Cumulative NNRTI 
(years) 
 1.0 (0-3.5) 1.8 (0.3-3.2) 
Current ART 
   NRTI      
   NNRTI      
   PI      
 31(96.9%) 
31(100%)   
14(45.2%)   
18(58.1%)   
22(95.7%) 
22(100%)   
14(63.6%)   
12(54.5%)   
VAT L4 (cm²)*  84.5(54.1-136.5) 158.8(139.1-285.4) 
SAT L4 (cm²)*  134.7(71.2-190.5) 82.8(23.5-106.5) 
SAT/TAT*  0.58(0.51-0.65) 0.36(0.12-0.49) 
Limb fat (gram)*  6157(4242-7685) 3645(2533-4503) 
Limb/total fat*  0.48(0.41-0.53) 0.30(0.29-0.33) 
Lipodystrophy score*  -14.3(-22.7 to –8.0) 16.8(5.0-24.2) 
 
Data are median(IQR) unless otherwise indicated. 
*p<0.05 between groups (Kruskal Wallis/ Mann Whitney U for continuous variables, Chi 
square for categorical data). 
ART antiretroviral therapy, PI protease inhibitor, NNRTI non-nucleoside reverse 
transcriptase inhibitor, NRTI nucleoside reverse transcriptase inhibitor, VAT visceral adipose 
tissue, SAT subcutaneous adipose tissue, TAT total adipose tissue, LD lipodystrophy. 
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Table 3a. C-IMT and arterial stiffness estimates. 
 
 Control 
(n=52) 
All HIV 
(n=77) 
HIV, no ART 
(n=22) 
HIV, ART 
(n=55) 
HIV, ART, no LD  
(n=32) 
Carotid artery      
Intima-media 
thickness (mm) 
0.62±0.015 0.69±0.012 0.66±0.023 0.70±0.014 0.70±0.02 
Distensibility 
coefficient 
(10-3/kPa) 
25.4±0.78 22.0±0.62 22.2±1.2 21.9±0.73 23.0±1.08 
Compliance 
coefficient   
(mm²/kPa) 
1.05±0.042 0.90±0.034 0.89±0.067 0.90±0.04 0.96±0.07 
Elastic modulus 
(103/kPa) 
0.51±0.019 0.53±0.016 0.54±0.031 0.52±0.018 0.48±0.03 
Diameter (mm) 7.28±0.087 7.23±0.070 7.25±0.14 7.22±0.081 7.17±0.12 
Distension (mm) 0.54±0.019 0.46±0.016 0.48±0.031 0.46±0.018 0.47±0.03 
Femoral artery      
Distensibility 
coefficient 
(10-3/kPa) 
13.6±0.68 9.58±0.55 11.86±1.05 8.79±0.62 9.91±0.65 
Compliance 
coefficient 
(mm²/kPa) 
1.09±0.048 0.75±0.038 0.90±0.074 0.70±0.044 0.78±0.05 
Diameter (mm) 10.31±0.18 10.18±0.15 10.16±0.29 10.19±0.17 10.16±0.24 
Distension (mm) 0.45±0.02 0.31±0.016 0.37±0.031 0.29±0.018 0.32±0.02 
Brachial artery      
Distensibility 
coefficient 
(10-3/kPa) 
14.32±0.83 12.46±0.67 12.46±1.3 12.46±0.78 13.0±0.89 
Compliance 
coefficient 
(mm²/kPa) 
0.23±0.012 0.21±0.009 0.19±0.019 0.21±0.011 0.22±0.02 
Diameter (mm) 4.64±0.073 4.70±0.059 4.62±0.12 4.73±0.069 4.75±0.09 
Distension (mm) 0.21±0.011 0.18±0.009 0.17±0.017 0.19±0.01 0.19±0.01 
Regional 
stiffness 
     
Pulse wave 
velocity (m/s) 
6.7±0.135 7.0±0.11 7.0±0.21 7.0±0.12 6.8±0.18 
 
Shown are estimated means ± standard error of the mean, with correction for differences in 
age, BMI, mean arterial blood pressure, smoking and creatinine clearance. 
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Table 3b. C-IMT and arterial stiffness estimates. 
 
 HIV, ART, LD 
(n=23) 
P for HIV vs 
control 
P for ART vs 
no ART 
P for LD vs no 
LD 
Carotid artery     
Intima-media 
thickness (mm) 
0.69±0.03 0.001 0.18 
 
0.90 
Distensibility 
coefficient (10-
3/kPa) 
22.3±1.30 0.001 0.80 0.70 
Compliance 
coefficient 
(mm²/kPa) 
0.90±0.08 0.009 0.91 0.58 
Elastic modulus 
(103/kPa) 
0.54±0.03 0.64 0.66 0.15 
Diameter (mm) 7.29±0.14 0.69 0.90 0.52 
Distension (mm) 0.48±0.03 0.005 0.49 0.81 
Femoral artery     
Distensibility 
coefficient (10-
3/kPa) 
8.74±0.78 <0.001 0.013 0.28 
Compliance 
coefficient 
(mm²/kPa) 
0.69±0.06 <0.001 0.026 0.28 
Diameter (mm) 10.23±0.28 0.61 0.93 0.85 
Distension (mm) 0.29±0.03 <0.001 0.023 0.44 
Brachial artery     
Distensibility 
coefficient (10-
3/kPa) 
12.94±1.07 0.09 1.0 0.97 
Compliance 
coefficient 
(mm²/kPa) 
0.20±0.02 0.08 0.34 0.41 
Diameter (mm) 4.58±0.11 0.57 0.44 0.25 
Distension (mm) 0.19±0.02 0.07 0.48 0.91 
Regional 
stiffness 
    
Pulse wave 
velocity (m/s) 
7.1±0.21 0.21 0.93 0.37 
 
Shown are estimated means ± standard error of the mean, with correction for differences in 
age, BMI, mean arterial blood pressure, smoking and creatinine clearance. 
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Table 4. Multiple linear regression analysis for the whole study population with C-IMT and 
arterial stiffness estimates of carotid, brachial and femoral artery as dependent variables. 
 
 Standardized beta R² p 
Carotid artery    
IMT    
     Age 0.545 0.318 <0.001 
     HIV 0.298  <0.001 
     BMI 0.192  0.011 
Distensibility coefficient    
     Age -0.603 0.501 <0.001 
     HIV -0.230  0.001 
     BMI -0.190  0.005 
     MAP -0.203  0.004 
Compliance coefficient    
     Age -0.193 0.248 0.088 
     HIV -0.227  0.007 
     BMI -0.285  0.005 
     Creat. Clear. 0.399  0.002 
Elastic modulus    
     Age 0.319 0.339 <0.001 
     MAP 0.382  <0.001 
Brachial artery 
   
Distensibility coefficient    
   HIV -0.156 0.207 0.071 
   Age -0.122  0.172 
   MAP -0.272  0.003 
   BMI -0.270  0.001 
Compliance coefficient    
   HIV -0.202 0.111 0.021 
   MAP -0.283  0.002 
   BMI -0.087  0.320 
Femoral Artery    
Distensibility coefficient    
     Age -0.273 0.305 0.001 
     HIV -0.357  <0.001 
     BMI -0.356  <0.001 
     MAP -0.167  0.045 
Compliance coefficient    
     BMI -0.353 0.278 <0.001 
     HIV -0.444  <0.001 
     MAP -0.217  0.012 
     Creat. Clear. 0.188  0.05 
 
For each model the following potential confounders were considered: age, mean arterial 
blood pressure (MAP), body mass index (BMI), creatinine clearance, smoking, total 
cholesterol. Factors that were found to be actual confounders for the relationship between 
HIV and C-IMT /stiffness estimates were retained in the model. The regression coefficients 
are expressed as standardized beta per change of 1 standard deviation of the independent 
variables. IMT intima-media thickness, BMI body mass index, MAP mean arterial blood 
pressure, creat.clear creatinine clearance. 
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Figure 1a. C-IMT and arterial stiffness estimates for healthy controls, HIV-infected 
patients not exposed to ART and HIV- infected patients exposed to ART. 
Shown are estimated means ± standard error of the mean, with correction for differences 
in age, BMI, mean arterial blood pressure, smoking and creatinine clearance. 
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Figure 1b. C-IMT and arterial stiffness estimates for healthy controls, HIV-infected 
patients not exposed to ART and HIV- infected patients exposed to ART. 
Shown are estimated means ± standard error of the mean, with correction for differences 
in age, BMI, mean arterial blood pressure, smoking and creatinine clearance. 
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Abstract 
 
Background 
Cardiovascular disease risk is an increasing concern in HIV-infected patients. We 
studied changes in vascular properties after initiation of combination antiretroviral 
therapy (cART) and the contribution of different drug classes. 
 
Methods 
cART-naïve men were randomized to lopinavir/ritonavir(LPV/r) 
+zidovudine/lamivudine (ZDV/3TC) (n=19) or LPV/r+nevirapine (NVP) (n=18). 
Carotid artery intima-media thickness (C-IMT), arterial stiffness (distensibility (DC), 
and compliance (CC) coefficients of the carotid, femoral, and brachial arteries, 
carotid elastic modulus, augmentation index) and markers of endothelial function 
(soluble vascular cell and intercellular adhesion molecules-1 (sVCAM-1, sICAM-1), 
plasma von Willebrand factor (vWF) antigen, Plasminogen Activator Inhibitor-1 
antigen (PAI-1)), and inflammation (high sensitive C-reactive protein) were 
measured before and after 3, 12 and 24 months of cART.  
 
Results 
C-IMT increased by 0.061 ± 0.016 mm (p=0.0002) in the ZDV/3TC/LPV/r arm and 
by 0.044 ±0.018 (p=0.012) in the NVP/LPV/r arm. Femoral artery DC (-1.66±0.78 
10-3/kPa (p=0.035)) and CC (-0.11±0.053 mm2/kPa (p=0.043)) decreased in the 
ZDV/3TC/LPV/r arm, femoral DC decreased in the NVP/LPV/r arm (-1.72 ±0.85 10-
3/kPa (p=0.046)), with no significant difference between groups in C-IMT or arterial 
stiffness. sVCAM-1, sICAM-1 and vWF decreased significantly in both groups. 
 
Conclusion 
C-IMT and femoral artery stiffness increased after initiation of cART, while several 
markers of endothelial function improved regardless of cART composition. 
 
(ClinicalTrials.gov number: NCT 00122226, http://www.clinicaltrials.gov) 
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Introduction 
 
Cardiovascular disease risk is an increasing concern in HIV-infected patients. 
Although retrospective cohort studies addressing the risk contributed by use of 
combination antiretroviral therapy (cART) and HIV protease inhibitors (PI) in 
particular were equivocal[1-6], a large prospective study found a significant 
association between cumulative exposure to PI-but not NNRTI-containing cART 
and myocardial infarction risk[7]. Recently, the same association was shown for 
current use of abacavir, which, contrary to what was found for PI, could not be 
explained through any effect on lipid profiles[8] . 
Apart from the risk contributed by cART, several other factors may also contribute 
to increased cardiovascular risk in HIV-infected patients, including conventional 
cardiovascular risk factors as well as HIV infection itself. Current evidence for the 
role of cART in cardiovascular disease risk is based mainly on large cohort studies, 
as large numbers would be needed in intervention trials with clinical endpoints. 
Surrogate markers of atherosclerosis and cardiovascular risk can be used to 
investigate the contribution of various risk factors more in detail. Carotid artery 
intima-media thickness (C-IMT) is a valid measure of subclinical atherosclerosis, 
which has consistently been related to future cardiovascular events in population 
studies[9]. Arterial stiffening is also an independent predictor of cardiovascular 
morbidity and mortality in a variety of populations[10-13]. In addition, biochemical 
markers of endothelial dysfunction, which potentially links infection, inflammation 
and atherosclerosis, are commonly employed as biomarkers of early stages of 
atherosclerosis[14]. 
We aimed to gain further insight into the development of vascular abnormalities 
after initiation of cART and the contribution of different drug classes. Therefore we 
performed sequential measurements of C-IMT, arterial stiffness, and markers of 
endothelial function and inflammation in treatment-naïve patients after initiation of 
cART in a randomized clinical trial comparing a regimen of zidovudine/lamivudine/ 
lopinavir/ritonavir (ZDV/3TC/LPV/r) with a NRTI sparing regimen of nevirapine/ 
lopinavir/ritonavir (NVP/LPV/r). We previously reported that during 24 months 
follow-up peripheral fat loss, visceral fat accumulation and insulin resistance 
developed in the ZDV/3TC/LPV/r group, whereas lipid increases were greater in 
the NVP/LPV/r group[15, 16]. We hypothesized that, against the background of 
similar effects of these regimens on suppression of HIV and immune restoration, 
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these different metabolic profiles might be reflected in different, mainly deleterious 
effects on the abovementioned markers of cardiovascular risk. 
 
Patients and methods 
 
Subjects and study design 
We studied a subgroup of participants in the MEDICLAS (Metabolic effects of 
different classes of antiretrovirals) trial. This is a multicenter, multinational, single-
blinded, randomized trial of 36 months duration in previously antiretroviral-naïve 
male patients, 18-70 years old, with an indication to start cART, comparing a NRTI-
containing regimen of LPV/r (400/100 mg bd)+ZVD/3TC (300/150 mg bd) with a 
NRTI-sparing regimen of LPV/r (533/133 mg bd)+NVP (200 mg bd). The main 
objective of the trial is to assess and compare the impact of both treatments on 
body fat distribution and metabolic complications. Subjects with severe obesity 
(body mass index (BMI)>35 kg/m2), a history of hyperlipidemia or diabetes mellitus 
were excluded. For the purpose of the sub-study, patients using medication that 
could influence vascular measurements were also excluded.  
Patients were recruited into the sub-study if they were recruited at the VU 
University Medical Center, the Netherlands, or were referred from other 
participating centers. The study was approved by the Ethical Committee of all 
participating centers. Written informed consent was obtained from all participants 
prior to study entry. We currently report the results after 24 months follow-up. 
 
Randomisation  
At the central study co-ordinating center a treatment allocation sequence (1:1 for 
LPV/r+ZVD/3TC and LPV/r+NVP) was generated using the minimisation variable 
BMI (≤25 kg/m2 versus >25 kg/m2).  
 
Procedures 
C-IMT, arterial stiffness, and markers of endothelial function and inflammation were 
measured at baseline and 3, 12, and 24 months after start of treatment. At the 
same timepoints, body fat distribution, fasting lipid profile and glucose metabolism 
markers were assessed as previously described[15]. Limb and trunk fat were 
quantified by DEXA (Hologic QDR-4500W, software version whole body v8.26A:5). 
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A standardized single slice abdominal CT-scan was performed from which the area 
of visceral (VAT) subcutaneous (SAT), and total adipose tissue (TAT) was 
determined. Lipid levels included total, high-density lipoprotein (HDL) and 
(calculated) low-density lipoprotein (LDL) cholesterol and triglycerides. Insulin 
sensitivity was estimated by the homeostasis model assessment of insulin 
resistance (HOMA), calculated as (fasting insulin (µU/ml) x fasting glucose 
(mmol/l))/22.5.  
 
Arterial properties 
All C-IMT and arterial stiffness measurements were performed by a single blinded 
investigator. Arterial properties for the estimation of arterial stiffness were assessed 
according to guidelines for user procedures and with the use of reproducible and 
valid methods and devices[17]. All measurements were done after an 8-hour fast. 
Participants abstained from smoking on the study day and rested in a supine 
position for 15 minutes in a quiet, temperature-controlled room before 
measurements. Properties of the right common carotid and common femoral and 
brachial arteries were obtained using an ultrasound scanner equipped with a 7.5-
MHz linear array probe (Pie Medical Imaging, Maastricht, the Netherlands). This 
scanner was connected to a computer equipped with an acquisition system and a 
vessel wall movement detector software system (Wall Track System 2; Pie Medical 
Imaging). This device enables measurements of arterial diameter, distension, and 
C-IMT as described elsewhere[17]. The mean diameter, distension, and C-IMT of 3 
consecutive measurements were used in the analyses. The carotid artery was 
measured approximately 10 mm proximal to the beginning of the bulb, the femoral 
artery 20 mm proximal to the flow divider and the brachial artery 20 mm above the 
antecubital fossa. C-IMT was measured in a region free of plaque (defined as C-
IMT > 1.5 mm). 
Throughout the period of ultrasonography, blood pressure and heart rate were 
assessed at 5-minute intervals with an oscillometric device (model BP-8800; Colin 
Press-Mate, Komaki-City, Japan). Brachial artery pulse pressure was defined as 
systolic minus diastolic blood pressure, and pulse pressure at the carotid and 
femoral arteries was calculated according to the calibration method first described 
by Kelly and Fitchett[18], with the use of distension waveforms as adapted by Van 
Bortel et al[19].  
The mean diameter, distension, and local pulse pressure were used to estimate the 
distensibility (DC) and compliance (CC) coefficients as described previously[17]. 
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Distensibility reflects the elastic properties, whereas compliance reflects the 
buffering capacity of the artery. DC and CC are indices of elasticity and therefore 
inversely related to arterial stiffness. From C-IMT, diameter, and DC, we calculated 
carotid Young elastic modulus (YEM)[17], an estimate of intrinsic elastic properties 
of the vessel wall.  
Radial applanation tonometry was used to obtain the aortic augmentation index 
and was performed with a Millar piezoresistive pressure transducer connected to an 
arterial waveform analysis device (Sphygmocor, Atcor Medical Ltd, Moreton in 
Marsh, UK). The aortic augmentation index was calculated as augmented pressure 
divided by (tonometrically derived) central pulse pressure.  
Reproducibility for arterial properties measurements was assessed in 10 healthy 
subjects (5 men, age 30.3 ±8.5 years) who were examined by the same observer 
twice, 1 week apart. The median intra-observer intersession coefficients of 
variation were: C-IMT, 2.4%; diameters: 1.0% (carotid), 0.3% (femoral), 1.1 % 
(brachial); distension, 1.9% (carotid), 1.4% (femoral), 2.4% (brachial); DC: 4.2% 
(carotid), 5.6% (femoral), 2.2% (brachial); CC: 4.0% (carotid), 3.3% (femoral), 3.3% 
(brachial); YEM, 5.4%; augmentation index, 19.6%. 
 
Markers of endothelial function and inflammation  
Plasma von Willebrand factor (vWf) antigen was measured by sandwich enzyme 
immunoassay, using rabbit anti-vWF antigen IgG as catching antibody and 
peroxidase-conjugated rabbit anti-vWF-antigen as detecting antibody (Dako, 
Copenhagen, Denmark). O-Phenylenediamine (Sigma Chemical Co., St. Louis, 
USA) was used as substrate. vWf levels are expressed as percentage of antigen 
levels in normal pooled plasma, which is defined as 100%. The intra- and inter-
assay coefficients of variation are 2.0% and 8.2%.  
Soluble vascular cell adhesion molecule-1 (sVCAM-1) and soluble intercellular 
adhesion molecule-1 (sICAM-1) were measured in duplicate by commercially 
available ELISA kits (Diaclone, Besançon, France). The intra- and inter-assay 
coefficients of variation are 4.4% and 4.6% for sVCAM-1, and 4.0% and 7.3% for 
sICAM-1, respectively.  
Human Plasminogen Activator Inhibitor-1 antigen (PAI-1) was measured by 
sandwich enzyme immunoassay (Elitest, HYPHEN BioMed, Neuville sur Oise, 
France), with intra- and inter-assay coefficients of variation of 2.7% and 9.8%. 
High sensitive C-reactive protein (hs-CRP) was measured with a highly sensitive 
in-house sandwich enzyme immunoassay, using rabbit anti-human CRP 
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immunoglobulin and peroxidase-conjugated rabbit anti-human CRP 
immunoglobulin as catching and detecting antibody (Dako, Copenhagen, 
Denmark), with O-Phenylenediamine (Sigma Chemical Co., St. Louis, USA) as 
substrate, with intra- and inter-assay coefficients of variation of 3.9% and 6.8%[20].  
Statistical analysis 
Analyses were by intent-to-treat. Within group changes, between-group differences 
in overall course and at study visits were analyzed by mixed model repeated 
measures analysis with adjustment for baseline values. Alpha<0.05 was 
considered statistically significant. Data are presented as estimated means ± 
standard error of the mean. SAS statistical software version 9.2 was used.  
 
 
Results 
 
Patient characteristics (Table 1) 
Fifty patients were included in the ‘MEDICLAS’ study, 37 of who were enrolled in 
this sub-study. Nineteen were randomized to ZDV/3TC/LPV/r and 18 to NVP/LPV/r. 
Baseline characteristics are shown in Table 1. Two patients in each arm used 
antihypertensive medication (in the ZDV/3TC/LPV/r arm one used nifedipine and 
lisinopril, another used metoprolol, in the NVP/LPV/r arm one used 
hydrochlorothiazide, with atenolol added just before 24 months and another used 
metoprolol and hydrochlorothiazide, with losartan added after 12 months). None of 
the patients used lipid-lowering drugs at baseline, but 1 patient randomized to 
ZDV/3TC/LPVr started fish oil capsules after 3 months, with phenofibrate added 
after 19 months, and 3 patients randomized to NVP/LPV/r started pravastatin (after 
8, 20 and 23 months, respectively). 
Antiretroviral therapy was modified in six patients. In the ZDV/3TC/LPV/r arm, one 
patient switched from ZDV to tenofovir after 3 months for anemia, another switched 
to tenofovir/lamivudine/efavirenz after 4 months for anemia and 
hypercholesterolemia and one switched from LPV/r to NVP for 
hypercholesterolemia after 17 months. In the NVP/LPV/r arm, two patients 
switched to ZDV/3TC/NVP, one after 3 months for diarrhea and one after 24 
months at the patient’s request. In one patient NVP was replaced by efavirenz for 
hepatotoxicity and rash after 2 months. One patient in the NVP/LPV/r arm died at 
home, presumably due to an acute myocardial infarction, after 14 months.  
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Body composition, lipid profile and insulin sensitivity (table 2) 
Patients randomized to ZDV/3TC/LPV/r had a progressive decline in limb fat after 
the first three months, whereas limb fat increased in patients randomized to 
NVP/LPV/r. Trunk fat increased in both groups, but VAT increased in patients on 
ZDV/3TC/LPV/r only. Total and HDL cholesterol increased in both arms, but after 
24 months patients randomized to NVP/LPV/r had higher total and HDL cholesterol 
than those randomized to ZDV/3TC/LPV/r. LDL cholesterol increased in the 
NVP/LPV/r arm only. HOMA did not change in either of the arms. However, in a 
subgroup of patients in whom glucose metabolism was studied in more detail with 
hyperinsulinemic, euglycemic clamps, peripheral insulin sensitivity was shown to 
decrease after three months in the ZDV/3TC/LPV/r arm only[16]. Changes in body 
composition and lipid profile in sub-study participants were comparable to patients 
in the main study, except that in the main study the between-group difference in 
HDL cholesterol was not significant[15]. 
 
Virology and immunology (table 2) 
Patients in both arms had similar immunologic and virologic responses to cART. 
The median CD4 cell increase over 24 months was 280 (205-455) and 310 (210-
370) x 106 cells/l in the ZDV/3TC/LPV/r and NVP/LPV/r arm, respectively. At 24 
months, 17/19 (89%) of patients randomized to ZDV/3TC/LPV/r  and 15/18 (83%) 
randomized to NVP/LPV/r had a plasma HIV-RNA below 50 copies/ml.  
 
Carotid intima-media thickness (table 3) 
C-IMT increased significantly over 24 months by 0.061 ± 0.016 mm (p=0.0002) in 
the ZDV/3TC/LPV/r arm and by 0.044 ±0.018 (p=0.012) in the NVP/LPV/r arm, with 
no significant difference between groups.  
 
Stiffness of the carotid, brachial and femoral arteries and 
augmentation index (table 3) 
There was no change in carotid DC or CC over 24 months in either of the groups. 
Carotid artery YEM decreased by -0.08 ±0.03 103/kPa (p=0.0018) in the 
ZDV/3TC/LPV/r arm, and by -0.05±0.03 (p=0.07) in the NVP/LPV/r arm, with no 
overall difference between groups. Brachial artery stiffness (DC and CC) did not 
change in either of the arms.  
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In the ZDV/3TC/LPV/r arm, femoral artery DC and CC decreased during 24 months 
(-1.66±0.78 10-3/kPa (p=0.035) and -0.11±0.053 mm2/kPa (p=0.043) for DC and 
CC respectively), mainly due to a decrease in distension. In the NVP/LPV/r arm, 
femoral artery DC decreased over time (-1.72 ±0.85 10-3/kPa (p=0.046)), mainly 
due to an increase in diameter, but femoral artery CC did not change (-
0.041±0.059 mm2/kPa (p=0.48)). There was no overall difference in femoral artery 
stiffness between groups. 
Augmentation index did not change in either of the arms.  
 
Markers of endothelial function and inflammation (table 3) 
Levels of sICAM-1, sVCAM-1 and vWF decreased significantly after initiation of 
cART in both groups. After 24 months, levels of sVCAM-1 were higher in patients 
in the ZDV/3TC/LPV/r arm compared to the NVP/LPV/r arm (difference 178±87 
ng/ml, p=0.043)), whereas there was no difference in sICAM-1 and vWF between 
groups.  
PAI-1 increased by 61±26 ng/ml (p=0.024) in the NVP/LPV/r arm, but remained 
unchanged in the ZDV/3TC/LPV/r arm, leading to a difference of 57±27 ng/ml 
(p=0.034) between arms after 24 months. 
Although hsCRP did not change significantly over 24 months in either of the arms, 
there was an overall significant difference between groups, due to higher levels in 
the NVP/LPV/r arm after 3 and 12 months. 
 
All analyses were repeated after exclusion of patients using antihypertensive and 
lipid-lowering drugs, and after exclusion of patients who changed antiretroviral 
medication.  Also, analyses were repeated with adjustment for baseline differences 
in age and smoking. Results for these analyses were essentially identical to the 
results reported above (same effect sizes, slight loss of significance levels to 
0.05<p<0.08 for some parameters). 
 
 
Discussion 
 
The main findings were that patients initiating cART had a deterioration of several 
arterial wall properties, i.e. an increase in C-IMT and in femoral artery stiffness, 
which appeared regardless of allocated treatment. In contrast, levels of vWF, an 
endothelial cell molecule involved in coagulation, and the endothelial adhesion 
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molecules sICAM-1 and sVCAM-1 significantly decreased in both groups, 
indicating an improvement in endothelial function after initiation of cART. PAI-1, a 
marker of antifibrinolytic activity, increased only in the NVP/LPV/r arm. 
 
C-IMT increased progressively in both groups after initiation of cART, with no 
difference between groups, despite their different metabolic profiles. This may be 
due to our limited sample size resulting in lack of power to reveal differences 
between regimens or, alternatively, differences in effects on the vascular wall may 
only become apparent after longer exposure. The C-IMT progression rate observed 
over 24 months (+0.061 ± 0.016 mm (p=0.0002) in the ZDV/3TC/LPV/r arm and 
+0.044 ±0.018 (p=0.012) in the NVP/LPV/r arm) appears to suggest a higher 
progression rate than the approximately 0.01 mm/year reported in HIV-negative 
subjects[21, 22].  
Previous longitudinal studies studying C-IMT in HIV-infected patients have had 
conflicting results, possibly partially explained by differences in selection of 
participants. Progression rates in two studies including both cART-naïve and 
cART-exposed patients were 0.02 (0.012-0.029) and 0.074±0.13 mm/year [23, 24]. 
Another study found no significant difference in C-IMT progression rates between 
patients using a PI, those without prior PI exposure, and matched HIV-negative 
controls (median progression rates of 0.0096, 0.0058 and 0.0085 mm/year 
respectively)[25]. None of these studies investigated C-IMT progression in patients 
initiating cART for the first time. In this setting, a number of factors besides direct or 
indirect effects of antiretroviral drugs may simultaneously play a role, such as 
suppression of viral replication and restoration of immunity. The extent to which 
such factors contribute to changes in vascular risk remains to be established. 
 
The increase in arterial stiffness after start of cART was observed only in the 
femoral artery. Different cardiovascular risk factors are known to have diverse 
effects on different arterial segments. The effects of fat accumulation and 
distribution, as well as of impaired glucose tolerance and metabolic syndrome are 
most pronounced in the muscular femoral artery[26, 27], suggesting that this artery 
is particularly susceptible to metabolic changes. Stiffness of the elastic carotid 
artery, on the other hand, is mainly associated with aging and hypertension[28]. It 
is therefore not surprising that in patients experiencing metabolic complications of 
cART, the most pronounced changes in arterial stiffness occurred in the femoral 
artery. These findings are also consistent with those of a previous cross-sectional 
study, in which we found an independent association between use of ART and 
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femoral artery stiffness (van Vonderen, M.G.A., Smulders, Y.M., Stehouwer C.D.A. 
et al: Carotid intima-media thickness and arterial stiffness in HIV infected patients: 
the role of HIV, antiretroviral therapy and lipodystrophy. Submitted). Given the fact 
that most treatment related risk factors developed in the ZDV/3TC/LPV/r arm, 
including decreased insulin sensitivity, central fat accumulation and limb fat loss, 
one might have expected a greater deterioration in arterial stiffness in this group 
compared to the NVP/LPV/r arm. Although in the NVP/LPV/r arm only femoral 
artery DC decreased, in contrast to decreases in both DC and CC in the 
ZDV/3TC/LPV/r arm, differences between groups were not significant. Again, 
sample size may have been insufficient to detect smaller differences. On the other 
hand, the negative effects of the LDL cholesterol increase on arterial stiffness in 
the NVP/LPV/r arm may be speculated to overshadow any beneficial effects of 
increased HDL cholesterol and the absence of insulin resistance.  
 
We found no change in augmentation index, a measure of systemic arterial 
stiffness. This is in agreement with findings of another study, in which no difference 
was found in this parameter between cART-treated patients with and without 
clinical lipodystrophy[29]. In that study, duration of treatment with and cumulative 
exposure to antiretroviral drugs were independent predictors of augmentation 
index. As cumulative exposure to cART was relatively short in our study, we cannot 
rule out that any effects of cART on augmentation index may take longer to appear. 
The coefficient of variation for augmentation index measurements was relatively 
high, but comparable to previous studies[30, 31]. This is a known limitation of the 
measurement technique, which, in combination with the limited sample size, could 
have played a role in not finding any significant changes. 
 
In contrast to the deterioration in arterial wall thickness and stiffness, we observed 
an improvement in several endothelial markers after start of cART. In the pre-
HAART era, HIV-infected patients were shown to have increased levels of sICAM-
1, sVCAM-1, vWF and PAI-1[32-34]. Most studies also reported an association 
between levels of endothelial markers and progression of HIV infection. 
Endothelium may be activated either directly by HIV or HIV-associated proteins, or 
indirectly through an inflammatory cascade triggered by HIV[35]. Antiretroviral 
therapy may therefore reduce endothelial activation by suppressing HIV. Studies 
showing decreases in levels of adhesion molecules and vWF after start of cART 
support this theory[36-38]. However, not all markers of endothelial function improve 
with antiretroviral treatment. Elevated PAI-1 was found in patients using PI-
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containing cART[39, 40], not improving after initiation of cART in one longitudinal 
study[41], similar to our observations. Antiretroviral drugs, by their metabolic side 
effects, may therefore also contribute to endothelial dysfunction, and the balance 
between beneficial effects of suppression of HIV and potential deleterious effects 
of complications of cART may differ between antiretroviral drug classes and 
individual drugs. 
In HIV-infected patients, PAI-1 has been associated with hyperlipidemia, insulin 
resistance, visceral and subcutaneous fat accumulation and lipodystrophy[40, 42, 
43]. Therefore it seems surprising that in our study PAI-1 increased only in the 
NVP/LPV/r arm and not in the ZDV/3TC/LPV/r arm, in which lipodystrophy and 
insulin resistance developed. The higher lipid levels in the NVP/LPV/r arm may 
have affected the between-group difference in course of hs-CRP. The observed 
differences in markers of inflammation and coagulation activation between groups, 
despite their comparable effects on viral suppression, might suggest a greater 
degree of residual immune activation in those on NVP/LPV/r early on. 
 
The disconnect between observed changes in arterial stiffness and endothelial 
function is interesting. These findings may suggest that the microcirculation and 
large vessels respond differently in this setting. Another potential explanation may 
be that the increase in arterial stiffness is mediated by non- endothelial 
mechanisms, including changes in extracellular matrix properties, vascular smooth 
muscular function or advanced glycation endproducts, as has been shown in 
patients with diabetes mellitus[44-46]. 
 
Our study had several limitations. As the study was limited to men, findings may 
not be applicable to women. Also, as recent data suggest differences in terms of 
cardiovascular risk and inflammatory markers comparing different NRTI[8, 47], the 
changes observed for ZDV/3TC may not apply to all NRTI. Furthermore, there 
appeared to be differences between groups in age and smoking, both to the 
disadvantage of the NVP/LPV/r arm. Analyses were therefore corrected for these 
potential confounders. 
Due to the relatively small sample size, our study had limited power to detect 
between-group differences in arterial properties. However, our findings are highly 
consistent with studies in non-HIV-infected patients, and also with the scarce 
cross-sectional data available in HIV-infected patients, as outlined above. 
Therefore, although we cannot draw definite conclusions concerning differences 
between groups, our results support further prospective exploration within 
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comparative trials of different antiretroviral regimens concerning their effects on 
metabolism and the vasculature. We suggest that such studies also account for 
changes in immune activation, inflammation and coagulation.  
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Table 1. Baseline characteristics.  
 
 ZDV/3TC/LPV/r 
(n=19) 
NVP/LPV/r 
(n=18) 
age (years) 38.0 (35.0-43.1) 44.8 (39.7-54.7) 
CD4 (106/l) 220 (170-264) 200 (140-258) 
HIV-RNA ( log 10 copies/ml) 5.1 (5.0-5.3) 4.9 (4.7-5.1) 
blood pressure 
  systolic 
  diastolic 
  mean 
 
120 (113-127) 
71 (61-77) 
87 (80-93) 
 
117 (112-138) 
66 (61-78) 
84 (79-95) 
fasting glucose (mmol/l) 5.1 (4.7-5.5) 5.0 (4.7-5.5) 
smoking 6/19 (31.6%) 11/18 (61.1%) 
history CVD 3/19 (15.8%) 2/18 (11.1%) 
family history CVD 10/19 (52.6%) 10/18 (55.6%) 
 
 
Shown are median (interquartile range) or number (percentage). 
CVD cardiovascular disease.  
ZDV/3TC/LPV/r: zidovudine, lamivudine, lopinavir/ritonavir 
NVP/LPV/r: nevirapine/lopinavir/ritonavir
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Table 2a. Body composition, lipid profile, insulin sensitivity, virology and immunology.  
 
ZDV/3TC/LPV/r  
Mo 0 Mo 3 Mo 12 Mo 24 
BMI (kg/m2) 23.0±0.2 23.0±0.2 23.3±0.2# 23.3±0.2 
CT/Dexa     
Limb fat (gram)† 5966±215 6267±224 6065±220# 5584±221# 
Trunk fat (gram) 6790±236 6754±247 7389±242 7512±242* 
Total fat (gram)† 12752±386 13016±405 13451±397# 13094±397# 
VAT (cm2) 105.1±6.9 97.1±7.1 109.2±7.3* 126.8±7.1 
SAT (cm2) 110.7±4.7 108.4±4.8 118.2±4.9 114.7±4.8 
Lipid profile (fasting)     
Total cholesterol 
(mmol/l)† 
4.2±0.2 5.2±0.2 5.3±0.2# 5.2±0.2*# 
HDL cholesterol 
(mmol/l) 
1.10±0.05 1.23±0.05# 1.37±0.05# 1.38±0.05*# 
LDL cholesterol 
(mmol/l) † 
2.5±0.1 2.7±0.1# 2.7±0.1 2.6±0.1 
Triglycerides (mmol/l) 1.3±0.4 2.8±0.4 3.1±0.4 2.7±0.4* 
Insulin sensitivity 
(fasting) 
    
HOMA 1.8±0.2 1.5±0.2 1.8±0.2 1.6±0.2 
Virology/immunology     
CD4 cell count (x 106/l) 220 (170-264) 344 (250-450) 424 (360-538) 502 (385-685) 
HIV-RNA (<50 
copies/ml) 
0/19 (0%) 11/19 (58%) 18/19 (95%) 17/19 (89%) 
 
 
Data represent estimated means±standard error of the mean, median (interquartile range) 
(for CD4 cell count) and number (percentage) (for HIV-RNA). 
 
*p<0.05 within group 0-24 months 
†p<0.05 between groups difference overall course 0-24 months 
#p<0.05 between groups at visit 
BMI body mass index, SAT subcutaneous adipose tissue, VAT visceral adipose tissue, TAT 
total adipose tissue, HDL high density lipoprotein, LDL low density lipoprotein, HOMA 
homeostasis model assessment of insulin resistance 
ZDV/3TC/LPV/r: zidovudine, lamivudine, lopinavir/ritonavir 
NVP/LPV/r: nevirapine/lopinavir/ritonavir 
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Table 2b. Body composition, lipid profile, insulin sensitivity, virology and immunology. 
 
NVP/LPV/r  
Mo 0 Mo 3 Mo 12 Mo 24 
BMI (kg/m2) 23.0±0.2 23.3±0.2 24.2±0.2 23.8±0.2* 
CT/Dexa     
Limb fat (gram)† 5966±221 6075±231 7094±232 6799±240* 
Trunk fat (gram) 6781±242 6469±254 7984±256 7711±264* 
Total fat (gram)† 12754±397 12551±417 15083±419 14515±433* 
VAT (cm2) 105.5±7.1 94.9±7.5 117.1±7.5 118.3±7.8 
SAT (cm2) 111.0±4.8 109.4±5.0 129.2±5.0 124.4±5.2 
Lipid profile (fasting)     
Total cholesterol 
(mmol/l)† 
4.2±0.2 5.7±0.2 6.0±0.2 5.9±0.2* 
HDL cholesterol 
(mmol/l) 
1.10±0.05 1.41±0.06 1.45±0.06 1.47±0.06* 
LDL cholesterol 
(mmol/l) † 
2.5±0.1 3.2±0.1 3.1±0.2 3.4±0.1* 
Triglycerides (mmol/l) 1.4±0.4 2.5±0.4 3.4±0.4 2.4±0.5 
Insulin sensitivity 
(fasting) 
    
HOMA 1.7±0.2 1.7±0.2 1.9±0.2 1.9±0.2 
Virology/immunology     
CD4 cell count (x 106/l) 200 (140-258) 295 (220-406) 370 (295-500) 460 (400-590) 
HIV-RNA (<50 
copies/ml) 
0/18 (0%) 13/18 (77%) 16/18 (89%) 15/18 (83%) 
 
 
Data represent estimated means±standard error of the mean, median (interquartile range) 
(for CD4 cell count) and number (percentage) (for HIV-RNA). 
 
*p<0.05 within group 0-24 months 
†p<0.05 between groups difference overall course 0-24 months 
 #p<0.05 between groups at visit 
BMI body mass index, SAT subcutaneous adipose tissue, VAT visceral adipose tissue, TAT 
total adipose tissue, HDL high density lipoprotein, LDL low density lipoprotein, HOMA 
homeostasis model assessment of insulin resistance 
ZDV/3TC/LPV/r: zidovudine, lamivudine, lopinavir/ritonavir 
NVP/LPV/r: nevirapine/lopinavir/ritonavir 
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Table 3a Carotid artery intima-media thickness (C-IMT), arterial stiffness estimates and 
biochemical markers of endothelial function and inflammation.  
 
 ZDV/3TC/LPV/r 
 Mo 0 Mo 3 Mo 12 Mo 24 
Carotid artery 
    
C-IMT 0.62±0.01 0.62±0.01 0.66±0.01 0.69±0.01* 
Distensibility coefficient 23.8±0.8 25.9±0.8# 23.8±0.8 23.0±0.8 
Compliance coefficient 0.99±0.03 1.05±0.03 0.97±0.03 0.94±0.03 
Elastic modulus 0.57±0.02 0.51±0.02 0.50±0.02 0.49±0.02* 
Brachial artery 
    
Distensibility coefficient 12.7±1.0 13.5±1.0 14.0±1.0 13.1±1.0 
Compliance coefficient 0.19±0.01 0.21±0.01 0.22±0.01 0.21±0.01 
Femoral artery 
    
Distensibility coefficient 12.1±0.6 11.6±0.7 11.3±0.7 10.4±0.7* 
Compliance coefficient 0.88±0.05 0.83±0.05 0.85±0.05 0.77±0.05* 
     
Augmentation index 12.1±1.6 10.8±1.6 13.2±1.6 12.6±1.6 
     
sICAM-1 (ng/ml) 880±37 775±38 723±39 682±38* 
sVCAM-1 (ng/ml) 1566±55 1257±56 1126±59 1077±57*# 
vWF (%) 219±9 170±9 155±10 157±9* 
PAI-1 (ng/ml) 111±17 103±17 149±18 108±17# 
hsCRP (mg/l) † 2.5±0.8 1.9±0.8# 1.2±0.8# 1.7±0.8 
 
 
Data represent estimated means±standard error of the mean. 
*p<0.05 within group 0-24 months 
†p<0.05 between groups overall difference 0-24 months 
#p<0.05 between groups at visit 
 sICAM-1: soluble intercellular adhesion molecule-1, sVCAM-1: soluble vascular cell 
adhesion molecule, vWF: plasma von Willebrand factor antigen, PAI-1: Plasminogen 
Activator Inhibitor-1 antigen, hsCRP: high sensitive C-reactive protein. 
ZDV/3TC/LPV/r: zidovudine, lamivudine, lopinavir/ritonavir 
NVP/LPV/r: nevirapine/lopinavir/ritonavir   
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Table 3b Carotid artery intima-media thickness (C-IMT), arterial stiffness estimates and 
biochemical markers of endothelial function and inflammation.  
 
 NVP/LPV/r 
 Mo 0 Mo 3 Mo 12 Mo 24 
Carotid artery 
    
C-IMT 0.63±0.01 0.65±0.01 0.66±0.01 0.68±0.02* 
Distensibility coefficient 23.7±0.8 23.2±0.9 24.0±0.9 24.2±0.9 
Compliance coefficient 0.99±0.03 0.96±0.03 0.99±0.03 0.99±0.04 
Elastic modulus 0.55±0.02 0.54±0.02 0.52±0.02 0.50±0.02 
Brachial artery 
    
Distensibility coefficient 12.4±1.0 11.9±1.0 12.0±1.0 12.4±1.1 
Compliance coefficient 0.19±0.01 0.19±0.01 0.19±0.01 0.19±0.01 
Femoral artery 
    
Distensibility coefficient 11.5±0.7 10.9±0.7 10.0±0.7 9.8±0.7* 
Compliance coefficient 0.83±0.05 0.82±0.05 0.80±0.05 0.79±0.05 
     
Augmentation index 12.9±1.6 15.3±1.7 14.9±1.7 16.0±1.7 
     
sICAM-1 (ng/ml) 928±38 833±40 780±40 761±43* 
sVCAM-1 (ng/ml) 1609±56 1215±59 1003±60 899±65* 
vWF (%) 229±9 164±10 151±10 158±11* 
PAI-1 (ng/ml) 105±17 127±18 152±18 165±20* 
hsCRP (mg/l) † 2.8±0.8 4.5±0.8 5.4±0.8 3.5±0.9 
 
 
Data represent estimated means±standard error of the mean. 
*p<0.05 within group 0-24 months 
†p<0.05 between groups overall difference 0-24 months 
#p<0.05 between groups at visit  
sICAM-1: soluble intercellular adhesion molecule-1, sVCAM-1: soluble vascular cell 
adhesion molecule, vWF: plasma von Willebrand factor antigen, PAI-1: Plasminogen 
Activator Inhibitor-1 antigen, hsCRP: high sensitive C-reactive protein. 
ZDV/3TC/LPV/r: zidovudine, lamivudine, lopinavir/ritonavir 
NVP/LPV/r: nevirapine/lopinavir/ritonavir   
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Abstract  
 
Objectives 
We studied which factors influence changes in lipids after switching to atazanavir 
(ATV), and the effectiveness of ATV in maintaining virus suppression. 
  
Methods 
Retrospective cohort study in patients with sustained viral suppression, comparing 
patients switching to ATV with those not switching to ATV. Primary outcome 
measures were changes in total (TC), high density (HDL) and low density 
lipoprotein (LDL) cholesterol and triglycerides (TG) during 48 weeks, stratified for 
dyslipidemia and physician-reported lipodystrophy. Secondary outcome measure 
was virological failure (time to first of two consecutive plasma viral load > 50 
copies/ml).  
 
Results 
225 patients switched to ATV (193 (85.8%) RTV boosted), 3120 patients continued 
cART. In patients with high (>6.2 mmol/L) baseline TC, a greater mean (95% 
confidence interval) decrease in TC was observed in the switch group compared to 
the continued cART group (-1.26 (-1.63 to -0.89) and -0.54 (-0.64 to -0.44) mmol/l, 
respectively, p=0.002). Likewise greater changes in TG were observed in patients 
with high (> 2.3 mmol/L) baseline TG (-1.44 (-2.05 to -0.83) and -0.54 (-0.70 to -
0.38) mmol/l, respectively, p=0.002). These effects were seen irrespective of the 
presence of lipodystrophy. Virological failure was observed more frequently after 
switching to ATV (17/224 (7.8%) compared to 73/3100 (2.4%) in those continuing 
cART, p<0.0001).  
 
Conclusions 
Patients on cART with sustained virological suppression, including those with 
reported lipodystrophy, may benefit from switching to ATV with an improvement in 
lipid profile, especially if baseline lipid levels are high. This benefit should be 
balanced against a possible higher risk of virological failure.  
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Introduction 
 
Dyslipidemia is common in HIV infected patients receiving combination 
antiretroviral therapy (cART). In the largest survey of dyslipidemia in HIV-infected 
patients, the Data Collection on Adverse Events of Anti-HIV drugs (D:A:D) Study, 
hypercholesterolemia (defined as total cholesterol (TC) ≥ 6.2 mmol/l) was found in 
22.2% of all patients, hypertriglyceridemia (triglycerides (TG)  ≥  2.3 mmol/l) in 
33.8% and low high density lipoprotein (HDL) cholesterol (HDL ≤ 0.9 mmol/l) in 
25.7%[1]. The pathogenesis underlying cART-associated dyslipidemia may include 
direct effects of antiretroviral drugs and potentially may be reinforced by body 
shape changes indicative of lipodystrophy.  As cART is to be used lifelong, concern 
has arisen about the potential increase in cardiovascular disease risk resulting from 
various risk factors including dyslipidemia. A 26% increase in estimated risk of 
myocardial infarction was reported per additional year of exposure to cART [2], 
which was found to be mainly associated with the use of protease inhibitors (PI), 
and which could at least partially be explained by the dyslipidemic effects of this 
drug class[3]. Control of dyslipidemia has therefore become a relevant part of the 
management of cardiovascular risk in HIV-infected patients receiving cART. One of 
the strategies to ameliorate cART-related dyslipidemia is to switch from an existing 
PI to atazanavir (ATV), a PI which, as part of cART, has been demonstrated to 
have no significant effects on total and LDL-cholesterol and TG levels in cART-
naive patients [4-6].  Concordant with the results in therapy-naive patients, patients 
switching from other PIs to ATV experienced significant decreases of lipid 
parameters when compared to those continuing the other PI [7-11].  Less is known 
however regarding which factors may influence the degree of improvement in lipid 
levels after switching to ATV. These may include the degree of dyslipidemia before 
switch, the (type of) drug in the previous regimen which is being replaced, the use 
of ritonavir-boosted or unboosted ATV, as well as the presence of body shape 
changes resulting from LD. 
Concerning the efficacy of ATV in maintaining virus suppression in those switching 
to ATV after having obtained undetectable plasma HIV-1 RNA levels (pVL) on 
other PI based cART regimens, the limited available information suggests that in 
these patients switch to ATV does not lead to an increased risk of virological failure 
[12, 13]. Whether this also applies to patients switching from non-PI based 
regimens and those with a longer history of cART remains to be determined.  
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The primary objective of the present observational cohort study therefore was to 
describe the changes in lipid profile, and the factors influencing the extent of these 
changes, in cART-experienced patients with sustained virological suppression 
switching to ATV, compared to patients not switching to ATV. As a secondary 
objective we also evaluated virological failure rates and factors predicting 
virological failure following switch to ATV. 
 
 
Patients and methods 
 
Study population 
This study was conducted within the ATHENA cohort, a nationwide observational 
cohort study of HIV-infected individuals in the Netherlands[14]. This cohort includes 
patients followed up at  all 25 hospitals that provide care to HIV-infected patients in 
the Netherlands.  Informed consent is obtained by an opt-out method. 
The ATHENA database contains anonimized information on patient demographics, 
HIV-related clinical events, use of drugs against opportunistic infections, use of 
type and dose of antiretroviral drugs, reasons for changing cART, and treatment-
associated adverse effects. In addition, data on plasma HIV-1 RNA concentration, 
CD4+ T-cell counts and laboratory parameters including plasma lipids are 
recorded. 
The population for the current analysis consists of all patients in the ATHENA 
cohort who used  a cART regimen not containing ATV, on June 1, 2004, which is 
the date ATV became available in the Netherlands to be prescribed as part of 
routine care. cART was defined as the use of at least three drugs from at least two 
different drug classes, or at least 3 drugs from the NRTI class including abacavir or 
tenofovir. Patients had to have initiated cART at age 16 or older. From this subset 
of participants, ATV switchers were identified as patients switching to ATV-
containing cART on or after June 1, 2004, with or without switching other 
antiretrovirals in their regimen. The continued cART group included all patients who 
did not switch to ATV during the follow-up period after June 1, 2004. Switches to 
antiretroviral drugs other than atazanavir were allowed in this group. Baseline was 
defined as the day of switch to ATV for the switch group and as June 1, 2004 for 
the continued cART group. 
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Only patients with sustained virological suppression were included, defined as 
having a plasma viral load (pVL) < 50 copies/ml on all occasions in the 6 months 
prior to baseline, as well as a pVL < 50 copies/ml on the last measurement prior to 
these 6 months. Patients with transient low level HIV viraemia, defined as one pVL 
> 50 copies/ml in the 6 months prior to baseline, were included if this episode was 
preceded and also followed by a pVL < 50 copies/mL. 
Only patients with a follow-up of at least 24 weeks from baseline were considered 
for the analysis. Data were collected up to June 1, 2006. 
 
Outcome measures. 
The primary outcome measures were changes in lipid parameters from baseline to 
24 and 48 weeks in patients without virological failure during the period of follow 
up. Lipid parameters included TC, TG and (where available) HDL and low density 
lipoprotein (LDL) cholesterol levels. LDL levels were calculated using the 
Friedewald formula, provided concomitantly determined TG values were < 4.52 
mmol/l[15]. No information was available concerning whether bloods had been 
drawn fasting or not.  
Based on the most recent lipid profile prior to baseline, patients were categorized 
as having dyslipidemia (TC > 6.2 mmol/l (for outcome TC) and/or TG > 2.3 mmol/l 
(for outcome TG)) or not.   
In addition, patients were stratified into those with or without LD at baseline 
(lipoatrophy, fat accumulation or both) based on body shape changes reported by 
the treating physician. 
The secondary outcome measure was virological failure during follow-up, defined 
as time to the first of two consecutive pVL > 50 copies/ml whilst on cART. 
 
Statistical analysis 
Baseline characteristics were compared using the Wilcoxon test for continuous 
variables and chi square tests for categorical variables. T-tests were used to 
assess differences in changes in TC and TG levels at week 24 and 48 relative to 
baseline, comparing patients switching to ATV to those continuing cART. A 
sensitivity analysies was conducted restricted to those patients in both groups who 
at baseline were being treated with a PI-containing cART regimen, and within this 
group to patients who did not change their background treatment at the time of the 
switch to ATV. In patients switching to ATV, linear regression models were used to 
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identify parameters independently associated with a more pronounced change in 
TC and TG levels at week 24. The following variables were tested for their 
association with changes in lipid levels: gender, use of lipid lowering drugs, use of 
RTV as a booster, TC at baseline(< or ≥ 6.2 mmol/l and continuously),TG at 
baseline (< or ≥ 2.3 mmol/l and continuously), prior diagnosis of diabetes mellitus, 
prior LD, BMI (per kg/m2 increase), age at baseline (per year increase), cumulative 
time on cART (per additional year of exposure), cumulative time on thymidine 
analogues (per additional year of exposure), discontinuation of stavudine, 
zidovudine, an NNRTI or a PI from the regimen used prior to switching to ATV. The 
normality assumption was checked. 
The percentage of patients with virological failure was estimated using Kaplan 
Meier survival analysis. Cox proportional hazards models were used to test the 
independent effect of potential determinants of time to virological failure. All 
comparisons used a 2-sided α level of 0.05.  
Analyses were performed using SAS version 9.1 (SAS Institute, Cary, North 
Carolina, USA). 
 
 
Results 
 
The ATV switch group consisted of 225 patients, the continued cART group of 
3120 patients. Baseline characteristics are summarized in Table 1. Patients in the 
ATV switch group were older, had more advanced HIV-1 infection, had been 
exposed to antiretroviral treatment for longer, were less often ART-naive at the 
start of cART and had more often experienced virological failure on a previous PI-
based regimen. Patients in the ATV switch group also had significantly higher 
baseline TC and TG levels (59/225 had TC >6.2 mmol/l and 107/225 had TG> 2.3 
mmol/l) and more often had diabetes mellitus and LD than patients in the continued 
cART group. Twentyeight (12.4%) patients in the ATV switch group and 255 (8.2%) 
patients in the continued cART group were using a lipid-lowering drug at baseline, 
mostly consisting of an HMG Co A-reductase inhibitor (“statin”) (24/28 in the switch 
group, 241/255 in the continued cART group) or fibrate (4/28 and 14/255 in the 
switch and continued cART group, respectively). Of the patients switching to ATV, 
193 (85.8%) started RTV boosted ATV and 44 (19.6%) started it in combination 
with a NNRTI. Switch patterns are shown in Table 2. Most common reasons for 
switching to ATV were toxicity (in 130 (57.8%) of cases) and simplification of the 
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previous cART regimen (in 51 (22.7%) of cases). Of the patients switching because 
of toxicity, 24 (19.2%) did so because of hyperlipidemia, 30 (24%) because of 
lipodystrophy and 19 (15.2%) because of diarrhea.  
In the ATV switch group, at baseline 12/225 (5.3%) patients used stavudine and 
50/225 (22.2%) zidovudine as part of their regimen. During follow up, none of these 
12 and 5/50 (10%) of patients discontinued, and 2/213 and and 5/175 started 
stavudine or zidovudine, respectively. 19/225 (8.4%) patients discontinued ATV. 
In the continued cART group, at baseline  316/3120 (10.1%) patients used 
stavudine and 1941/3120 (62.2%) zidovudine as part of their regimen. During 
follow up, 108/316 (34.2%) and 172/1941 (8.9%) of patients discontinued, and only 
4/2804 and and 34/1179 started stavudine or zidovudine, respectively. Only 
15/2386 (<1%) patients not on a PI at baseline started a PI, and 91/734 (12.4%) on 
PI at baseline discontinued PI during follow up.  
 
Lipid profiles (table 3) 
In patients with dyslipidemic TC levels switching to ATV, mean (95% confidence 
interval) TC levels decreased significantly by -1.23  (-1.56 to -0.90) mmol/l after 24 
weeks. This decrease was significantly greater than the mean decrease of -0.42  (-
0.52 to -0.32) mmol/l seen in the continued cART group, and persisted after 48 
weeks. In patients with baseline TC < 6.2 mmol/L, switch to ATV resulted in a 
smaller, non-significant mean decrease in TC over 24 and 48 weeks.  
Mean (95% CI) triglyceride levels decreased significantly by -1.73 (-2.18 to -1.28) 
mmol/l after 24 weeks in patients with baseline dyslipidemic TG levels switching to 
ATV. This decrease was significantly greater than the decrease of -0.46 (-0.6 to -
0.32) mmol/l observed in the continued cART group and persisted after 48 weeks. 
The same was true for patients with lower baseline TG levels, although the 
difference was apparent only after 48 weeks. 
For patients categorized as having LD, similar patterns in course of TC and TG 
levels after switch to ATV were observed as in patients without LD. Subgroups of 
patients with lipoatrophy only, lipohypertrophy only and combined lipoatrophy and 
lipohypertrophy were too small to study separately.  
A sensitivity analysis restricted to those patients in both groups who were being 
treated with a PI-containing cART-regimen at baseline, and for the switch group to 
those with no change in their background regimen also yielded similar results (table 
4). 
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In a multivariate regression analysis, baseline TC level, use of RTV- boosted as 
opposed to unboosted ATV, presence of diabetes mellitus, and discontinuation of a 
NNRTI or a PI in the previous regimen were independent significant predictors for 
the change in TC from baseline to 24 weeks in patients switching to ATV (table 5). 
For each mmol/l higher baseline TC, the decrease in TC after switch to ATV was 
0.38 (0.30 to 0.46) mmol/l (p<0.00001) greater. Patients starting RTV-boosted ATV 
had a 0.49 (0.06 to 0.92) mmol/l smaller decrease in TC after 24 weeks than those 
starting unboosted ATV (p=0.02). Patients stopping an NNRTI from their previous 
regimen had a similar decrease in TC compared to those stopping a PI from their 
previous regimen (-0.79 ±(-1.26 to -0.32) mmol/l and -1.02 (-1.41 to -0.63) mmol/l, 
respectively, difference 0.22 (-0.13 to 0.57) mmol/l, p=0.22). LD was not an 
independent  predictor (p=0.60) for the change in TC between baseline and 24 
weeks in patients switching to ATV, neither was stopping stavudine (p=0.92) or 
zidovudine (p=0.08) in the previous regimen. Patients with diabetes mellitus had a 
0.41 (0.0 to 0.82) mmol/l (p=0.049) smaller decrease in TC after switch to ATV 
than patients without diabetes mellitus. 
For the change in TG 24 weeks after switch to ATV, baseline TG level, use of lipid 
lowering drugs (prior to switch (28/29) or after switch (1/29) and use of a PI in the 
previous regimen were independent predictors (table 6). For each mmol/l higher 
baseline TG, the decrease in TG level after switch to ATV was 0.61 (0.53 to 0.69) 
mmol/l (p<0.0001) greater. Patients stopping a PI from their previous regimen had 
a 0.52 (0.05 to 0.99) mmol/l (p=0.03) greater decrease in TG level after switch to 
ATV compared to patients without a PI in their previous regimen. Use of RTV 
boosted ATV was not an independent predictor of changes in TG levels after 
switch to ATV. Patients using a lipid lowering drug had a 0.97 (0.36 to 1.58) mmol/l 
(p=0.002) smaller decrease in TG levels than those not using lipid lowering drugs, 
possibly indicating a selected patient population who had already benefited from 
the use of a lipid-lowering drug and therefore had less reversibility of 
hyperlipidemia. 
 
As HDL and LDL levels were available for only a limited number of patients, 
analyses for these parameters were performed without stratification for baseline 
levels. At 24 and 48 weeks, there was no significant change in HDL or in LDL 
cholesterol in the ATV switch group compared to the continued cART group. 
However, mean (95% CI) non-HDL cholesterol levels in the ATV switch group 
decreased both over time (-0.47 (-0.86 to -0.08) mmol/l, p=0.02 after 48 weeks) 
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within this group, and to a significantly greater extent when compared to the 
continued cART group (p=0.04 after 48 weeks, data not shown). 
Between baseline and week 48, 3 patients in the ATV switch group (1.3%) started 
lipid- lowering drugs (all statins), in the continued cART group this occurred in 107 
patients (3.4%)(n.s.), of whom 104 started a statin and 3 a fibrate. At week 48, 
32/138 (23.2%) patients in the ATV switch group had dyslipidemic TC levels (>6.2 
mmol/l), compared to 449/2269 (19.8%)in the continued cART group (p=0.33). 
Dyslipidemic TG levels (>2.3 mmol/l) were seen in 54/134 (40.3%) patients in the 
ATV switch group and in 704/2177 (32.3 %) in the continued cART group (p=0.06).  
 
Virological failure 
Of the patients for whom plasma HIV-RNA measurements were available, 17/224 
(7.8%) patients switching to ATV experienced virological failure within 48 weeks, 
compared to 73/3100 (2.4%) in the continued cART group (p<0.0001). Of the 17 
patients with virological failure after switch to ATV, 10 had been pretreated prior to 
starting cART and 5 had previously experienced virological failure on a PI-based 
regimen. Ten of these patients used unboosted ATV, two used a NNRTI in 
combination with unboosted ATV, none used tenofovir with unboosted ATV. 
Of these 17 patients meeting the definition of virological failure after switch to ATV, 
five had low level viraemia (between 54 and 153 copies/ml), of whom three 
achieved undetectable pVL (< 50 c/ml) while continuing the same ATV based 
regimen and two after intensifying their regimen with a boosting dose of RTV (n=1) 
or with a third NRTI. In two patients, the ATV based regimen was stopped because 
of very high pVL, suggesting nonadherence. Both these patients later achieved 
undetectable pVL after resuming the same ATV based regimen. One patient had 
virological failure only after ATV was switched to LPV/r. Of the other 9 patients with 
virological failure, 5 switched to other regimens during the follow-up period. 
In a univariate Cox proportional hazards regression model, although limited by the 
small number of patients with virological failure, patients who were antiretroviral-
experienced prior to start of cART had a significantly shorter time to viral rebound 
(HR 2.49 (95% CI 1.04-5.94, p=0.04). Although none of these associations 
reached statistical significance, female gender and use of unboosted ATV were 
also associated with shorter time to viral rebound (HR of 2.17 (0.89-5.34) and 2.44 
(0.95-6.24), respectively), whereas lipoatrophy was inversely associated with 
shorter time to viral rebound (HR of 0.27 (0.06-1.2)).  
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When the analysis was restricted to those patients in both groups who were being 
treated with a PI-containing cART-regimen at baseline, and for the switch group to 
those who did not change their background regimen at the time of the switch, the 
virological failure rate within 48 weeks was also higher in the ATV switch group 
(11/91(13%)) compared to the continuous cART group (24/616(4.0%), logrank 
p=0.0002). 
 
When the analysis was restricted to patients who had started cART while ART-
naïve, and within the switch group to those who switched to RTV-boosted ATV, the 
difference in virological failure rate between the switch group and the continued 
cART group was smaller (5/106 (4.7%) and 58/2419 (2.4%) failure for the switch 
and continued cART group, respectively; the Kaplan Meier estimates for failure 
within one year after baseline were 6.4% (2.6-15.0) and 2.4 (1.9-3.1), respectively; 
logrank p =0.052).  
 
 
Discussion 
 
This study demonstrates that switching to ATV may have beneficial effects on 
dyslipidemia in patients on cART with sustained virological suppression. A 
significant decrease in TC and TG was observed in patients switching to ATV 
compared to those continuing cART, with the greatest changes seen in patients 
with higher TC and TG levels prior to the switch. The number of patients starting or 
stopping lipid lowering drugs or antiretroviral drugs with potential effect on lipid 
levels appears to be too small to have importantly contributed to the observed 
changes in TC and TG in the ATV switch group. In contrast, in those not switching 
to ATV a substantial proportion of patients discontinued a thymidine analogue 
NRTI or PI which provides an explanation for the, albeit significantly lower, 
reduction in TC and TG during follow up in these patients. Regression to the mean 
is also likely to contribute to the found reduction in TC and TG in patients not 
switching to ATV. A number of patients not switching had a random one-off high 
baseline TC or TG level which at the next measurement went back to lower, normal 
levels. In contrast, those switching to ATV are more likely to have had a longer 
period with high lipid levels. The observed differences in reduction of TC and TG 
between patients switching to ATV and patients not switching are therefore biased 
toward zero, or no difference.  
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The magnitude of the effects of switching to atazanavir on TC and TG were similar, 
irrespective of the presence of LD. Switching to RTV-boosted rather than 
unboosted ATV and the presence of diabetes mellitus, led to significantly smaller 
decreases in TC but not in TG. Patients stopping a PI or an NNRTI from their 
previous regimen had a significantly greater decline in TC than those not stopping 
these drugs. Stopping a PI from the previous regimen was an independent 
predictor for the decrease in TG after switch to ATV. Discontinuation of stavudine 
or zidovudine from the previous regimen did not significantly contribute to the 
decrease in TC or TG, but the low number of patients discontinuing these drugs 
provided limited power to detect potentially small effects on lipids. Patients 
switching to ATV had a higher rate of virological failure compared to patients in the 
continued cART group. 
 
We found that patients with LD had similar improvements in both TC and TG levels 
after switch to ATV as patients without LD, after adjusting for baseline TC and TG 
levels. The presence of diabetes mellitus however was associated with a reduced 
effect on TC of switching to atazanavir. This may suggest that a clinically important 
degree of insulin resistance rather than the presence of the body composition 
changes characteristic of LD per sé is the more important contributor to the 
dyslipidemia in these patients. Others did report a more marked improvement in 
lipid profile after replacing a PI with efavirenz, nevirapine or abacavir in non-
lipodystrophic patients compared to those with LD, although these differences were 
only significant for HDL but not for TC and TG levels [16].  
 
Patients switching to ATV had a higher rate of virological failure compared to 
patients in the continued cART group, and this difference remained when the 
analysis was restricted to patients switching from another PI to ATV without 
changes in their background regimen. An important limitation of this analysis is  
that there were significant differences between patients and controls with respect to 
factors expected to influence virological failure rates. Patients in the ATV switch 
group had been exposed to cART significantly longer than those in the continued 
cART group, had used a greater number of cART regimens, were more often 
antiretroviral-experienced prior to start of cART, and had more often experienced 
virological failure on a PI-based regimen, factors presumably having resulted in a 
greater likelihood of emergence of resistance, including against PI. Pretreatment 
before start of cART was significantly associated with shorter time to virological 
rebound, which may suggest that virological failure in this population may be 
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mainly related to ineffectiveness of the NRTI backbone due to resistance mutations 
acquired during previous NRTI mono- or dual therapy. In addition, the use of 
unboosted ATV in this treatment experienced population, also when combined with 
NNRTI, may also play a role. As was previously demonstrated, use of unboosted 
ATV led to lower viral suppression compared to LPV/r in treatment experienced 
patients who had failed one prior PI-containing regimen and with baseline NRTI 
mutations[17]. Our findings are in contrast with two recent studies that found 
comparable or lower rates of virological failure in patients switching to ATV 
compared to patients continuing their PI based regimen [12, 13]. These trials 
however included patients with a shorter duration of cART, and one of these 
excluded those with a history of virologic failure while receiving PI-based cART[12], 
in whom the risk of PI-associated resistance mutations would be expected to be 
low compared to our more experienced study population. Also, it should be noted 
that, although we found a higher virological failure rate in the ATV switch group 
compared to the continued cART group, the percentage of patients failing in the 
ATV switch group is comparable to that reported in these two recent randomized 
trials [12, 13]. However, the virological failure rate in the control population 
continuing their PI-based regimens in these trials was much higher than in the 
continued cART group in our study (16% and around 10% compared to 2.4% in our 
study). This may suggest, as the authors of one of these studies propose, that 
these trials included a selected patient population, who were dissatisfied with their 
current PI based regimen. Interestingly, in our study the difference in virological 
failure rates between the switch group and the continued cART group diminished 
after excluding patients with treatment experience prior to start of cART and those 
using unboosted ATV. However, this analysis included only a very small subgroup 
and results should therefore be interpreted with caution.   
 
This study has several limitations. First, the analyses were based on data from an 
observational cohort, in which treatment switches are not performed randomly. As 
a consequence, the ATV switch group and the continued cART group differed 
significantly in baseline characteristics. Although our multivariate analyses were 
adjusted to account for these differences, it is possible that additional differences 
remain which we cannot account for. Second, no information was available as to 
whether lipids had been drawn fasting, which may influence our results particularly 
concerning TG levels. Furthermore, LD was documented and categorized 
according to the treating physician, which may represent an underestimation of the 
true prevalence. Finally, the use of lipid-lowering drugs may have had an effect on 
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the observed changes in lipid profiles. However, the number of patients starting a 
lipid- lowering drug during follow-up was very limited in the ATV switch group and 
thus not likely to have importantly contributed to the lipid changes observed in this 
group. The somewhat higher rate of use of lipid lowering agents in the continued 
cART group may partially explain the limited improvement in lipid profile observed 
in this group. 
 
In conclusion, our findings suggest that patients with sustained virological 
suppression on cART experience potentially beneficial reductions in TC and TG 
levels after switching to ATV. Interestingly, such benefit seems irrespective of the 
presence of LD, which may indicate that LD per sé is not contributing as much to 
the hyperlipidemia in cART treated patients as is sometimes assumed. The extent 
of improvement in lipids is greater in those with a higher level of hyperlipidemia. 
The beneficial effect on lipid profile after switching to ATV should be balanced 
against a possible higher risk of virological failure. 
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Table 1. Baseline characteristics of the study population. 
 ATV switch 
(n=225) 
Continued cART 
(n=3120) 
p 
age 46 (40.2-52.1) 42.9(37.7-50.1) 0.0002 
male 179(79.6%) 2530(81.1%) 0.57 
Transmission group 
    Homosexual 
    Intravenous drugs 
    Heterosexual 
    Other 
 
133(59.1%) 
10(4.4%) 
63(28%) 
19(8.4%) 
 
1803(57.8%) 
96(3.1%) 
943(30.2%) 
278(8.9%) 
0.63 
CDC-C event prior to baseline 89(39.6%) 1021(32.7%) 0.04 
CD4 count at start cART (cells/ml) 160(70-290) 
(n=210) 
198(80-320) 
(n=2885) 
0.03 
Plasma HIV-RNA at start cART 
(copies/ml) 
81000(15453- 200000) 
(n=188) 
83700(25000- 219000) 
(n=2719) 
0.32 
ART-naive at start cART  126(56%) 2492(79.9%) <0.0001 
Variables at baseline    
Prior failure on PI based regimen 61(27.1%) 367(11.8%) <0.0001 
Diabetes mellitus 21(9.3%) 121(3.9%) <0.0001 
CD4 count (cells/ml) 540(360-740) 
(n=209) 
510(350-690) 
(n=2938) 
0.1 
Years since start cART  7.1(4.0-8.1) 4.9(2.8-6.9) <0.0001 
cART use*  
    PI 
    NNRTI 
    Zidovudine 
    Stavudine 
 
161 (71.6%) 
74 (32.9%) 
78 (34.7%) 
30 (13.3%) 
 
734 (23.5%) 
2107 (67.5%) 
1941 (62.2%) 
316 (10.1%) 
 
 
<0.0001 
<0.0001 
<0.0001 
0.13 
Total cholesterol (mmol/l) 5.4(4.6-6.6) 
(n=202) 
5.2(4.5-6.0) 
(n=2526) 
0.02 
Triglycerides (mmol/l) 2.5(1.7-4.1) 
(n=198) 
1.8(1.2-2.9) 
(n=2451) 
<0.0001 
HDL cholesterol (mmo/l) 1.2(1.0-1.5) 
(n=100) 
1.3(1.1-1.6) 
(n=1243) 
0.12 
LDL cholesterol (mmol/l) 2.9(2.2-3.5) 
(n=100) 
2.8(2.2-3.6) 
(n=1234) 
0.91 
Lipodystrophy  
    Any 
    Only lipoatrophy 
    Only fat  accumulation 
    Both 
    Unknown 
 
128(56.9%) 
57(25.3%) 
11(4.9%) 
56(24.9%) 
4(1.8%) 
 
990(31.7%) 
433(13.9%) 
154(4.9%) 
321(10.3%) 
82(2.6%) 
 
<0.0001 
 
Data are presented as medians (interquartile range) unless otherwise indicated. P values 
were obtained using Wilcoxon and Chi square tests for continuous and categorical variables, 
respectively. ATV atazanavir, cART combination antiretroviral therapy, HDL high density 
lipoprotein cholesterol, LDL low density lipoprotein cholesterol 
*For the ATV switch group cART at baseline consists of drugs used in the regimen prior to 
switch.
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Table 2a Switch patterns in 225 patients switching to atazanavir (ATV). 
 
Drug Number of 
patients using 
drug in previous 
regimen 
Number of 
patients stopping 
drug at switch 
Number of 
patients 
starting drug at 
switch 
Number of patients 
using drug in current 
regimen (after switch 
to ATV) 
Stavudine 30 19 1 12 
Zidovudine 78 28 0 50 
Tenofovir 97 5 31 123 
Nevirapine 39 17 2 24 
Efavirenz 35 18 2 19 
Ritonavir (all 
doses) 
133 14 74 193 
 
 
 
 
 
 
 
Table 2b Switch patterns to unboosted or boosted ATV in 225 patients switching to 
atazanavir. 
 
Previous regimen Number of 
patients  
Number of patients 
switching to 
unboosted ATV 
Number of patients 
switching to boosted 
ATV 
No PI 64 11 53 
PI regimens without ritonavir (total) 
  Indinavir 
  Saquinavir 
  Nelfinavir 
  Saquinavir+ nelfinavir 
28 
6 
3 
18 
1 
8 
2 
0 
6 
0 
20 
4 
3 
12 
1 
Ritonavir containing PI regimens 
(total) 
    Indinavir+RTV 
    Saquinavir + RTV 
    Lopinavir/r 
    Lopinavir/r+Indinavir 
    Lopinavir/r+Saquinavir 
    Tipranavir+RTV 
    Ritonavir (full dose) 
 
133 
14 
28 
83 
1 
4 
1 
2 
 
13 
1 
4 
9 
0 
0 
0 
0 
 
120 
13 
24 
74 
1 
4 
1 
2 
 
PI protease inhibitor, ATV atazanavir, RTV ritonavir 
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Table 3a. Mean Total cholesterol and triglyceride baseline values and changes from 
baseline to 24 and 48 weeks (95%confidence interval), stratified for high or low baseline 
cholesterol, high or low triglyceride levels, presence or absence of lipodystrophy at baseline 
and use of a PI (protease inhibitor) in the last regimen. 
 
  ATV switch 
  Mean value at 
baseline (mmol/l) 
n Mean change 
(mmol/l), 95%CI 
P within 
group* 
Total cholesterol 
(mmol/l) 
     
Low baseline 
cholesterol  
W 24 
 
4.75 117 -0.10 (-0.26; 0.06) 0.23 
(≤6.2 mmol/l) W 48  86 -0.14 (-0.32; 0.04) 0.14 
High baseline 
cholesterol  
W 24 7.52 46 -1.23 (-1.56; -0.9) <0.0001 
(>6.2 mmol/l) W 48  38 -1.26 (-1.63; -0.89) <0.0001 
No lipodystrophy W 24 5.37 63 -0.33 (-0.58; -0.08) 0.02 
 W 48  45 -0.33 (-0.58; -0.08) 0.02 
Lipodystrophy W 24 5.63 100 -0.47 (-0.69; -0.25) <0.0001 
 W 48  79 -0.57 (-0.82; -0.32) <0.0001 
PI in last / current 
regimen 
W 24 5.57 89 -0.61 (-0.81; -0.41) <0.0001 
 W 48  68 -0.65 (-0.90; -0.40) <0.0001 
Triglycerides 
(mmol/l) 
     
Low baseline 
triglycerides 
W 24 1.57 72 -0.13 (-0.42; 0.16) 0.37 
(≤2.3 mmol/l) W 48  54 -0.22 (-0.42; -0.02) 0.0007 
High baseline 
triglycerides 
W 24 4.92 84 -1.72 (-2.17; -1.27) <0.0001 
(>2.3 mmol/l) W 48  66 -1.44 (-2.05; -0.83) <0.0001 
No lipodystrophy W 24 3.01 61 -0.75 (-1.30; -0.20) 0.009 
 W 48  44 -0.63 (-0.98; -0.28) 0.001 
Lipodystrophy W 24 3.61 95 -0.94 (-1.33; -0.55) <0.0001 
 W 48  76 -1.04 (-1.57; -0.51) 0.0003 
PI in last / current 
regimen 
W 24 3.44 84 -0.96 (-1.31; -0.61) <0.0001 
 W 48  66 -0.99 (-1.40; -0.58) <0.0001 
 
ATV atazanavir, cART combination antiretroviral therapy 
* P values within group apply to the changes from baseline to 24 and 48 weeks (paired t-
test). 
** P values between groups compare changes from baseline to 24 and 48 weeks between 
the ATV switch group and the non-switch group (t-test). 
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Table 3b. Mean Total cholesterol and triglyceride baseline values and changes from 
baseline to 24 and 48 weeks (95%confidence interval), stratified for high or low baseline 
cholesterol, high or low triglyceride levels, presence or absence of lipodystrophy at baseline 
and use of a PI (protease inhibitor) in the last regimen. 
 
  Continued cART  
  n Mean value at 
baseline (mmol/l) 
Mean change 
(mmol/l), 95%CI 
P between 
group** 
Total cholesterol 
(mmol/l) 
     
Low baseline 
cholesterol  
W 24 1668 4.87 0.07 (0.03; 0.11) 0.046 
(≤6.2 mmol/l) W 48 1596  0.08 (-0.02; 0.18) 0.009 
High baseline 
cholesterol  
W 24 453 7.03 -0.42 (-0.52; -0.32) <0.0001 
(>6.2 mmol/l) W 48 446  -0.54 (-0.64;-0.44) 0.0002 
No lipodystrophy W 24 1353 5.21 -0.02 (-0.06; 0.02) 0.02 
 W 48 1310  -0.04 (-0.08; -0.001) 0.03 
Lipodystrophy W 24 768 5.55 -0.06 (-0.12; -0.001) 0.0005 
 W 48 732  -0.08 (-0.14; -0.02) 0.0006 
PI in last / current 
regimen 
W 24 457 5.45 -0.05 (-0.15; 0.05) <0.0001 
 W 48 430  -0.13 (-0.23; -0.03) 0.0003 
Triglycerides 
(mmol/l) 
     
Low baseline 
triglycerides 
W 24 1278 1.35 0.21(0.17; 0.25) 0.62 
(≤2.3 mmol/l) W 48 1240  0.17 (0.13; 0.21) 0.0007 
High baseline 
triglycerides 
W 24 762 3.97 -0.46 (-0.60; -0.32) <0.0001 
(>2.3 mmol/l) W 48 727  -0.54 (-0.70; -0.38) 0.002 
No lipodystrophy W 24 1308 2.08 -0.05 (-0.13; 0.03) 0.016 
 W 48 1271  -0.12 (-0.20; -0.04) 0.02 
Lipodystrophy W 24 732 2.78 -0.04 (-0.16; 0.08) <0.0001 
 W 48 696  -0.06 (-0.20; 0.08) 0.0008 
PI in last / current 
regimen 
W 24 441 2.78 -0.11 (-0.27; 0.05) <0.0001 
 W 48 413  -0.22 (-0.38; -0.06) 0.0008 
 
ATV atazanavir, cART combination antiretroviral therapy 
* P values within group apply to the changes from baseline to 24 and 48 weeks (paired t-
test). 
** P values between groups compare changes from baseline to 24 and 48 weeks between 
the ATV switch group and the non-switch group (t-test). 
 
 
Chapter 8 
188 
Table 4a. Sensitivity analysis restricted to patients in both groups who were being treated 
with a PI-containing cART-regimen at baseline, and for the switch group to those who did 
not change their background regimen at the time of the switch. 
 
  ATV switch 
  Mean value at 
baseline 
(mmol/l) 
n Mean change 
(mmol/l) (95% CI) 
P within 
group* 
Total cholesterol 
(mmol/l) 
     
PI in last / current 
regimen 
W 24 5.62 64 -0.60 (-0.86, -0.34) <0.0001 
 W 48  49 -0.65 (-0.96, -0.33) 0.0001 
Low baseline 
cholesterol  
W 24 4.69 43 -0.29 (-0.54, -0.04) 0.02 
(≤6.2 mmol/l) W 48  33 -0.24 (-0.49, 0.02) 0.07 
High baseline 
cholesterol  
W 24 7.54 21 -1.22 (-1.77, -0.67) 0.0002 
(>6.2 mmol/l) W 48  16 -1.49 (-2.17, -0.81) 0.0003 
No lipodystrophy W 24 5.65 24 -0.67 (-1.12, -0.21) 0.006 
 W 48  16 -0.56 (-1.00, -0.11) 0.002 
Lipodystrophy W 24 5.61 40 -0.56 (-0.89, -0.22) 0.002 
 W 48  33 -0.69 (-1.12, -0.26) 0.003 
Triglycerides 
(mmol/l) 
     
PI in last / current 
regimen 
W 24 3.58 62 -1.10 (-1.55, -0.64) <0.0001 
 W 48  48 -1.08 (-1.59, -0.56) 0.0001 
Low baseline 
triglycerides 
W 24 1.62 25 0.00 (-0.46, 0.47) 0.99 
(≤2.3 mmol/l) W 48  20 -0.29 (-0.60 0.02) 0.06 
High baseline 
triglycerides 
W 24 4.91 37 -1.84 (-2.43, -1.24) <0.0001 
(>2.3 mmol/l) W 48  28 -1.64 (-2.45, -0.82) 0.0003 
No lipodystrophy W 24 3.24 24 -1.08 (-1.85, -0.31) 0.008 
 W 48  17 -0.47 (-0.78, -0.16) 0.005 
Lipodystrophy W 24 3.80 38 -1.11 (-1.70, -0.52) 0.0005 
 W 48  31 -1.41 (-2.18, -0.64) 0.0008 
 
 
Mean total cholesterol and triglyceride baseline values and changes from baseline to 24 and 
48 weeks (95% confidence interval), stratified for high or low baseline cholesterol, high or 
low triglyceride levels, and presence or absence of lipodystrophy at baseline. ATV 
atazanavir, cART combination antiretroviral therapy 
* P values within group apply to the changes from baseline to 24 and 48 weeks (paired t-
test). 
** P values between groups compare changes from baseline to 24 and 48 weeks between 
the ATV switch group and the non-switch group (t-test). 
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Table 4b. Sensitivity analysis restricted to patients in both groups who were being treated 
with a PI-containing cART-regimen at baseline, and for the switch group to those who did 
not change their background regimen at the time of the switch. 
 
  Continued cART 
  Mean value at 
baseline 
(mmol/l) 
n Mean change 
(mmol/l) 
P between 
group** 
Total cholesterol 
(mmol/l) 
     
PI in last / current 
regimen 
W 24 5.45 457 -0.05 (-0.14, 0.04) <0.0001 
 W 48  430 -0.13 (-0.23, -0.03) 0.001 
Low baseline 
cholesterol  
W 24 4.94 345 0.11 (-0.02, 0.21) 0.004 
(≤6.2 mmol/l) W 48  326 -0.09 (-0.01, 0.19) 0.04 
High baseline 
cholesterol  
W 24 7.02 112 -0.56 (-0.79, -0.34) 0.02 
(>6.2 mmol/l) W 48  104 -0.81 (-1.04, -0.58) 0.04 
No lipodystrophy W 24 5.37 295 -0.08 (-0.20, 0.03) 0.008 
 W 48   -0.14 (-0.26, -0.02) 0.12 
Lipodystrophy W 24 5.61 162 0.01 (-0.15, 0.16) 0.002 
 W 48   -0.10 (-0.27, 0.07) 0.005 
Triglycerides 
(mmol/l) 
     
PI in last / current 
regimen 
W 24 2.78 441 -0.11 (-0.27, -0.05) <0.0001 
 W 48  413 -0.22 (-0.37, -0.07) 0.0004 
Low baseline 
triglycerides 
W 24 1.46 210 0.33 (0.19, 0.47) 0.14 
(≤2.3 mmol/l) W 48  202 0.22 (0.09, 0.34) 0.02 
High baseline 
triglycerides 
W 24 3.98 232 -0.50 (-0.77, -0.24) 0.0002 
(>2.3 mmol/l) W 48  211 -0.63 (-0.88, -0.37) 0.009 
No lipodystrophy W 24 2.64 285 -0.15 (-0.33, 0.03) 0.005 
 W 48  270 -0.35 (-0.53, -0.17) 0.49 
Lipodystrophy W 24 3.05   156 -0.03 (-0.34, 0.27) 0.002 
 W 48    143 0.04 (-0.23, 0.31) 0.0009 
 
 
Mean total cholesterol and triglyceride baseline values and changes from baseline to 24 and 
48 weeks (95% confidence interval), stratified for high or low baseline cholesterol, high or 
low triglyceride levels, and presence or absence of lipodystrophy at baseline. ATV 
atazanavir, cART combination antiretroviral therapy 
* P values within group apply to the changes from baseline to 24 and 48 weeks (paired t-
test). 
** P values between groups compare changes from baseline to 24 and 48 weeks between 
the ATV switch group and the non-switch group (t-test). 
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Table 5. Change in total cholesterol (TC) between baseline and week 24 after switch to ATV 
in 163 patients. 
 
  Univariate Multivariate  
  Mean 
change 
in mmol/l 
Diff with 
ref. 
(mmol/l) 
95%CI p-value Diff with 
ref. 
(mmol/l) 
95%CI p-value 
No  -0.80 0.00   0.00   RTV boosted 
Yes -0.38 0.42 -0.13; 
0.97 
0.14 0.49 0.06; 
0.92 
0.02 
>6.2 -1.23 -1.13 -1.46;  
-0.80 
<0.0001    TC at baseline 
<6.2 -0.10 0.00      
TC at baseline (per 
mmol/l increase) 
 -0.42 -0.50;  
-0.34 
<0.0001 -0.38 -0.46;  
-0.30 
<0.0001 
No -0.42 0.00   0.00   Diabetes 
mellitus 
diagnosis prior 
to baseline 
Yes -0.35 0.07 -0.48; 
0.62 
0.80 0.41 0.0; 
0.82 
0.049 
No -0.33 0.00   0.00   Prior 
lipoatrophy or 
fat acumulation Yes -0.47 -0.14 -0.47; 
0.19 
0.43 -0.07 -0.34; 
0.20 
0.60 
No -0.46 0.00   0.00   NNRT in 
previous reg. 
stopped Yes -0.22 0.24 -0.19; 
0.67 
0.29 -0.79 -1.26;  
-0.32 
0.0001 
No 0.16 0.00   0.00   PI in previous 
regimen 
Yes -0.66 -0.81 -1.16;  
-0.46 
<0.0001 -1.02 -1.41;  
-0.63 
<0.0001 
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Table 6 Change in triglycerides between baseline and week 24 after switch to ATV in 156 
patients. 
 
  Univariate Multivariate  
  Mean 
change 
(mmol/l) 
Difference 
with 
reference 
(mmol/l) 
95%CI p-value Difference 
with 
reference 
(mmol/l) 
95%CI p-
value 
No -0.90 0.00   0.00   Lipid 
lowering 
drug 
used 
Yes -0.64 0.26 -0.62; 
1.14 
0.56 0.97 0.36; 
1.58 
0.002 
No  -1.19 0.00      RTV 
boosted 
Yes -0.82 0.36 -0.66; 
1.38 
0.48    
<3.1 0.13 0.00      TG at 
baseline 
>3.1 -1.72 -1.85 -2.42; 
-1.28 
<0.0001    
TG at baseline (per 
mmol/l increase) 
 -0.60 -0.70; 
-0.50 
<0.0001 -0.61 -0.69; 
-0.53 
<0.0001 
No -0.82 0.00      Diabetes 
mellitus 
diagnosis prior 
to baseline 
Yes -1.24 -0.42 -1.50; 
0.66 
0.45    
No -0.75 0.00   0.00   Prior 
lipoatrophy or 
fat 
accumulation 
Yes -0.94 -0.19 -0.84; 
0.46 
0.56 0.09 -0.36; 
0.54 
0.69 
No -0.93 0.00      NNRT in 
previous 
regimen 
stopped 
Yes -0.57 0.36 -0.46; 
1.18 
0.40    
No -0.25 0.00   0.00   PI in previous 
regimen 
Yes -1.13 -0.88 -1.55; 
-0.21 
0.01 -0.52 -0.99; 
-0.05 
0.03 
 
 
 
 192 
 193 
Chapter 9 
 
 
Summary and discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• Introduction. 
• Summary of main findings. 
o Body fat distribution. (chapter 2)  
o Dyslipidemia. (chapters 2 and 8) 
o Insulin resistance. (chapters 3 and 4)  
o Bone mineral density. (chapter 5)  
o Vascular properties. (chapters 6 and 7)  
• Overall interpretation of main findings. 
o Pathogenesis of metabolic complications and the role of ZDV/3TC. 
o Clinical strategies to limit metabolic complications. 
 The TA-NRTI sparing strategy. 
 The atazanavir switch strategy.  
• Implications for current treatment of HIV infection. 
• Future perspectives. 
o Pathogenesis of metabolic complications. 
o Novel strategies to limit metabolic complications of treatment for 
HIV infection. 
.
Chapter 9 
194 
Introduction 
 
Since the introduction of combination antiretroviral therapy (cART) in 1996, the life 
expectancy of patients with HIV-1 infection who have access to antiretroviral drugs 
has greatly increased and the incidence of opportunistic infections has diminished 
considerably[1]. However, longer term side effects were soon recognized, including 
changes in body fat distribution, dyslipidemia, and insulin resistance, together often 
called lipodystrophy syndrome. In addition, reduced bone mineral density has been 
observed.  
The potential consequences of these side effects are becoming more and more 
clear. Fat distribution changes often lead to stigma and psychological distress, and 
may have a negative impact on treatment adherence [2], potentially leading to 
therapy failure due to the emergence of drug resistant virus. Furthermore, several 
of these metabolic side effects may increase the risk of cardiovascular disease, 
thereby partly counteracting the beneficial effects of cART on life expectancy. 
Limiting the metabolic complications of cART is therefore of importance for quality 
of life, long-term viral suppression and, hopefully, reduction of the risk for 
cardiovascular disease in patients with HIV-1 infection. 
 
The aim of this thesis was to evaluate the effects of two potential treatment 
strategies to limit the metabolic complications of treatment of HIV infection. The 
first strategy consists of a thymidine analogue nucleoside reverse transcriptase 
inhibitor (TA-NRTI) sparing first-line therapy in cART naïve patients. This was 
studied in the MEDICLAS (Metabolic Effects of DIfferent CLasses of 
AntiretroviralS) trial, a multicenter, randomized trial comparing the TA- NRTI-
containing regimen of zidovudine/lamivudine + lopinavir/ritonavir (ZDV/3TC/LPV/r) 
with the TA-NRTI-sparing regimen of nevirapine + lopinavir/ritonavir (NVP/LPV/r) in 
antiretroviral-naïve HIV-1-infected men. This thesis describes the effects of these 
regimens on body composition, lipid profile, insulin sensitivity, bone mineral density 
and vascular properties during 24 months of follow-up. This study was designed to 
gain more insight into the pathophysiology of metabolic complications and 
specifically the role of the TA-NRTI zidovudine in combination with lamivudine 
(ZDV/3TC).  
With the second strategy, consisting of switching effective cART to a regimen 
based on atazanavir, a protease inhibitor with no significant effect on lipid profile, 
we aimed to investigate the reversibility of drug-induced hyperlipidemia in 
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treatment- experienced patients. This was evaluated within the ATHENA cohort, a 
nationwide observational cohort study of HIV-infected individuals in the 
Netherlands. In a retrospective cohort study in patients with sustained viral 
suppression, we compared patients who switched to atazanavir with those not 
switching to this drug. We studied which factors influence changes in lipids after 
switching to atazanavir, including the degree of hyperlipidemia and the presence of 
lipodystrophy prior to the switch. 
 
 
Summary of main findings 
 
Body fat distribution (chapter 2) 
In patients randomized to the TA-NRTI containing regimen of ZDV/3TC/LPV/r in 
the MEDICLAS study, a progressive loss of limb fat (subcutaneous fat in arms and 
legs) was observed, commencing after 3 months of treatment. During the same 
time period, these patients experienced selective gain of visceral abdominal 
adipose tissue without any change in subcutaneous abdominal fat. These changes, 
loss of peripheral subcutaneous fat and accumulation of abdominal (visceral) fat, 
are characteristic for HIV-associated lipodystrophy. In contrast, patients assigned 
to the TA-NRTI sparing regimen of NVP/LPV/r demonstrated a generalized 
increase in fat mass, which included both subcutaneous and deep adipose tissue 
compartments, and may be seen as a “restoration to health” phenomenon. 
Consistent with these observations, lipodystrophy as defined according to the 
International Case Definition in those patients with complete 24 months follow up 
was present in 3/18 patients allocated to ZDV/3TC/LPV/r, but in none of the 22 
evaluable patients allocated to NVP/LPV/r.  
 
Dyslipidemia (chapters 2 and 8) 
Total cholesterol and triglycerides increased significantly in all patients using both 
regimens in the MEDICLAS study. Due to the concomitant rise in HDL cholesterol, 
the total/HDL cholesterol ratio did not increase over time in either of the study 
arms. However, patients using the TA- NRTI sparing regimen of NVP/LPV/r 
developed higher total cholesterol levels than patients using ZDV/3TC/LPV/r, and 
an increase in LDL cholesterol was observed only in those on NVP/LPV/r. Other 
than what may have been expected considering that the use of NVP has been 
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demonstrated to be associated with an HDL increase, the HDL cholesterol rise in 
the NVP/LPV/r arm was not significantly greater than in the ZDV/3TC/LPV/r arm.  
The potential reversibility of cART-related dyslipidemia was studied in the 
retrospective cohort study of cART-experienced patients with sustained virological 
suppression. A significant decrease in total cholesterol and triglycerides was 
observed in patients switching to atazanavir from other regimens, compared to 
those continuing cART. The greatest changes were seen in patients with higher 
total cholesterol and triglyceride levels prior to the switch. Patients with physician 
reported lipodystrophy had similar improvements in both total cholesterol and 
triglyceride levels after switch to atazanavir as patients without lipodystrophy, after 
adjusting for baseline lipid levels. The presence of diabetes mellitus however was 
associated with a reduced effect of switching to atazanavir on total cholesterol. 
Virological failure was observed more frequently in patients switching to atazanavir 
compared to those continuing cART.  
 
Insulin resistance (chapters 3 and 4) 
Glucose metabolism and lipolysis were studied in depth by hyperinsulinemic 
euglycemic clamps using stable isotopes in a substudy of the MEDICLAS trial. In 
patients randomised to ZDV/3TC/LPV/r, but not in those randomised to the TA-
NRTI-sparing regimen of NVP/LPV/r, an early decrease in insulin mediated 
peripheral glucose uptake was observed within three months of initiating cART, in 
the absence of any change in body fat distribution. This was accompanied by a 
transient increase in basal  lipolysis. During further follow-up a persistence of this 
change was demonstrated, followed by a transient reduced insulin sensitivity 
regarding inhibition of lipolysis after 12 months. In the NVP/LPV/r arm, increased 
insulin-mediated inhibition of hepatic glucose production was observed after 24 
months, probably explained by lower glucagon levels and possibly by the 
increased adiponectin.  
Insulin sensitivity was also estimated in the whole study population of the 
MEDICLAS study by the homeostasis model assessment of insulin resistance 
(HOMA), calculated from fasting glucose and insulin. We found no difference 
between the treatment arms in this measure of insulin sensitivity in all study 
patients.  
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Bone mineral density (chapter 5) 
In all patients in the MEDICLAS trial, lumbar spine and femoral neck bone mineral 
density decreased considerably in the first year after initiation of antiretroviral 
therapy, and appeared to stabilize thereafter. However, patients randomised to 
ZDV/3TC/LPV/r had significantly greater bone loss measured by DXA scan in both 
locations compared to patients allocated to NVP/LPV/r. The difference in bone loss 
of the lumbar spine between the two study arms was not visible when measured by 
quantitative CT scan. Furthermore, markers of bone formation (osteocalcin), and 
bone resorption (urine deoxypyridinoline /creatinine ratio) increased significantly 
after start of cART in all patients, indicating an increase in bone turnover. 
Parathyroid hormone also increased in all patients, but to a significantly greater 
degree in those randomized to NVP/LPV/r. 
 
Vascular properties (chapters 6 and 7) 
We first attempted to determine the relative contribution of HIV infection itself, 
antiretroviral therapy and lipodystrophy to cardiovascular disease risk in patients 
with HIV infection. In a cross-sectional study we evaluated carotid artery intima-
media thickness (C-IMT), a surrogate measure of atherosclerosis, and arterial 
stiffness, an independent predictor of cardiovascular morbidity and mortality, in 
HIV-infected patients and in healthy controls. After adjustment for traditional 
cardiovascular risk factors, HIV infected patients had a 0.067 mm (10.8%) greater 
C-IMT compared to controls, and significantly greater stiffness of the carotid and 
femoral arteries. Patients exposed to ART had similar C-IMT compared to ART-
naïve patients, but significantly increased stiffness of the femoral artery. 
Cumulative use of PI and NRTI was independently associated with femoral artery 
stiffness after adjustment for traditional cardiovascular risk factors while no such 
association was found for cumulative NNRTI use. Arterial properties did not differ 
between patients with and without objectively determined lipodystrophy.  
To further explore the role of antiretroviral therapy, in particular ZDV/3TC 
containing versus TA-NRTI sparing regimens, on C-IMT and arterial stiffness, we 
investigated these markers in patients initiating antiretroviral treatment in the 
MEDICLAS study. In addition, biochemical markers of endothelial dysfunction, 
which are commonly employed as biomarkers of early stages of atherosclerosis, 
were evaluated. We found that patients initiating cART had a deterioration of 
arterial wall properties, characterized by an increase in c-IMT, which appears 
greater than expected in healthy controls, and in arterial stiffness of the femoral 
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artery. These changes appeared regardless of allocated treatment. In contrast, 
levels of von Willebrand factor (vWF), an endothelial cell molecule involved in 
coagulation, and the endothelial adhesion molecules soluble vascular cell adhesion 
molecule-1 (sVCAM-1) and soluble intercellular adhesion molecule-1 (sICAM-1) 
significantly decreased in both arms. PAI-1, a marker of fibrinolytic activity, 
increased only in the NVP/LPV/r arm.  
In conclusion, we demonstrated a deterioration of structural and functional arterial 
properties, related to an increase in cardiovascular risk, in the first two years after 
initiation of cART, but an improvement in several markers of endothelial function. 
 
 
Overall interpretation of main findings  
 
Both regimens in the MEDICLAS study led to excellent and similar virological 
suppression and restoration of immunity, but to different metabolic profiles. As 
described, patients randomized to ZDV/3TC/LPV/r developed body composition 
changes consistent with lipodystrophy, insulin resistance, an increase in total and 
HDL cholesterol and triglycerides, bone loss and deterioration of vascular 
properties. In contrast, patients using NVP/LPV/r did not develop lipodystrophy or 
insulin resistance and lost bone mineral density to a lesser degree than patients 
using ZDV/3TC/LPV/r. However, one of the expected advantages of including 
nevirapine in the NRTI sparing regimen, a higher increase in HDL cholesterol, was 
not observed, and patients allocated to this regimen had higher increases in total 
and LDL cholesterol, but similar deterioration of arterial properties. 
The prospective evaluation of all these parameters and the comparison between 
the two study arms may increase our understanding of the pathogenesis of the 
metabolic adverse effects of antiretroviral therapy, and more specifically, 
considering that nevirapine has not been implicated in the pathogenesis of these 
adverse effects, of the role of ZDV/3TC in the pathogenesis of these metabolic side 
effects. In addition, they may give insight into the possibilities and limitations of a 
TA-NRTI sparing regimen in general, and the combination of NVP/LPV/r in 
particular, to limit the occurrence of these metabolic changes. Furthermore, the 
advantages and limitations of the atazanavir switch strategy will be discussed. 
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Pathogenesis of metabolic complications and the role of ZDV/3TC   
Our findings clearly suggest that ZDV/3TC contributes to limb fat loss. Whether this 
is a synergistic effect in combination with LPV/r cannot be formally determined from 
this study, but seems unlikely given that treatment with LPV/r without ZDV/3TC (in 
the NVP/LPV/r arm) did not lead to loss of limb fat, but rather to an increase in fat 
in both arms and legs. Also, the recent results from a randomized trial in which 
antiretroviral naive subjects treated with dual NRTI’s plus LPV/r exhibited 
significantly less loss of limb fat than those treated with two NRTI’s plus efavirenz 
argue against an important contribution from LPV/r towards limb fat loss[3]. The 
role of ZDV/3TC in visceral fat accumulation is less clear. As there was a trend for 
patients on ZDV/3TC to have gained more intra-abdominal fat after 24 months, a 
contribution from these NRTI to this feature of lipodystrophy cannot be ruled out. 
The finding that visceral fat accumulation in patients on ZDV/3TC/LPV/r was 
observed in the context of stable subcutaneous adipose tissue, whereas in patients 
on NVP/LPV/r subcutaneous adipose tissue increased in parallel with visceral fat 
would seem to support a contribution of ZDV/3TC to visceral fat accumulation. 
Potential mechanisms for ZDV/3TC associated adipose tissue toxicity include 
mitochondrial toxicity, leading to depletion of mitochondrial DNA and adipocyte 
apoptosis, and interference with cellular transcription factors that are essential for 
adipocyte function. Alternatively, a selective autonomic neuropathy, with 
predominant sympathetic activity in subcutaneous fat and parasympathetic activity 
in visceral fat, has been proposed as a mechanism[4], which, if a link with 
ZDV/3TC would be established, might explain both subcutaneous fat loss and 
visceral fat accumulation.  
 
The increase in total cholesterol and triglycerides in all patients in the MEDICLAS 
study was an expected finding considering that all patients used LPV/r and this 
drug is known for its lipid raising effects. Less is known on the effects of ZDV/3TC 
on the lipid profile, but as total cholesterol and triglyceride levels have been shown 
to decrease in patients in whom ZDV is replaced by tenofovir[5], a negative effect 
on lipids may exist. NVP, on the other hand, has been associated with marked 
increases in HDL cholesterol[6]. Our findings that the combination of NVP/LPV/r 
led to the highest total and LDL cholesterol levels, without the expected beneficial 
difference in HDL cholesterol, were somewhat surprising. Concerning the higher 
total and LDL cholesterol, differences in plasma or intracellular levels of lopinavir or 
ritonavir (the two components of LPV/r) between the two study groups may be 
speculated to play a role. However, only lopinavir plasma levels were available and 
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adjustment for differences in these levels between the two study arms did not 
change the results. Our findings are consistent with the dyslipidaemia described in 
patients switching to regimens of LPV/r with efavirenz, another NNRTI[7], but 
contrast with results from another small trial which also included a regimen of 
NVP/LPV/r in treatment-naive subjects[8].  Concerning the absence of a difference 
in HDL cholesterol between the two study arms, we calculated that our sample size 
was only sufficient to demonstrate a statistically significant difference between 
arms if this was 33% (or 0.29 mmol/l) or greater. Therefore it is possible that the 
true difference is smaller and a larger sample size would be required to detect this.  
Our finding that the dyslipidemia associated with cART is (partially) reversible after 
switching to an atazanavir based regimen, is compatible with the current view that 
cART-associated dyslipidemia is al least partially caused by direct effects of 
antiretroviral drugs. This improvement in lipid profile was similar in patients with 
lipodystrophy, but the presence of diabetes mellitus was associated with a reduced 
effect of switching to atazanavir on total cholesterol, suggesting that a clinically 
important degree of insulin resistance rather than the presence of the body 
composition changes characteristic of lipodystrophy is more important for 
maintaining or aggravating the dyslipidemia in these patients.  
 
 
Concerning the early decrease in peripheral insulin sensitivity observed in patients 
using ZDV/3TC/LPV/r, we hypothesize that this also is a direct effect of ZDV/3TC 
since no changes in body fat distribution occurred at that time. The fat distribution 
changes occurring later on may have contributed to the persistence of this 
peripheral insulin resistance. Again, a synergistic effect with LPV/r cannot be 
excluded, but patients treated with LPV/r without ZDV/3TC (in the NVP/LPV/r arm) 
did not develop any reduced insulin sensitivity during two years after start of cART. 
Several mechanisms may be responsible for the effects of ZDV/3TC on peripheral 
insulin sensitivity, of which the most plausible is ZDV- induced mitochondrial 
dysfunction. This hypothesis is supported by a study in healthy volunteers, in which 
a similar effect on peripheral glucose uptake without changes in body composition 
was observed after treatment with stavudine for 4 weeks and was associated with 
a significant reduction in muscle mitochondrial DNA and reduced mitochondrial 
function[9]. How mitochondrial dysfunction interferes with peripheral insulin 
sensitivity has not been fully clarified yet, but accumulation of intracellular lipids 
due to reduced oxidative capacity may be one mechanism[10]. The transient 
increase in basal lipolysis and the transient decrease in insulin-mediated inhibition 
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of lipolysis may also be explained by direct effects of NRTI on adipocytes, either 
through mitochondrial dysfunction leading to oxidative stress or via inflammatory 
changes with production of pro-inflammatory cytokines, both resulting in enhanced 
lipolysis.  
The apparent discrepancy between the clamp results in the sub-study and HOMA 
in the whole study population may imply that HOMA as a marker of insulin 
resistance may not be sensitive enough to detect the development of reduced 
insulin sensitivity in this population. Also, it should be kept in mind that the 
hyperinsulinemic euglycemic clamp measures insulin stimulated glucose disposal 
at high insulin levels, whereas HOMA reflects insulin sensitivity at basal insulin 
levels. Comparisons between these indices in non HIV infected populations have 
had heterogeneous results, ranging from high to non-significant correlation[11-13].  
 
The mechanism of the rapid bone loss in patients initiating cART, as observed in all 
patients in the MEDICLAS study, has not been fully clarified. The contribution of 
antiretroviral drugs to reduced bone mineral density in HIV- infected patients is 
controversial. Different drugs appear to have heterogeneous effects on osteoblasts 
and osteoclasts in vitro[14-16]. On the other hand, as HIV infection has been 
associated with disturbed bone formation and resorption, and restoration of the 
bone remodelling process was observed after start of cART[17], suppression of 
HIV by cART may even have a beneficial effect on bone mineral density. The 
design of our study does not enable us to discern between direct effects of cART in 
general or any effect of suppression of HIV. In particular, the role of LPV/r in this 
process cannot be determined. Previous studies on the role of PI, including LPV/r, 
in bone loss have had conflicting results[18-20]. However, the greater bone loss in 
patients in the ZDV/3TC/LPV/r arm in the MEDICLAS study suggests that 
ZDV/3TC contributes to this feature. Both zidovudine and lamivudine have been 
shown to enhance osteoclastogenesis in vitro[16], which may lead to bone loss. 
Lactic acidemia due to NRTI related mitochondrial dysfunction has also been 
suggested to play a role in reduced BMD[21]. The increase in PTH does not 
appear to explain the greater degree of bone loss on ZDV/3TC/LPV/r, as 
parathyroid hormone actually increased to a significantly greater degree in patients 
randomized to NVP/LPV/r.  
There was an apparent contrast between the results of the DXA scan and the 
quantitative CT scan concerning bone mineral density loss in the lumbar spine. It 
should be noted that quantitative CT scan in our study measured the central part of 
the vertebral body, i.e. trabecular bone, whereas a DXA scan cannot differentiate 
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between trabecular and cortical bone. Our findings therefore suggest that cortical 
bone is mainly affected in the ZDV/3TC/LPV/r group, whereas trabecular bone loss 
was similar in the two treatment groups. A histomorphometric study of bone 
biopsies could confirm this hypothesis. Another possible explanation for this 
discrepancy, underestimation of bone mineral density by DXA scan due to changes 
in surrounding fat and lean tissue, appears to be unlikely as analyses adjusted for 
local fat and lean mass did not change the results. 
 
In order to investigate the effect the different cART-associated metabolic 
complications on the risk for cardiovascular disease, we studied various surrogate 
markers of atherosclerosis. These include carotid artery intima-media thickness (C-
IMT), a valid measure of subclinical atherosclerosis, which has consistently been 
related to future cardiovascular events in population studies[22] and arterial 
stiffness, an independent predictor of cardiovascular morbidity and mortality[23-26]. 
In addition, biochemical markers of endothelial dysfunction, which are commonly 
employed as biomarkers of early stages of atherosclerosis[27], were studied. The 
findings of our cross-sectional study suggest that HIV infection itself is 
independently associated with increased C-IMT and generally increased arterial 
stiffness. A low degree of inflammation due to HIV may be a potential explanation, 
as both C-IMT and arterial stiffness have been shown to be elevated in chronic 
inflammatory conditions. Recent findings of a study in which patients who 
interrupted cART were shown to have an increase in several markers of 
inflammation and coagulation, which was independently associated with an 
increased risk of death[28, 29], appear to support this hypothesis. Theoretically, the 
use of cART could therefore have both beneficial and detrimental effects on the 
vascular wall, by suppressing HIV and inflammation and by influencing traditional 
risk factors such as hyperlipidemia and insulin resistance. Our findings that femoral 
artery stiffness deteriorated after start of cART, whereas carotid artery stiffness 
remained unchanged and several markers of endothelial function improved, 
suggest that both beneficial and detrimental effects of cART exist, and that the 
balance of these two may differ between arterial segments and in different parts of 
the arterial wall. Also, our finding that cumulative PI use is associated with femoral 
artery stiffness, while no such association was found for cumulative NNRTI use, 
may suggest that effects of ART on arterial stiffness vary between different drug 
classes. In conclusion, our findings indicate that the effects of HIV and cART on the 
arterial wall are complex. The net effect of different treatment strategies and 
interventions on the risk of cardiovascular disease may eventually only be revealed 
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by large intervention studies with clinical cardiovascular endpoints. It is unlikely 
however that such trials of sufficient size will ever be feasible in the context of HIV. 
 
 
Clinical strategies to limit metabolic complications 
The TA-NRTI sparing strategy 
We found that lipodystrophy and insulin resistance did not occur in patients using a 
first line regimen of NVP/LPV/r, at least during the first two years after initiation of 
cART. In addition, the use of this TA-NRTI sparing regimen may limit the extent of 
bone mineral density loss after start of treatment. However, an important limitation 
of this regimen is the observed worse lipid profile. Although the total/HDL 
cholesterol ratio, a powerful predictor of cardiovascular risk, did not increase, the 
observed LDL cholesterol elevation gives rise to concern. Comparison of the 
ZDV/3TC containing with the ZDV/3TC sparing regimen with respect to their 
potential impact on longer- term cardiovascular risk is quite complex. Given our 
results with respect to the effects on insulin sensitivity and fat distribution, 
NVP/LPV/r should be expected to be superior to ZDV/3TC/LPV/r in terms of 
cardiovascular risk, whereas regarding lipid profiles the opposite would be 
expected to be true. Our study on surrogate markers of atherosclerosis and 
cardiovascular risk did not clarify this issue, there was no significant difference in 
deterioration of vascular properties between the two study groups. The absence of 
abnormalities in fat distribution and insulin sensitivity in the NVP/LPV/r arm may 
have been counteracted by the more severe dyslipidemia observed in patients 
using this regimen, although this remains speculative. Another possibility is that 
negative effects of some of these cardiovascular risk factors on the vascular wall 
may take longer to develop. Furthermore, due to the small number of patients, the 
MEDICLAS study had limited power to detect differences between study groups. 
Smaller differences may therefore have remained undetected. 
 
The atazanavir switch strategy  
We clearly demonstrated that the dyslipidemia associated with cART is (partially) 
reversible after switching to an atazanavir- based regimen, even in patients with 
reported lipodystrophy. Although it remains preferable to prevent lipid abnormalities 
from developing by choosing a first line therapy with relatively lipid friendly drugs, 
no such possibility existed in the past for many patients, especially for those with a 
longer history of antiretroviral treatment. A potential limitation of this strategy may 
be an increased risk of virological failure. This risk should always be taken into 
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account when switching from an effective antiretroviral regimen in a cART-
experienced patient with possible resistant virus. In our study, patients switching to 
atazanavir had a higher rate of virological failure compared to patients in the 
continued cART group, and this difference remained when the analysis was 
restricted to patients switching from another PI to atazanavir without changes in 
their background regimen. Many factors, including higher rates of pretreatment 
before start of cART (leading to resistance mutations) and use of unboosted 
atazanavir (leading to lower atazanavir levels and therefore potentially less 
effective viral suppression), may have played a role. In apparent contrast with our 
findings, two other studies found comparable or lower rates of virological failure in 
patients switching to atazanavir compared to patients continuing their PI based 
regimen[30, 31]. These trials however included patients with a shorter duration of 
cART, and one of these excluded those with a history of virologic failure while 
receiving PI-based cART[30], in whom the risk of PI-associated resistance 
mutations would be expected to be low compared to our more experienced study 
population. A careful review of antiretroviral treatment history, previous virological 
failure and, when possible, resistance testing, will always be necessary before 
considering any switch of antiretroviral treatment, and the beneficial effect on lipid 
profile after switching to atazanavir should be balanced against a possible higher 
risk of virological failure. 
 
 
Implications for current treatment of HIV infection 
 
Our findings support to no longer recommend ZDV/3TC as one of the preferred 
backbones of first-line antiretroviral therapy. Recent updates of treatment 
guidelines in Europe and the United States have removed ZDV/3TC from the list of 
preferred components of initial cART[32-34]. However, worldwide ZDV/3TC is still 
widely used and both TA-NRTI (stavudine and ZDV) are currently recommended 
as one of the preferred first line NRTI options in many resource- limited countries 
for reasons of cost and availability. As antiretroviral treatment availability expands, 
lipodystrophy and other metabolic abnormalities are increasingly being reported 
from resource- limited settings. Hopefully, non TA-NRTI will become affordable and 
available for patients in these countries in the near future. 
Despite its beneficial effects on body composition and insulin sensitivity, the 
NVP/LPV/r regimen does not appear to be the best choice for first-line antiretroviral 
therapy due to its detrimental effects on lipid profile. With the currently available 
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drugs, combinations of non-TA-NRTI with an NNRTI or a PI with less effects on 
lipid profile would seem preferable in order to limit most metabolic abnormalities, 
although longer term comparisons between these regimens should be performed.  
 
 
Future perspectives  
 
Many of the metabolic complications of treatment of HIV infection may become 
more prominent as patients age. Thus, as patients with HIV infection are getting 
older, prevention of these complications is becoming an even more important 
issue. Unraveling the underlying mechanisms may eventually aid the development 
of new drugs and treatment strategies that not only effectively suppress viral 
replication and restore immunity, but also have the least possible side effects. 
 
Pathogenesis of metabolic complications 
Concerning the pathogenesis of metabolic complications of antiretroviral therapy, 
many questions remain. One of the possibilities to gain more insight into the 
pathogenesis of the lipodystrophy syndrome is to study molecular effects of cART 
on adipose tissue. In the MEDICLAS study, adipose tissue biopsies from the 
abdomen and thigh were performed. This stored material will be used to 
prospectively analyse changes in mitochondrial DNA content and quality, 
mitochondrial function, markers of inflammation and expression of a range of 
genes involved in lipid and glucose metabolism.  
Another topic of interest is microvascular function. Microvascular dysfunction 
(impaired capillary recruitment and microvacular vasodilatation) has been 
postulated to form a pathophysiological link between obesity, insulin resistance and 
hypertension[35]. Obesity, especially visceral adiposity, is associated with impaired 
capillary recruitment [36], which in turn has been postulated to play a causative role 
in decreased insulin mediated peripheral glucose uptake[35]. Defects in 
microcirculation have also been observed in patients with hypertension[37, 38]. 
Although hypertension is not a recognized part of the constellation of metabolic 
abnormalities in HIV- infected patients treated with cART, it would be interesting to 
explore whether decreased peripheral insulin sensitivity in patients with 
lipodystrophy is also associated with disturbances in microcirculation. The 
prospective measurements of microvascular function (capillary recruitment induced 
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by post-occlusive reactive hyperemia and endothelium-dependent vasodilatation in 
response to iontophoresis of acetylcholine) performed in a subgroup of patients in 
the MEDICLAS study will give us the opportunity to study any changes in 
microcirculation after initiation of cART and associations between microvascular 
function, objectively determined insulin sensitivity and (visceral) fat accumulation.  
 
Novel strategies to limit metabolic complications of treatment for HIV 
infection 
As new antiretroviral drugs are being developed and become available, alternative 
TA-NRTI sparing regimens are becoming feasible, which may have less 
detrimental effects on lipids than the TA-NRTI sparing regimen of NVP/LPV/r used 
in the MEDICLAS study, while maintaining the beneficial effects on body 
composition and insulin sensitivity. These include regimens with non TA-NRTI such 
as abacavir or tenofovir in combination with lamivudine or emtricitabine. In two 
studies, the TA-NRTI sparing regimen of tenofovir/lamivudine with efavirenz was 
associated with significantly less lipoatrophy and smaller increases in total 
cholesterol and triglycerides after 144 weeks than the TA-NRTI containing 
regimens of ZDV/3TC and efavirenz [39] and stavudine/lamivudine/efavirenz[40]. 
Other potential regimens include PI – NNRTI combinations with other PI than 
LPV/r, but also NRTI class sparing regimens incorporating the latest antiretroviral 
drug classes such as CCR5 inhibitors and HIV integrase inhibitors. Long term 
prospective evaluation of such alternative treatment strategies incorporating 
assessments of both body composition and metabolic effects may eventually 
identify first line regimens which lack detrimental effects on both body composition 
and lipid and glucose metabolism. These evaluations should also include bone 
density measurements, especially when using tenofovir- containing regimens, as 
some concern has risen that this frequently used non TA-NRTI may lead to more 
bone loss. 
Similarly, as more antiretroviral drugs with less unfavorable effects on lipid profile 
are becoming available, switching to drugs other than atazanavir may become a 
valuable strategy to ameliorate cART-associated dyslipidemia in cART-
experienced patients.  
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Inleiding en probleemstelling 
 
In 1981 werden de eerste patiënten met “AIDS” beschreven. Zij hadden ernstige 
infecties veroorzaakt door ziekteverwekkers die gewoonlijk niet tot ziekte leiden. 
Twee jaar later werd ontdekt dat dit syndroom veroorzaakt werd door een virus, 
HIV (humaan (menselijk) immunodeficientie (afweerverlagend) virus). Dit virus 
verzwakt de afweer door aantasting van bepaalde afweercellen. Hierdoor kan het 
lichaam bepaalde ziekteverwekkers niet meer goed bestrijden en kunnen allerlei 
ernstige infecties optreden. De afkorting “AIDS” staat voor acquired immune 
deficiency syndrome ofwel verworven aantasting van het afweersysteem. Sinds de 
beschrijving van de eerste patiënten is het aantal mensen met HIV infectie 
wereldwijd fors toegenomen. Naar schatting waren in 2007 33,2 miljoen mensen 
besmet met HIV, en kwamen er in dat jaar 2,5 miljoen nieuwe infecties bij. Voordat 
een behandeling tegen HIV beschikbaar was, overleden vrijwel alle patiënten met 
HIV ten gevolge van ernstige infecties. 
Het eerste geneesmiddel tegen HIV, zidovudine, kwam in 1987 beschikbaar. 
Sindsdien zijn meer dan 20 verschillende geneesmiddelen tegen HIV 
geregistreerd. Deze middelen worden ingedeeld in 6 verschillende klassen op 
basis van hun aangrijpingspunt in de levenscyclus van het virus. Door het gebruik 
van een combinatie van verschillende geneesmiddelen tegen HIV kan het virus 
sterk onderdrukt worden en de afweer tegen infecties (gedeeltelijk) herstellen. 
Nadat deze behandeling in 1996 werd geïntroduceerd, is de sterfte onder patiënten 
met HIV fors gedaald en is het aantal ernstige infecties ook afgenomen. 
Levenslange behandeling is echter noodzakelijk, aangezien het (nog) niet mogelijk 
is om de ziekte te genezen. Helaas worden met langdurig gebruik van deze 
geneesmiddelen in toenemende mate ook bijwerkingen van de behandeling 
gezien. Zo kan na verloop van tijd een verandering van de vetverdeling in het 
lichaam plaatsvinden. Dit houdt in dat de buik dikker wordt en tegelijkertijd de 
armen en benen dunner worden. Ook het gezicht kan er meer ingevallen uitzien. 
Een andere bijwerking is een verminderde gevoeligheid voor het hormoon insuline, 
dat normaal de bloedsuikerspiegel verlaagt (insulineresistentie). Hierdoor kan in 
sommige gevallen zelfs suikerziekte ontstaan. Ook kan het cholesterol- en 
vetgehalte in het bloed stijgen. Deze bijwerkingen worden samen ook wel 
“lipodystrofie syndroom” genoemd. De laatste jaren wordt ook steeds vaker een 
toegenomen botontkalking (osteoporose) beschreven bij mensen met HIV infectie. 
Of dit een gevolg is van de behandeling is nog niet duidelijk. 
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Deze genoemde bijwerkingen kunnen belangrijke gevolgen hebben voor mensen 
die behandeld worden voor HIV infectie. De veranderingen in het uiterlijk kunnen 
erg ingrijpend zijn. Dit kan leiden tot minder goed innemen van de geneesmiddelen 
met als gevolg het ontwikkelen van resistentie (verminderde gevoeligheid) voor de 
behandeling en uiteindelijk het falen van de behandeling. Verder zouden sommige 
van deze bijwerkingen, zoals de hogere suiker- en cholesterolwaarden, kunnen 
leiden tot een hoger risico voor hart- en vaatziekten. Het gunstige effect van de 
behandeling op de levensverwachting kan hierdoor voor een deel teniet worden 
gedaan. Het beperken van deze bijwerkingen is daarom van groot belang, 
enerzijds voor de kwaliteit van leven van mensen met HIV infectie, en anderzijds 
voor het bereiken van langdurige onderdrukking van het virus, en hopelijk ook voor 
het verminderen van het risico voor hart- en vaatziekten. 
 
Het doel van dit proefschrift is om twee mogelijke strategieën te beschrijven om de 
bovengenoemde bijwerkingen van de behandeling voor HIV infectie te beperken. 
De eerste strategie is het weglaten van bepaalde geneesmiddelen uit een 
bepaalde klasse (de zogenaamde nucleoside reverse transcriptase remmers 
oftewel NRTI) uit de combinatiebehandeling. Dit werd onderzocht in de MEDICLAS 
studie (Metabolic effects of different classes of antiretrovirals / Effecten op de 
stofwisseling van verschillende klassen geneesmiddelen tegen HIV). In dit 
onderzoek werd een behandeling met 2 NRTI (zidovudine en lamivudine ofwel 
ZDV/3TC) samen met lopinavir/ritonavir vergeleken met een behandeling zonder 
NRTI (bestaande uit lopinavir/ritonavir samen met nevirapine). In de verdere tekst 
worden deze behandelingen aangeduid als de ZDV/3TC bevattende en de 
ZDV/3TC sparende behandeling. Vijftig mannen met HIV infectie die nog niet 
eerder een behandeling tegen HIV hadden gebruikt deden mee aan dit onderzoek.  
De verdeling tussen de twee behandelingen werd door het lot bepaald. Gedurende 
drie jaar werden de effecten van deze twee behandelingen op 
lichaamssamenstelling, insulinegevoeligheid, cholesterol- en vetgehalte, 
botdichtheid en bloedvaten onderzocht.  
De tweede strategie bestaat uit het vervangen van een van de geneesmiddelen in 
een effectieve behandeling tegen HIV door het middel atazanavir. Omdat van 
atazanavir bekend is dat het vrijwel geen effect heeft op het cholesterol- en 
vetgehalte in het bloed, zou hierdoor een verbetering kunnen optreden bij 
patiënten die een verhoogd cholesterol- en vetgehalte hebben door de 
behandeling. Dit werd onderzocht in het ATHENA cohort, een landelijk onderzoek 
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waarbij van vrijwel alle in Nederland behandelde patiënten met HIV infectie 
anoniem gegevens worden verzameld.  
 
 
Samenvatting van de belangrijkste bevindingen. 
 
Lichaamssamenstelling (hoofdstuk 2). 
Het onderhuidse vet in de armen en benen begon na 3 maanden behandeling af te 
nemen bij patiënten die behandeld werden met de ZDV/3TC bevattende 
behandeling in het MEDICLAS onderzoek. Tegelijkertijd nam de hoeveelheid vet in 
de buik rondom de ingewanden toe. Deze veranderingen, zich uitend in dunner 
wordende armen en benen en een dikker wordende buik, zijn kenmerkend voor het 
lipodystrofiesyndroom. Daarentegen was er bij patiënten die de ZDV/3TC sparende 
behandeling kregen een toename van vet in het gehele lichaam, zoals te 
verwachten bij herstel van een ernstige ziekte. 
Aangezien het onderhuids vetverlies in de armen en benen alleen voorkwam bij 
patiënten die behandeld werden met de ZDV/3TC bevattende behandeling, lijkt het 
er op dat ZDV/3TC een rol speelt bij het ontstaan van deze bijwerking.  
 
Cholesterol- en vetgehalte (hoofdstukken 2 en 8). 
Bij alle patiënten in het MEDICLAS onderzoek nam het totale cholesterol- en 
vetgehalte in het bloed toe na de start van de behandeling. Dit is een bekende 
bijwerking van het middel lopinavir/ritonavir, waarmee alle patiënten behandeld 
werden. De toename in het totale cholesterol gehalte was het grootst bij de 
patiënten die met de ZDV/3TC sparende behandeling kregen, en alleen bij deze 
patiënten steeg ook het LDL cholesterol (ook wel het “slechte” cholesterol 
genoemd). Dit was een verrassende bevinding, en er wordt nog verder onderzocht 
waardoor dit veroorzaakt werd. Het HDL cholesterol (het zogenaamde “goede” 
cholesterol) nam ook toe bij alle patiënten. Omdat van het geneesmiddel 
nevirapine bekend is dat het leidt tot een stijging van het HDL cholesterol, was de 
verwachting dat patiënten die dit middel kregen (in de ZDV/3TC sparende 
behandeling) een grotere toename van het HDL cholesterol zouden hebben 
vergeleken met de andere behandelingsgroep. Dit bleek echter niet het geval. 
Mogelijk is een groter onderzoek met meer patiënten nodig om dit aan te tonen. 
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In het ATHENA cohort werd een afname gezien in het totale cholesterol- en 
bloedvetgehalte bij patiënten bij wie een ander geneesmiddel omgezet werd naar 
atazanavir, vergeleken met patiënten die doorgingen met hun huidige behandeling. 
Het lijkt er dus op dat een deel van de verhoging in cholesterol- en vetgehalte een 
direct effect is van de gebruikte geneesmiddelen, en dat dit (deels) omkeerbaar is 
na het stoppen van deze geneesmiddelen. De grootste verbetering werd gezien bij 
patiënten die voorafgaand aan de verandering van behandeling de hoogste 
cholesterol- en bloedvetgehaltes hadden. Patiënten met lipodystrofie hadden een 
vergelijkbare verbetering in cholesterol- en bloedvetgehalte na verandering van de 
behandeling als patiënten zonder lipodystrofie. Bij patiënten met suikerziekte was 
er minder verbetering te zien. Patiënten die hun behandeling veranderden hadden 
echter wel een hoger risico op falen van de behandeling tegen HIV dan patiënten 
die doorgingen met hun behandeling. Hierbij moet worden opgemerkt dat de 
patiënten die de behandeling veranderden al veel langer behandeld waren tegen 
HIV infectie, en meer kans hadden op resistentie van het virus dan de mensen die 
doorgingen met de behandeling.  
 
Insulinegevoeligheid (hoofdstukken 3 en 4) 
Na drie maanden behandeling werd bij patiënten in de MEDICLAS studie die 
behandeld werden met de ZDV/3TC bevattende behandeling een afname in de 
suikeropname in de spier onder invloed van insuline vastgesteld, een teken van 
verminderde insulinegevoeligheid. Deze verminderde insulinegevoeligheid bleef 
gedurende het hele onderzoek bestaan, daarnaast was er ook tijdelijk een afname 
in de remming van de vetafbraak, een ander teken van verminderde 
insulinegevoeligheid. Bij patiënten die behandeld werden met de ZDV/3TC 
sparende behandeling was er geen sprake van verminderde insulinegevoeligheid, 
na twee jaar leek er zelfs een verbetering van insulinegevoeligheid in de lever te 
zijn. Insulineresistentie werd dus alleen vastgesteld bij de patiënten die de 
ZDV/3TC bevattende behandeling kregen. Dit pleit ervoor dat ZDV/3TC een rol 
speelt in het ontstaan van insulineresistentie.  
 
Botdichtheid (hoofdstuk 5) 
Bij alle patiënten in het MEDICLAS onderzoek nam de botdichtheid in de heup en 
de ruggenwervels af in het eerste jaar na het starten van de behandeling, daarna 
leek de botdichtheid te stabiliseren. De afname in botdichtheid was het grootst bij 
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patiënten die behandeld werden met de ZDV/3TC bevattende behandeling. 
ZDV/3TC lijkt dus ook bij deze bijwerking een rol te spelen. Uit bloed- en urine 
onderzoek bleek verder bij alle patiënten een toename van de botstofwisseling. 
 
Vaatwandeigenschappen (hoofdstukken 6 en 7) 
Eerst zijn verschillende vaatwandeigenschappen onderzocht in een groep 
patiënten met HIV infectie vergeleken met een groep gezonde vrijwilligers. Er werd 
door middel van geluidsgolvenonderzoek gekeken naar de dikte van de vaatwand 
in een slagader in de hals (intima-media dikte) en naar de stijfheid van 
verschillende bloedvaten in het lichaam. In andere onderzoeken is vastgesteld dat 
deze vaatwandeigenschappen een maat zijn voor “aderverkalking” 
(atherosclerose) en hart- en vaatziekten kunnen voorspellen. Patienten met HIV 
infectie bleken een dikkere vaatwand (intima-media dikte) te hebben en stijvere 
slagaderen dan gezonde vrijwilligers. Verder bleek dat bij patiënten met HIV 
infectie die een behandeling kregen tegen HIV de slagaderen in de benen stijver 
waren dan bij patiënten die geen behandeling hadden. Er was geen verschil in 
vaatwandeigenschappen tussen patiënten met of zonder lipodystrofie. 
 
In het MEDICLAS onderzoek werd bij alle patiënten na start van behandeling een 
achteruitgang van verschillende vaatwandeigenschappen gezien. Dit betrof zowel 
een toename van de dikte van de vaatwand als een toename van de stijfheid van 
de slagaderen in de benen. Daarnaast werd gekeken naar de functie van de 
vaatwand door het meten van bepaalde eiwitten in het bloed die door de vaatwand 
geproduceerd worden. Hiermee werd aangetoond dat de vaatwand functie juist 
verbeterde na het starten van behandeling bij alle patiënten. 
 
Het lijkt er daarom op dat HIV infectie zelf kan leiden tot atherosclerose 
(“aderverkalking”), mogelijk door chronische ontsteking. Behandeling tegen HIV 
infectie zou dus enerzijds een gunstig effect op de vaatwand kunnen hebben (door 
verminderen van ontsteking) en anderzijds een nadelig effect door het veroorzaken 
van een hoog cholesterol gehalte en insulineresistentie. 
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Conclusies en aanbevelingen 
 
Beide behandelingen in het MEDICLAS onderzoek waren even effectief in het 
onderdrukken van het virus en het verbeteren van de afweer. De bijwerkingen van 
de twee behandelingen verschilden echter duidelijk. Patiënten met de ZDV/3TC 
bevattende behandeling kregen dunnere benen en armen en een dikker wordende 
buik, passend bij lipodystrofie. Daarnaast kregen zij insulineresistentie, een 
verhoogd cholesterol- en bloedvetgehalte, afname van botdichtheid en een 
achteruitgang van een aantal vaatwandeigenschappen.  
Patiënten met de ZDV/3TC sparende behandeling daarentegen kregen geen 
lipodystrofie of insulineresistentie, en hadden minder achteruitgang van 
botdichtheid. Hoewel deze strategie dus duidelijk voordelen heeft vergeleken met 
de ZDV/3TC bevattende behandeling, is de grotere toename in cholesterol- en 
bloedvetgehalte een belangrijk nadeel. De achteruitgang in 
vaatwandeigenschappen, die hetzelfde was als in de andere behandelingsgroep, 
hangt hier mogelijk mee samen. 
 
Uit dit onderzoek concluderen wij dat ZDV/3TC niet langer gebruikt moet worden in 
de combinatiebehandeling tegen HIV infectie bij patiënten die voor het eerst 
beginnen met een dergelijke behandeling. Kort geleden is deze aanbeveling ook 
gedaan in de verschillende richtlijnen voor behandeling van HIV infectie in Europa 
en de Verenigde Staten. Wereldwijd wordt ZDV/3TC echter nog veel gebruikt 
omdat het goedkoop en goed te verkrijgen is. Hopelijk zullen andere 
geneesmiddelen die een alternatief zijn voor ZDV/3TC in de nabije toekomst ook 
beschikbaar komen voor patiënten in ontwikkelingslanden. 
 
Vanwege de grotere toename in cholesterol- en vetgehalte lijkt de ZDV/3TC 
sparende behandeling uit het MEDICLAS onderzoek ook niet de optimale eerste 
behandeling. Gelukkig komen er steeds meer geneesmiddelen tegen HIV 
beschikbaar die weinig of geen effect op cholesterol- en bloedvetgehalte hebben. 
Met deze nieuwe middelen is het naar verwachting mogelijk om combinaties van 
geneesmiddelen zonder ZDV/3TC te geven, zonder het nadelige effect op 
cholesterol en vetgehalte. 
 
Voor patiënten die door de behandeling reeds een verhoogd cholesterol- en 
vetgehalte hebben, heeft het overgaan op een atazanavir bevattende behandeling 
een gunstig effect op cholesterol- en vetgehalte. Hierbij moet wel altijd eerst 
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zorgvuldig het risico van resistentie van het virus overwogen worden, vanwege een 
mogelijk verhoogd risico op het falen van de behandeling. Het overgaan op 
nieuwere geneesmiddelen met weinig of geen effect op cholesterol- en vetgehalte 
wordt in de toekomst wellicht mogelijk, nu steeds meer geneesmiddelen tegen HIV 
beschikbaar komen. 
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